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Chronic obstructive pulmonary disease (COPD) and asthma account for most 
obstructive lung diseases that place a huge burden on health services and society. There are 
currently limited therapeutic options for severe asthmatic and COPD patients. 
Andrographolide and 14-deoxy-11,12-didehydroandrographolide (DDAG) are the main 
biologically active constituents isolated from Andrographis paniculata. Andrographolide has 
been shown to activate nuclear factor erythroid-2-related factor 2 (Nrf2). As Nrf2 activity is 
reduced in COPD, we hypothesize that andrographolide may have therapeutic value for 
COPD. Our group has also recently reported novel anti-inflammatory effects of 
andrographolide in a mouse asthma model as well. However, andrographolide has been 
shown to possess cytotoxic activity towards tumour cell lines. As DDAG is an analogue of 
andrographolide, we hypothesized that DDAG retains the anti-inflammatory effects for 
asthma but is devoid of cytotoxicity.  
Contrary to andrographolide, DDAG did not elicit any cytotoxic activity in A549 and 
BEAS-2B human lung epithelial cells and rat basophilic leukemia (RBL)-2H3 cells using a 
MTS assay. BALB/c mice sensitized and challenged with ovalbumin (OVA)-developed 
allergic airway inflammation. DDAG dose-dependently inhibited OVA-induced increases in 
total cell counts and eosinophil counts, IL-4, IL-5, and IL-13 levels in lavage fluid and serum 
OVA-specific IgE level in a mouse asthma model. In addition, DDAG attenuated OVA-
induced airway eosinophilia, mucus production, mast cell degranulation, pro-inflammatory 
biomarker expression in lung tissues, and airway hyperresponsiveness (AHR) to methacholine 
in mice. DDAG also blocked p65 nuclear translocation and DNA-binding activity in the 
OVA-challenged lung and in TNF-α -stimulate d human lung epithelial cells.  
Andrographolide suppressed cigarette smoke-induced increases in BAL fluid cell 
counts, levels of IL-1β, MCP-1, IP-10 and KC, and levels of oxidative biomarkers 8-
ix 
 
isoprostane, 8-OHdG and 3-nitrotyrosine in a dose-dependent manner. Andrographolide also 
promoted inductions of glutathione peroxidase (GPx) and glutathione reductase (GR) 
activities in lungs from cigarette smoke-exposed mice. In BEAS-2B cells, andrographolide 
markedly increased nuclear Nrf2 accumulation, promoted binding to antioxidant response 
element (ARE), and total cellular glutathione level in response to CSE. Andrographolide up-
regulated ARE-regulated gene targets including glutamate-cysteine ligase catalytic (GCLC) 
subunit, GCL modifier (GCLM) subunit, GPx, GR and heme oxygenase-1 (HO-1) in BEAS-
2B cells in response to CSE.  
Taken together, current study demonstrated that andrographolide possesses anti-
oxidative properties against cigarette smoke-induced lung injury probably via augmentation 
of Nrf2 activity. DDAG, on the other hand, retains the anti-inflammatory activities of 
andrographolide for asthma probably through the inhibition of NF-κB, and thus, DDAG may 
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1.1 Obstructive Lung Disease  
Respiratory disease is a common and important cause of illness and death around the 
world. Respiratory disease can be segregated into two major categories, which include 
obstructive lung disease and restrictive lung disorders. Obstructive lung diseases which are 
characterized by airway obstruction while restrictive lung disease is characterized by reduced 
lung volume due to restricted lung expansion. Obstructive lung diseases are far more common 
than restrictive diseases in a general population (Culver, 2011). To assess the pathophysiology 
of obstructive lung disease, spirometrical measurement which provides the initial lung 
function is commonly used. The main diagnostic criteria for a lung diseases lie in a 
diminished forced expiratory volume in 1 second (FEV1)/ the total volume of air exhaled 
during a forced manoeuvre, the forced vital capacity (FVC) (Macintyre, 2009).  
A person is said to have airway obstruction when the ratio of FEV1/FVC is less than 70% 
(Seemungal et al., 2008). Diseases resulting in obstructive pathophysiology primarily include 
asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and bronchiolitis 
(Ryu et al., 2001). Although a broad spectrum of disorders is associated with airflow 
obstruction, COPD and asthma account for most obstructive lung disease (Ryu et al., 2001).   
Both diseases are characterized by airway obstruction, which is variable and reversible in 
asthma but is progressive and largely irreversible in COPD (Barnes, 2008c). As the incidence 
of asthma and COPD is increasing globally, both diseases are placing an increasing burden on 
health services in industrialized and developing countries (Mannino et al., 2007; Pearce et al., 
2007). In asthma and COPD, there is chronic inflammation of the respiratory tract, and when 
the intensity of the inflammation increases, there are acute exacerbations in both diseases as 
well (Barnes, 2008c).  
Nonetheless, there are marked differences in inflammation pattern in asthma and COPD 




inflammatory cell types and production of mediators that underlie both of the diseases. Hence, 
asthma and COPD also have different consequence to inflammation and respond differently to 
therapy (Ichinose, 2009). There have been several recent important advances in our 
understanding of the immunopathology of asthma and COPD (Murphy et al., 2010; Yao et al., 
2009). The understanding of the similar and different immune mechanisms that are involved 
in both asthma and COPD has important implication for the development of new therapies for 
these troublesome diseases. 
 
1.2 Asthma 
Asthma is a chronic respiratory disease characterized by episodic attacks of impaired 
breathing (Akinbami et al., 2011). According to Global Initiative for Asthma’s (GINA) 
guidelines, asthma is defined as a chronic inflammatory disorder of the respiratory airways in 
which various cells and cellular elements play a role. The chronic inflammation is associated 
with AHR that leads to recurrent episodes of shortness of breath, coughing, wheezing, and 
chest tightness, particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment (GINA, 2011). Asthma comprises a range of 
heterogeneous phenotypes that differ in presentation, aetiology and pathophysiology. Allergic 
(extrinsic) and non-allergic (intrinsic) asthma are 2 well characterized asthma phenotypes. 
People with allergic asthma develop the disease early in life. They are atopic (producing IgE 
specific to identifiable allergens) and have identifiable allergic triggers, and other allergic 
diseases such as rhinitis or eczema or a family history of allergic diseases. Non-allergic 
asthma develops later in life (after 40 years of age) and it is associated with aspirin-
exacerbated respiratory disease (AERD) but not with allergic sensitization. Hence, non-




exercise-induced asthma, obesity-related asthma and neutrophilic asthma. Nonetheless, in 
patients with asthma of any severity, up to 50% of them have a T-helper Type 2 (Th2)-
predominant phenotype. Asthma that presents without evidence of Th2 immunity remains 
poorly understood (Wenzel, 2012). Although several types of asthma have been classified 
clinically, allergic asthma is the most common form of the disease (Mukherjee et al., 2011). 
Allergic asthma is a chronic respiratory condition characterized by airway inflammation, 
mucus hypersecretion, and AHR (Galli et al., 2008b). Increased mucus secretion and airway 
hyper-responsiveness leads to recurrent wheezing and shortness of breath (Moreira et al., 
2011). 
 
1.2.1 Epidemiology and Burden of Asthma 
Asthma is a widespread disease. There are 300 million people affected by asthma 
worldwide (Masoli et al., 2004). Nearly 30 million people in the United State alone are 
affected by asthma, accounting for about 12% of children and 9% of adults in the US (Juhn, 
2012). In Singapore, the prevalence of asthma has risen over the last 40 years but now appears 
to have stabilized, with approximately 5.5% of children in 1969 to 20% of children in 1994 
affected by the disease (Wang et al., 2004). Another recent survey estimated that almost 9% 
of school attending children have asthma and about quarter of them is inadequately controlled 
(Yang et al., 2007). In the United States, 10.5 million school days were reported to be missed 
by asthmatic children aged 5-17 years in the year 2008 alone. Each day, an average of 9 
persons in the United States dies from asthma. In addition, 2 out of 100 person with asthma 
are hospitalize and 8.4 out of 100 person with asthma have emergency department visit in 
2009 (Akinbami et al., 2012). The morbidity due to asthma, direct health care costs, indirect 
costs such as lost productivity, and mortality due to asthma continue to pose a high burden to 




1.2.2 Pathophysiology of Asthma  
Asthma is a chronic inflammatory disease accompanied by remodelling of the airways 
and AHR that result in the clinical expression of airway obstruction that usually is reversible. 
The symptoms and physiological changes in asthma often involved airway narrowing. Several 
factors contribute to the development of airway narrowing in asthma. Airway smooth muscle 
(ASM) contraction responding to multiple bronchoconstrictor mediators and neurotransmitter 
is the predominant mechanism of airway narrowing and is largely reserved by brochodilators. 
During acute exacerbations, airway oedema, which is due to increased microvascular leakage 
in response to inflammatory mediators, also play a role in airway narrowing. Structural 
changes, often termed "remodelling", lead to airway thickening that may play an important 
role in more severe disease and is not fully reversible by current therapy. Mucus 
hypersecretion, which is a product of increased mucus secretion and inflammatory exudates, 
may lead to luminal occlusion that is also known as mucus plugging (GINA, 2011). 
The structural changes are manifested by changes that involve all the layer of the 
respiratory airway wall.  Changes in the epithelium include an increased number of goblet 
cells and epithelial detachment. Subepithelial fibrosis results from the development of 
increased deposition of extracellular-matrix molecules in the lamina reticularis which lies 
beneath the epithelial basement membrane and changes in fibroblasts with increased 
development of myofibroblasts and increased vascularity. Blood vessels in the airway walls 
proliferate under the influence of growth factors such as vascular endothelial growth factor 
(VEGF) and may contribute to increased airway wall thickness. The increased size 
(hypertrophy), number (hyperplasia) and function of ASM cells contribute to the increased 



















Figure 1.1. Tissue sections from the airway of a non-asthmatic person (a–c). A normal 
small bronchus stained with haematoxylin and eosin (H&E) in a. There are few goblet cells 
(black arrows in insets) in the epithelium. The basement membrane and underlying lamina 
reticularis (at asterisk in a) are normal. Sections in b were stained with periodic acid–Schiff  
(PAS) and diastase to stain mucus red. The submucosa (the length of the double-headed 
arrows in a) contains few leukocytes and the occasional mast cell (blue arrows in c), and the 
bronchial smooth muscle (SM) has few adjacent mast cells (red arrow in c) visualize by 
staining with pinacyanol erythrosinate (PE) which stain mast cells purple. Adapted from Galli 


















Figure 1.2. Tissue sections from the airway of a patient with severe asthma (d–f). A small 
bronchus from a patient with a history of severe asthma are stained with H&E in d, PAS and 
diastase in e and PE in f. Mucus (M) fills the airway lumen (d and e). There are many goblet 
cells (black arrows in insets) and the occasional intra-epithelial mast cell (black arrows in f). 
The lamina reticularis (asterisk in inset in d) is noticeably thickened. The submucosa (double-
headed arrows in d) contains many eosinophils (green arrows in inset in d) and other 
leukocytes, as well as mast cells (blue arrows in f). There is more bronchial smooth muscle 
(SM) than in a–c in figure 1.1, and there are many mast cells (red arrows in f) among bundles 






1.2.2.1 Inflammatory and Structural Cells  
The inflammatory responses of allergic asthma are mediated by Th2 cells together 
with mast cells, B cells and eosinophils, as well as a number of inflammatory cytokines and 
chemokines (Galli et al., 2008a). 
 
T Lymphocytes  
T lymphocytes are critical mediators of the allergic airway inflammation in asthma. 
Pathogenic allergen-specific T lymphocytes are generated in regional lymph nodes and are 
then recruited into the airway by chemoattractants produced by the asthmatic lung. These 
recruited effector T lymphocytes and their products then mediate the cardinal features of 
asthma that includes airway eosinophilia, mucus hypersecretion, and AHR. 
Although T lymphocytes are important mediators of adaptive immune responses and 
are vital for host defence against infection, aberrant accumulation of T lymphocytes in the 
lung is seen in numerous non-infectious pulmonary inflammatory diseases such as asthma, 
where T lymphocytes in the lung are believed to orchestrate an abnormal inflammatory 
process. In asthma, the airways develop prominent inflammation with accumulation of 
activated effector T lymphocytes around the airways and in the airway lumen. It is thought 
that these cells are recruited into the lung and serve as the critical controllers of airway 
inflammation (Medoff et al., 2008). 
There are several subsets of T lymphocytes, each with a distinct function and these 
cell types can be distinguish based by the virtue that they express unique combinations of 
molecules in their membranes. Two major classes of T-lymphocytes are distinguished by the 
presence of either CD4, which presence on T helper (Th) and Regulatory (Treg) lymphocyte, 
or CD8, which presence on cytotoxic T lymphocyte (Tc). Different subtypes of T helper 




orchestrating T helper type 1 (Th1) and T helper type 2 (Th2) differentiations are IL-12 and 
IL-4, respectively (Lund et al., 2003). In turn, Th1 cells produce interferon-γ (IFNγ), whereas 
Th2 lymphocytes primarily produce IL-4, IL-5 and IL-13.  
Th2 lymphocyte plays a significant role in allergic asthma. Although clinical studies 
increasingly suggest that asthma is a heterogeneous disease, observational immunologic 
studies in human asthma, allergen challenge models in both human asthma and animal models, 
and substantial in vitro data has substantiated the notion that asthma is primarily a Th2 
disease (Lloyd et al., 2010). As an example, recent study has affirmed that Th2 driven 
inflammation defines major sub-phenotypes of asthma as Th2 biased response are seems to be 
detectable in 50% of individuals with asthma (Woodruff et al., 2009). In asthma patients, the 
Th2 lymphocytes become exuberant and drive mast cell, and eosinophilic inflammation 
(Robinson, 2010). The notion that Th1 lymphocytes could have an inhibitory role in asthma 
as they can directly inhibit the development of Th2 lymphocytes
 
has been substantiated by the 
deletion of the Th1 lymphocytes master transcription factor T-bet in mice results in the 
development of spontaneous AHR and IL-13-dependent eosinophilia (Finotto et al., 2002). 
Nonetheless, when IFNγ, the signature Th1-type cytokine, is administered to the airways of 
patients with asthma, there is no improvement of disease symptoms (Boguniewicz et al., 
1995). The positive correlations between the numbers of Th2 lymphocytes present in the 
airways with disease severity further strengthen the suggestion that Th2 lymphocytes plays an 
essential role in human asthma. 
Although atopic asthma has a substantial Th2 lymphocyte component, the disease is 
particularly heterogeneous, and the discovery of several of other T lymphocyte subsets, such 
as T helper type 17 (Th17) lymphocytes, T helper type 9 (Th9) lymphocytes and regulatory T 
(Treg) lymphocytes (Lloyd et al., 2010) has suggested that other T lymphocytes also 






lymphocyte activation is a critical determinant in generating these effector subsets, owing to 
the ability of certain cytokine to activate specific transcription factors required for the 
differentiation of the Th subsets. In the case of Th1 and Th2 cells, this process was dependent 
on IL-12 acting on T-bet and IL-4 acting on GATA-binding protein 3 (GATA3), respectively 
(Murphy et al., 2002). GATA3 is a transcription factor that is vital for the differentiation of 
uncommitted naive T lymphocytes into Th2 lymphocytes and regulates the secretion of Th2 
cytokines (Ho et al., 2007). Clinical studies have revealed that there is an increase in the 
number of GATA3
+
 T lymphocytes in the airways of stable asthmatic subjects (Caramori et 
al., 2001). Stimulation of T lymphocytes following ligation of the T cell receptor (TCR) and 
CD28 co-receptor by antigen-presenting cells (APCs), GATA3 is phosphorylated and 
activated by p38 mitogen-activated protein kinase (MAPK), and subsequently translocate to 
the nucleus, where it binding to the promoter region of Th2 cytokine genes 
(Maneechotesuwan et al., 2007). Nuclear factor of activated T cells (NFAT) is a T 
lymphocyte–specific transcription factor that enhances the transcriptional activation of the Il4 
promoter by GATA3 (Ho et al., 2007). Similarly, applying the concept that a specific 
cytokine exerts its effect on a transcription factor to mediate lymphocyte differentiation has 
led to the identification of other Th subsets, such as the regulatory T lymphocytes (Tregs) and 
Th17 lymphocytes (Zhou et al., 2009). 
Th9 lymphocytes are a discrete population of IL-9-secreting CD4
+
 T lymphocytes that 
depend on transforming growth factor-β (TGF-β) for their development (Veldhoen et al., 
2008). Th9 lymphocytes were first identified as a subpopulation of Th2 lymphocytes, but 
recent experimental analysis revealed that Th9 lymphocytes had divergent regulatory 
capabilities (Xing et al., 2011). Generation of these Th9 lymphocytes involves expression of 
PU.1, which is a transcription factor is expressed specifically in subpopulations of Th2 




upregulated by IL-25 (Angkasekwinai et al., 2010; Chang et al., 2010). These discoveries 
strongly establish Th9 lymphocytes as a distinctive Th lymphocytes subtypes. 
Th17 lymphocytes are a distinct lineage of CD4
+
 effector T lymphocytes that express 
IL-17 and the key transcription factors retinoic acid receptor-related orphan receptor-γt 
(RORγt) and RORα (Harrington et al., 2005; Park et al., 2005). Tissue-infiltrating CD4+IL-
17
+
 T lymphocytes and the up regulation IL-17 have been documented in the lungs of patients 
with asthma (Pene et al., 2008) and the levels of IL-17 correlate with disease severity (Chang 
et al., 2012; Wang et al., 2011). Furthermore, adoptive transfer of Th17 cells induces 
neutrophilia and imparts resistance to steroid therapy, suggesting that IL-17 may function to 
promote neutrophil recruitment (Kolls et al., 2004) and could therefore be particularly 
important in severe asthma which is often characterized by neutrophilic inflammation and 
steroid resistance (McKinley et al., 2008).  Besides IL-17, Th17 lymphocytes also produce a 
small amount of IFNγ and no IL-4 (Harrington et al., 2005).  
CD8
+
 T lymphocytes, which play a pivotal role in tumour cell killing and protection 
during viral infection through the secretion of IFN-γ and cytolytic factors, were considered to 
be less essential or even as a negative regulator for the development of allergic inflammation. 
Indeed, studies reported protective effects of CD8+ T lymphocytes in allergic airway disease 
because of production of IFN-γ and the ability to suppress Th2 responses (Huang et al., 1999; 
Suzuki et al., 1999). However, cell transfer studies using CD8
+
 αβ T lymphocytes has 
demonstrated that not only CD4
+
 T lymphocytes but also CD8
+
 T lymphocytes were essential 
to the development of AHR and allergic inflammation, either directly (Sawicka et al., 
2004) or in concert with sensitized CD4
+
 T lymphocytes (Isogai et al., 2004; Koya et al., 
2007; Miyahara et al., 2004). CD8-deficient mice are less susceptible to allergic airway 
inflammation, but the transfer of in vitro-generated antigen-primed effector memory CD8
+
 αβ 




and the levels of IL-13 in bronchoalveolar lavage (BAL) fluid (Miyahara et al., 2004). While 
CD8
+
 αβ T-lymphocytes have been demonstrated to have pro-inflammatory effects, CD8+ γδ 
T-lymphocytes are believed to have inflammation inhibitory effects (Isogai et al., 2003). 
Antibody based depletion studies has also shown that depletion of residential CD8
+
 T 
lymphocytes enhance the late airway response and airway inflammation in a rat model of 
asthma (Isogai et al., 2005), and enhance the effects on airway remodelling in a rat model of 
asthma (Tsuchiya et al., 2009). Cytotoxic T lymphocytes type 2 (Tc2) is a subsets of CD8
+
 T 
lymphocytes that produce IL-4, IL-5 and IL-13 but not IFN-γ. Recent studies have 
demonstrated in the absence of IFN-γ, CD8 T lymphocytes assume a Tc2-biased phenotype 
and potentiate inflammation (Tang et al., 2012). The presence of CD8
+
 T lymphocytes in 
asthmatic airways is well documented. Tc2 are increased in BAL fluid of atopic asthma 
patients (Cho et al., 2005). Additionally, bronchial biopsies from patients with atopic and 
non-atopic asthma contain CD8
+
 T cells that produce IL-4 and IL-5 (Ying et al., 1997). 
However, despite these correlations, the role play by CD8
+
 lymphocyte remains to be further 
explored. 
Regulatory T lymphocytes (Tregs) are T lymphocytes that suppress potentially 
harmful immune responses. The inappropriate immune response to allergens observed in 
asthmatic patients may be explain by the reduced or altered function of Treg lymphocytes 
populations in these patients. Several TReg lymphocyte subsets have been described, including 






 lymphocytes (nTreg) and 
inducible Treg (iTreg) lymphocytes, which develop in vitro or in vivo following antigen 
stimulation (Robinson, 2009). The majority of nTregs express the transcriptional factor 
FOXP3, and their development and function are dependent upon it. In contrast, iTregs are 
usually FOXP3 negative, but they can express this transcription factor in certain antigen 








cell-cell contact, other types of regulatory suppressive T lymphocytes that act via modulatory 
cytokines such as regulatory T helper lymphocytes type 3 (Th3) and regulatory T 
lymphocytes type 1 (Tr1) have been identified. Th3 are dependent on TGF-β and are 
observable in mice models in which low doses of the antigen exposure induces oral 
tolerization (Kumar et al., 2011a). Tr1 lymphocytes are defined by their specific cytokine 
production profile, which includes the secretion of high levels of IL-10 and TGF-β, and their 
ability to suppress antigen-specific effector T lymphocytes responses via cytokine-dependent 




 Treg lymphocytes attenuates 
airway inflammation and AHR as well as prevents the allergen-induced activation of DCs in 
the airways (Joetham et al., 2007; Leech et al., 2007; Strickland et al., 2006). Treg 
lymphocytes exert their inhibitory action through both direct and indirect mechanisms. In the 
direct mechanism, Treg produce anti-inflammatory cytokines, such as IL-10 and TGF-β, 
express inhibitory molecules, such as cytotoxic T lymphocyte antigen 4 (CTLA4) (Kearley et 
al., 2005; Ostroukhova et al., 2004) and induce the down regulation of MHC class II and the 
co-stimulatory molecules CD80 and CD86 by antigen-presenting cells (APC) (Cederbom et 
al., 2000). Intriguingly, Treg lymphocytes do not necessarily produce IL-10 themselves but, 
instead, the Treg lymphocytes can induce IL-10 production from bystander CD4
+
T 





 T lymphocytes in the airways correlated positively with the patient’s 




 T lymphocytes in the 
airways of patients with asthma (Hartl et al., 2007). The characterizations for cytokine 
dependent subset of regulatory T lymphocytes (Th3 and Tr1) have been impeded by the lack 
of a specific surface marker (Langier et al., 2012). Finally, T lymphocytes play a critical role 




our understanding about the disease and may lead to the development of a more specific 
treatment for asthma. 
Eosinophils  
Eosinophil in the sputum is a hall-mark of asthma and it has been used as marker for 
effective corticosteroid therapy or treatment compliance (Hargreave, 2007). In uncontrolled 
asthma, eosinophils are present in the sputum and also in BAL fluid (Holgate, 2008). 
Eosinophils differentiate and undergo trafficking under the regulation of the transcription 
factors GATA binding protein (GATA)-1&2, and CCAAT-enhancer-binding proteins 
(c/EBP), the chemokine eotaxin, as well as the CD4
+
 Th2 lymphocyte-derived survival 
cytokines such as IL-3, IL-5 and granulocyte macrophage colony-stimulating factor (GM-
CSF). Eosinophils express receptors for the pro-inflammatory mediators complement 
component 5a (C5a) and platelet-activating factor (PAF), the cytokines IL-2, IL-3, IL-5, IFN-
γ, and GM-CSF, as well as the immunoglobulins IgG and IgA, and C-C chemokine receptor 
type 3 (CCR3) (Minai-Fleminger et al., 2009). Eosinophils are a rich source of basic granule 
proteins, such as major basic protein (MBP), eosinophil peroxidase (EPO), and eosinophil 
cationic protein (ECP) which altogether have been shown to cause significant tissue 
destruction and involved in the development of AHR (Minai-Fleminger et al., 2009). MBP, 
which accounts for more than 50% of the eosinophil granule protein mass, was found to 
activate human lung mast cell and cause histamine release. EPO, which is a cationic enzyme 
that is capable of catalysing the formation of highly toxic oxidants, has significant potential to 
induce cellular injury as well (McElhinney et al., 2003). ECP, a ribonuclease which has been 
attributed with cytotoxic and fibrosis promoting functions, has been developed as a marker for 
asthma as elevated ECP levels are observed in asthmatic patients (Bystrom et al., 2011). 
Eosinophils also release and up to 28 cytokines, chemokines and growth factors such as IL-4, 




TGF-β as well as eosinophil-derived lipid mediators, such as leukotriene C4 (LTC4) and PAF, 
which potently act as bronchoconstrictors and secretagogues (Minai-Fleminger et al., 2009; 
Wegmann, 2011) and prostaglandin E2 (PGE2) has been shown to enhance eosinophil survival 
(Profita et al., 2003). Additionally, because eosinophils secrete considerable amounts of TGF-
β, eosinophils contribute to processes leading to airway remodelling. As a result, eosinophils 
have been identified as valuable targets for therapeutic intervention in asthma (Wegmann, 
2011).  
Mast cell  
Mast cells play a key role in asthma. Mast cells, along with dendritic cells are among 
one of the first immune cells to interact with allergens (Galli et al., 2008a). Mast cells are 
potentially long-lived cells and mast cell number, distribution, function and phenotype can be 
regulated by various factors whose local concentrations can change at the sites of innate or 
adaptive immune responses (Galli et al., 2005). In humans there are two main kinds of mast 
cell phenotypes, the first contains tryptase and the second stores tryptase, chymase 
carboxypeptidase A and cathepsin-G (Matsumoto et al., 2007). Mast cells are highly 
granulated high-affinity IgE receptor (FcεRI) bearing tissue-dwelling cells, which develop 
from myeloid progenitors expressing CD34, proto-oncogene c-Kit (CD117/c-kit) and alanine 
aminopeptidase (CD13). Mast cells are widely distributed in connective tissues and mucosal 
surfaces (Minai-Fleminger et al., 2009). Mast cells are recruited to the airways by stem-cell 
factor (SCF) released from epithelial cells. Additionally, mast cell are also recruited by 
interleukin 8 (IL-8/CXCL8) and interferon-γ-inducible protein 10 (IP10/CXCL10) produced 
by airway smooth muscle cells (Brightling et al., 2005; John et al., 2009). These chemokines 
also prime mast cells for heightened mediator secretion. In return, mast cells secrete CCL19 
which, through its CCR7, stimulates airway smooth muscle cell migration and contributes to 




bound FcεRI complexes in response to activation by specific allergens on mast cell surface 
leads to the “early phase” of the allergic reaction within minutes. The “early phase” of allergy 
is characterized by vasodilation, increased vascular permeability, vascular leakage and 
oedema in which mast cells degranulate and secrete of various granular preformed mediators 
such as tryptase, chymase, histamine and proteoglycans as well as of newly-synthesized 
mediators, such as arachidonic acid metabolites, such as prostaglandin D2 (PGD2), leukotriene 
B4 (LTB4) and LTC4 (Galli et al., 2008a; Li-Weber et al., 2003), as well as the later 
production of many cytokines, chemokines and growth factors such as IL-1, IL-3, IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-11, IL-13, GM-CSF, TNF-α, TGF-β, basic fibroblast growth factor (b-
FGF), vascular endothelial growth factor (VEGF) and NGF (Minai-Fleminger et al., 2009).  
These mediators are responsible for the increase in microvascular permeability and 
contraction of smooth muscle, which may account for the bronchoconstriction seen in asthma. 
Concomitantly, the recruitment of macrophages, T lymphocytes and eosinophils takes place 
(Galli et al., 2008b). These cytokines and chemokines liberated by the inflammatory cells in 
the early phase initiate the “late phase” that usually peaks a few hours later (Bloemen et al., 
2007; Gould et al., 2008). The release of these mediators is tightly controlled by signalling 
pathways that are propagated through the cell by specific phosphorylation and 
dephosphorylation events. IgE-dependent activation is mediated through a complex cascade 
of signal transduction initiated by tyrosine-protein kinase Lyn (Lyn), spleen tyrosine kinase 
(Syk) and Fyn kinases from the Src family (Roth et al., 2008). Mast cells homeostasis is 
controlled by IgE, IL-4, IL-10 and TGF-β1, which down regulate important effector proteins 
such as c-Kit and FcεRI in long-term mast-cells cultures (Ryan et al., 2007). Among the 
mediators released by mast cells, the lipid mediators as well as histamine have an essential 
role in the recruitment of Th2 lymphocytes and of eosinophils to the inflammatory site and in 





Macrophages are the most abundant immune cell population in normal lung tissue and 
serve critical roles in innate and adaptive immune responses. Macrophages exert its prominent 
defensive effects of the respiratory tract from airborne pathogens. Macrophages are 
specialized to recognize, phagocytose, and destroy these infectious agents and then promote 
appropriate tissue repair after successful pathogen clearance (Byers et al., 2011). 
Macrophages also play an important role in the pathogenesis of asthma. Studies have 
suggested that macrophages could be directly involved in the development of AHR as 
macrophages modulate the contractility of ASM by inducing histamine release from mast 
cells and basophils, by augmenting cholinergic neurotransmission via the generation of 
thromboxane A2, and by impairing airway β-adrenergic function through the production of 
oxygen radicals (Yang et al., 2012). Activated macrophages may also be an important effector 
cells in airway inflammation as experimental model of an acute exacerbation of chronic 
asthma have demonstrated that macrophages can stimulate Th2 cytokine secretion by primed 
CD4
+
 T lymphocytes via mechanisms involving the expression of CD80/86 costimulatory 
molecules (Herbert et al., 2010). 
Alveolar macrophages (AMs) and interstitial macrophages (IMs) represent the 2 major 
populations of macrophages that occupy different compartments in the lung (Moreira et al., 
2011). AMs are found in alveoli lumen, presiding a nonspecific innate defence mechanism 
while IM inhabit the interstitium where they interact with interstitial lymphocytes and help in 
mounting a specific immune response. In general, IMs are considered as antigen-presenting 
macrophages, but when AMs are primed with allergen ex-vivo, they can also help in 
expanding allergen-specific T-lymphocytes response (Balhara et al., 2012). AM can be 
derived from circulating blood monocytes, which colonize the tissues under inflammatory and 




macrophages, the IMs, which serve as obligate intermediate between blood monocytes and 
AMs (Yang et al., 2012).  Local proliferation in human and murine airways is also sustained 
by colony-stimulating factor (CSF) (Balhara et al., 2012). The monocytes migrate to the lungs 
in response to chemoattractants such as monocyte chemotactic protein-1 (MCP-1/CCL2), 
acting on C-C chemokine receptor type 2 (CCR2) (Deshmane et al., 2009). 
Generally, macrophages (including AMs and IMs), are exhibit unique activation 
patterns upon exposure to cytokines and/or toll-like receptor (TLR) agonists. Two such 
subpopulations have been extensively studied and these are the classical (M1) and 
alternatively activated (M2) macrophages (Mantovani et al., 2009). M1 macrophages are 
differentiated by IFN-γ and lipopolysaccharide (LPS) in both mice and humans (Joshi et al., 
2010; Moreira et al., 2010). M1 macrophages release inflammatory cytokines and chemokines 
such as IL-6, IL-12, TNF-α, interferon-γ-inducible protein 10 (IP-10/CXCL10), and 
Macrophage inflammatory protein-1α (MIP-1α/CCL3). These cells also produce high levels 
of nitric oxide (NO) and are known to drive inflammation in response to intracellular 
pathogens (Cassol et al., 2009). The Th2 cytokines IL-4 and IL-13 are involved in the 
polarization of alternatively activated (M2) macrophages (Moreira et al., 2011). Both mouse 
and human M2 macrophages have enhanced expression of scavenger and mannose receptors 
(Varin et al., 2010), and increased phagocytic activity of foreign pathogens and apoptotic 
cells (Mills et al., 2000), but are inept at the clearance of intracellular pathogens (Schuh et al., 
2003). Besides the classical M1 and M2 macrophages stimuli, other factors such as IL-10 and 
TGF-β or immune-complexes are also involved in polarizing the macrophage phenotype (Liu 
et al., 2011). The polarization of M2 macrophages by IL-4 and IL-13 is dependent on the 
induction of signal transducer and activator of transcription 6 (STAT6), which leads to the 
activation of pro-fibrotic cytokines, chitinase-like molecules (Moreira et al., 2010), and 




are shown to be involved in the developments of asthma although M2 are intuitively present 
given the Th2-driven lung environment in asthma (Moreira et al., 2011). The pro-
inflammatory cytokines IL-1β and IL-6 produce by the M1 macrophages have direct effects 
on Th2 lymphocytes proliferation (Doganci et al., 2005), and promote fibroblast activation 
(Gallelli et al., 2008). The recruitment and the survival of eosinophils in the lung is increase 
by IL-1β and IL-6 as both of this cytokine increase the production of GM-CSF by 
macrophages and fibroblast (Ilmarinen-Salo et al., 2010). M1 polarized macrophages are 
consider as a component of asthma exacerbation (Moreira et al., 2011). M2 polarized 
macrophage on the other hand are potent inflammatory cells release pro-fibrotic and pro-
inflammatory factors, that can cause increased inflammatory cell recruitment, mucus secretion, 
and AHR in asthma (Moreira et al., 2011). 
 
Epithelial Cells 
Airway epithelium is an important controller of inflammatory, immune and 
regenerative responses to allergens, viruses and environmental pollutants that contribute to the 
pathogenesis of asthma. Airway epithelial cells (ECs) represent the first line of defence 
against microorganisms, gases and allergens as they lie at the interface between the host and 
the environment (Xiao et al., 2011). As a barrier to the external environment, ECs express 
many pattern recognition receptors (PRRs) such as TLRs, NOD-like receptor (NLR), C-type 
lectins and protease-activated receptors (PAR) that rapidly detect and react to pathogen-
associated molecular patterns (PAMPs) originate from microbes or to damage-associated 
molecular patterns (DAMPs) released upon tissue damage, cell death or cellular stress 
(Lambrecht et al., 2012). Epithelial PRRs activation leads to the release of cytokines, 
chemokines and antimicrobial peptides that attract and activate innate and adaptive immune 




recent studies have demonstrated that EC activation is a play a central role in influencing the 
recognition of inhaled allergens that activates the local network of dendritic cells (DCs), 
which coordinate the ensuing immune response, and thereby bridging innate and adaptive 
immunity (Hammad et al., 2008). Human respiratory EC express huge number of TLRs and 
have been shown to react functionally to a number of TLR ligands. Upon ligand engagement, 
TLRs signal via a series of adaptor proteins, leading to the activation of transcription factor 
nuclear factor-κB (NF-κB) and the subsequent production of the expression of an array of 
inflammatory cytokine genes (Sha et al., 2004). Intriguingly, studies have demonstrated that 
the recruitment, activation and intraepithelial migration of DCs in response to inhaled 
endotoxin require only epithelial Toll-like receptor 4 (TLR4) triggering (Hammad et al., 
2009). The crucial role of NF-κB in regulating of airway inflammation was elucidated in mice 
deficient in the NF-κB subunits p50 or p65, which demonstrated reduced responses to 
endotoxin and allergens (Yang et al., 1998). Recent studies have also shown that constitutive 
activation of NF-κB in airway ECs was sufficient to activate DCs, breach inhalational 
tolerance and promote sensitization to OVA (Ather et al., 2011; Sheller et al., 2009), while 
inhibition of epithelial NF-κB in the contrary reduced Th2 lymphocytes recruitment and 
airway remodelling (Broide et al., 2005). Th2 effector cytokines may subsequently sustained 
the epithelial responses to allergens and provides an important feedback loop that can 
perpetuate disease (Lambrecht et al., 2012). IL-4 and IL-13 induce airway ECs to produce 
GM-CSF and the chemokines IL-8 (CXCL8), which attract neutrophils, eotaxin-1 (CCL11) 
which attract eosihophils and thymus and activation regulated chemokine (TARC/CCL17) 
which attract Th2 lymphocytes (Lordan et al., 2002). Hence it is evidence that airway ECs 







Mediators of Asthma  
 
Figure 1.3 Cytokines involved in asthma. Myeloid dendritic cells processed the allergens 
are by release the chemokines CC-chemokine ligand 17 (CCL17) and CCL22, which act on 
CC-chemokine receptor 4 (CCR4) to attract T helper 2 (TH2) cells. Th2 cells have a central 
role in orchestrating the inflammatory response in allergic asthma through the release of IL-4 
and IL-13 (which stimulate B cells to synthesize IgE), IL-5 (which is necessary for 
eosinophilic inflammation), and IL-9 (which stimulates mast cell proliferation). Epithelial 
cells play an important role in orchestrating the inflammation of asthma through the release of 
various cytokines. Epithelial cells release stem-cell factor (SCF), which is important for 
maintaining mucosal mast cells at the airway surface. Epithelial cells may also release CCL11, 
which recruits eosinophils via CCR3.  Inhaled allergens activate sensitized mast cells by 
crosslinking surface-bound IgE molecules to release several bronchoconstrictor mediators, 
including histamine, cysteinyl leukotrienes (CysLTs) and prostaglandin D2 (PGD2). Adapted 




1.2.2.2 Mediators of Asthma  
Th2 Cytokine 
Th2 cytokine play a vital role in the development of atopic asthma as the expression of 
Th2 cytokines could be related to activity of disease, symptom scores, airway eosinophilia, 
and airway hyperresponsiveness (Georas et al., 2005). In addition, the expression of Th2 
cytokines are increased after allergen inhalation challenge in patients with atopic asthma and 
decreased with corticosteroid treatment (Lloyd et al., 2010). The main Th2 cytokines involved 
are those encoded by the IL-4 gene cluster, which contains the genes encoding IL-4, IL-5, IL-
9, IL-13, and GM-CSF on chromosome 5q31-q33. This cluster of cytokine genes is co-
regulated, providing coordination of the allergic cascade (Robinson, 2010). Studies in mouse 
models in which Th2 cytokines such as IL-4, IL-5, IL-9 or IL-13 have been individually 
genetically knocked out or immunologically block antibodies have provided important 
evidence that the Th2 axis can drive eosinophilic airway inflammation and AHR (Lloyd et al., 
2010). When Th2 lymphocytes failed to develop in response to antigen, such as in IL-4Rα−/− 
or Stat6
−/−
 mice, allergic airway inflammation is not induced (Cohn et al., 2004). Both IL-4 
and IL-13 have a crucial role to promote isotype switching of B cells to IgE and goblet cell 
metaplasia by acting on epithelia,  whereas IL-4, but not IL-13, is crucial for maintaining the 
Th2-lymphocytes phenotype (Oettgen, 2000).  
IL-5 is a cytokine that play a key role in eosinophil differentiation, recruitment, 
activation, and survival at sites of allergic inflammation. Systemic and local (inhaled) 
administration of IL-5 to asthmatic patients results in an increase in circulating eosinophils 
(Stirling et al., 2001). Additionally, IL-5, which is mainly produced by Th2 lymphocytes and 
to a lesser degree by activated mast cells, is also involved in B-cell differentiation (Wegmann, 
2011). The expression of IL-5 is elevated in BAL fluid in patients with asthma and the level 




al., 2007). The roles of IL-5 underlying the pathogenesis of asthma have been demonstrated 
by a number of in vivo studies. Mice deficient for IL-5 do not develop the eosinophilia, lung 
damage, and airways hyperreactivity normally resulting from ovalbumin (OVA) sensitization 
and aeroallergen challenge (Foster et al., 1996). Similarly, the IL-5 receptor α-chain (IL-5R 
alpha)-deficient mice demonstrated an impaired IL-5 induce eosinophilia in response to 
parasitic infections (Yoshida et al., 1996). Furthermore, mice that constitutively 
overexpressed IL-5 in the lung spontaneously developed prominent airway eosinophilia 
associated with AHR (Lee et al., 1997). When IL-5 was targeted by antisense molecules or by 
an anti–IL-5 monoclonal antibody (mAb), significant reduction of airway eosinophilia and 
consequently the pathologic features of experimental asthma, including AHR was observed 
(Hamelmann et al., 1997; Lach-Trifilieff et al., 2001). In spite of these encouraging in vivo 
results, clinical trials with the anti–IL-5 monoclonal (mAb), mepolizumab reported a 
reduction in blood and sputum eosinophils in patients with mild-to-moderate asthma but lack 
of improvement in asthmatic symptoms, AHR, and allergic late-phase response (Flood-Page 
et al., 2007; Leckie et al., 2000). Although the outcomes of these clinical trial prompted 
discussion about the role of eosinophils in the pathogenesis of asthma, more recent clinical 
trials that investigated the therapeutic effect of mepolizumab in patients with severe 
corticosteroid-refractory and highly eosinophilic form of asthma, have shed new light on the 
role of eosinophils in asthma and especially in distinctive asthma phenotypes (Haldar et al., 
2009; Nair et al., 2009). Both of these clinical studies have reported a significantly reduced 
exacerbation rate and a reduction in blood and sputum eosinophils. As such, these studies also 
indicate the need of distinguishing distinct asthmatic phenotypes that might require different 
therapeutic approaches.  
IL-9 is involved in the onset and progression of asthma and IL-9 is detected in 
biopsies from patients with asthma and localizes to CD4
+




several other cellular sources of IL-9, including mast cells and eosinophils (Soroosh et al., 
2009). Biological targets for IL-9 include mast cells, B lymphocytes, T lymphocytes, T 
lymphocytes clones, hemopoietic progenitors, and immature neuronal cell lines (Steenwinckel 
et al., 2007). Overexpression of IL-9 in mice induces inflammation mediated by eosinophils, 
mucus hyperplasia, mastocytosis, AHR, and increased expression of other Th2 cytokines and 
IgE (Zhou et al., 2001). Targeting IL-9 with antibody inhibits pulmonary eosinophilia, mucus 
hypersecretion, and AHR after allergen challenge of sensitized mice.  The effects of IL-9 in 
mice such as pulmonary eosinophilia and mucus hypersecretion are mediated via the release 
of IL-13, whereas its effects on mastocytosis and B lymphocytes lung infiltration seem to be 
direct (Steenwinckel et al., 2007). IL-9 plays an key role in differentiation and proliferation of 
mast cells and interacts synergistically with SCF (Barnes, 2008a). The presence of IL-9 in 
mouse and human is highly associated with mast cell accumulation in the airways, as well as 
AHR and globlet cell metaplasia (Lambrecht et al., 2009).  
IL-13 induces AHR and mucus hypersecretion by activating STAT6 in the airway 
epithelium (Kuperman et al., 2002) and produces several of the structural changes seen in 
chronic asthma, including goblet cell hyperplasia, airway smooth muscle proliferation and 
subepithelial fibrosis (Wills-Karp, 2004). IL-13 also increases the expression of acid 
mammalian chitinase (AMCase) and neutralization of AMCase inhibits IL-13 mediated AHR 
and Th2-driven inflammation (Zhu et al., 2004). The airways of asthmatic patients have an 
increased expression of IL-13. Additionally, there is a transient increase in IL-4 in BAL fluid 
after allergen challenge, whereas the secretion of IL-13 is sustained and correlates with the 
increase in the number of eosinophils in the airways (Barnes, 2008a). In addition to Th2 cells, 







The IL-17 family consists of six members in mammals including IL-17 (now 
synonymous with IL-17A), IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-
17F. Among the IL-17 family members, the most investigated cytokine is IL-17 (Park et al., 
2010). IL-17 and IL-17F share the greatest similarity showing 50% identity at the amino acid 
level. Genes encoding IL-17 and IL-17F are located on chromosome 1-A4 region in mice and 
on chromosome 6p12 location in humans. IL-17 and IL-17F may have derived via a gene 
duplication event owing to their sequence similarity and proximity in the genome (Pappu et 
al., 2008). Other than Th17 lymphocyte, other cell types such as CD8
+ T cells, γδ T cells, and 
natural killer T cells also produce IL-17 while eosinophils, neutrophils, macrophages, and 
monocytes can also be sources of IL-17 in some cases (Park et al., 2010).  
Similar to the IL-17 cytokine family, IL-17 receptors form a unique family composed 
of five members which are IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE (Gaffen, 
2009). The IL-17 receptor (IL-17R, renamed IL17-RA) is ubiquitously expressed and ligand 
binding causes secretion of pro-inflammatory cytokines and chemokines such as IL-8, IL-6, 
growth-related oncogene α (GROα/CXCL1), macrophage inflammatory protein-2-beta (MIP-
2β/CXCL3), CXCL5 and granulocyte chemotactic protein 2 (GCP-2/CXCL6) (Nograles et al., 
2008). Signaling through the IL-17R is critically required to develop allergic asthma since IL-
17R-deficient mice fail to develop allergic asthma in response to intranasal ovalbumin (OVA) 
after intraperitoneal sensitization (Souwer et al., 2010). 
IL-17 exerts a wide variety of biological activities due to ubiquitous distribution of its 
receptor (Pappu et al., 2008). IL-17 plays an important role in driving allergic inflammation. 
IL-17 has been reported in the lungs, sputum, and BAL fluid of asthma patients (Park et al., 
2010). The up-regulation of IL-17 mRNA expression in the airways of an asthma mouse 




asthma (Hellings et al., 2003). Recent Study have reveal that inhibition of IL-17 by 
administration of IL-17-specific antibody resulted in significantly less AHR and fewer 
neutrophils in the BAL fluid and administration of recombinant IL-17 to mice increased their 
susceptibility to AHR (Lajoie et al., 2010). Activation of the IL-17RA by the binding of IL-17, 
activates NF-κB and MAPK pathways (Park et al., 2010). IL-17 orchestrate local 
inflammation by inducing the release of proinflammatory cytokines such as TNF-α, IL-1β, 
granulocyte colony-stimulating factor (G-CSF) production by bronchial fibroblasts and 
epithelial and airway smooth muscle cells. Additionally, IL-17 can act in synergy with IL-6 to 
induce mucus proteins (Muc5B and Muc5AC) or with IL-1β and TNF-α to enhance Vascular 
endothelial growth factor (VEGF) (Wang et al., 2008). Moreover, IL-17 induces the 
expression of not only eosinophil-guiding chemokines like regulated and normal T cell 
expressed and secreted (RANTES/CCL5) and eotaxin (CCL11) but also other inflammatory 
mediators like intercellular adhesion molecule 1 (ICAM-1) and cyclooxygenase-2 (COX-2). 
Taken together, IL-17 acts as an orchestrating cytokine in immune and inflammatory 
responses. 
Blockade of IL-17 activity with anti-IL-17 monoclonal antibody that is injected before 
allergen inhalation bronchial neutrophilic influx are significantly reduced. Because 
neutrophils may be important in airway remodeling in chronic severe asthma, targeting IL-17 
may hold therapeutic potential in human asthma (Hellings et al., 2003). Receptors for IL-17 
such as IL-17RA and IL-17RC may be the other possible targets for inhibition of IL-17 
activities as human bronchial epithelial cells pretreated with anti-IL-17R antibody 
demonstrated a decrease in IL-17 activity (McAllister et al., 2005). A soluble form of IL-
17RC, which binds to IL-17 and IL-17F with high affinity, has been shown to inhibit the 
signalling of IL-17 in fibroblast (Kuestner et al., 2007). Based on these data, the therapeutic 





IL-33, also called IL-1F11 or nuclear factor from high endothelial venules (NF-HEV), 
is a member of the IL-1 family of cytokine (Joshi et al., 2010; Prefontaine et al., 2010). IL-33 
is an inducer of the Th2 branch of adaptive immunity and signals through a complex 
membrane bound interleukin 1 receptor-like 1 (IL1RL1/ST2) protein (Schmitz et al., 2005). 
The IL-33/ST2 pathway also contributes to allergen-induced airway inﬂammation and AHR 
(Kearley et al., 2009), both important features of asthma. The IL-33/ST2 axis triggers the 
release of several proinﬂammatory mediators, such as chemokines and cytokines, and induces 
systemic Th2-type inﬂammation in vivo (Schmitz et al., 2005). In the presence of antigen, IL-
33 binds the surface receptor ST2 and polarized naïve CD4+ T lymphocytes into a population 
of T lymphocytes which produce IL-5 and IL-13, but not IL-4. This polarization are 
modulated by ST2 receptor and myeloid differentiation primary response gene (88) (MyD88), 
but not IL-4 or signal transducer and activator of transcription 6 (STAT6). The IL-33-induced 
T-lymphocytes differentiation is also dependent on the phosphorylation of mitogen-activated 
protein kinase and NF-κB, but not the induction of GATA-binding protein 3 (GATA3) or T 
lymphocytes–specific T-box transcription factor (T-BET) (Kurowska-Stolarska et al., 2008). 
Additionally, IL-33 also acts as a selective chemoattractant of Th2 lymhocytes (Komai-Koma 
et al., 2007). Aside from Th2 lymphocytes, ST2 is present on mast cells, basophils, 
eosinophils, macrophages, and ECs (Prefontaine et al., 2010). Human macrophages 
constitutively expressed the membrane-associated (ST2L) and the soluble (sST2) ST2 
receptors. Studies has demonstrated that bone marrow derived human macrophages primary 
responses to IL-33 by skewing in favours of M1 chemokine generation while IL-33 addition 
to polarized human macrophages promotes or amplifies M2 chemokine expression, thus 
signifying that IL-33 might amplify allergic responses by promoting an overall activation of 




ECs released IL-33 (Chustz et al., 2011). IL-33 is typically sequestered in the nucleus of ECs, 
but it can be secreted upon epithelial activation. IL-33 activates lung DCs during antigen 
presentation and thereby drives a Th2-type response in allergic lung inflammation by acting 
on the ST2 receptor (Besnard et al., 2011). By blocking IL-33, the development of Th2 
response due to sensitization to inhaled antigens by DCs was abolished (Lambrecht et al., 
2000). The expression of IL-33 is higher in airway ECs of subjects with asthma (Prefontaine 
et al., 2010). Taken together, these data support a role for IL-33 in the pathogenesis of allergic 
asthma. 
 
Tumour necrosis factor-alpha (TNF-α) 
TNF-α is a pro-inflammatory cytokine that has been implicated in many aspects of the 
airway pathology in asthma. Induced sputum and BAL fluid from asthmatic patients have 
elevated levels of TNF-α (Obase et al., 2001). An up-regulated expression of TNF-α has also 
been detected in alveolar macrophages, mast cells, leukocytes and bronchial epithelial cells 
(Ackerman et al., 1994; Cembrzynska-Nowak et al., 1993; Gosset et al., 1991; Ying et al., 
1991). Expression of TNF-α in the asthmatic airway play an important role in amplifying 
inflammation by the activation of NF-κB and the expression of numerous immune and 
inflammatory response genes (Berry et al., 2007). TNF-α induces the expression of multiple 
airway epithelial genes, including cytokines (IL-5, GM-CSF), chemokines (eotaxin, MCP-1, 
RANTES), adhesion molecules (ICAM-1) and mucins (Muc5AC) (Matera et al., 2010). Other 
than increasing the epithelial expression of adhesion molecules, TNF-α is also a 
chemoattractant for neutrophils and eosinophils (Lukacs et al., 1995). Furthermore, TNF-α 
directly induces histamine release from human mast cells (van Overveld et al., 1991) and 
induce transient AHR (Thomas et al., 1995). Additionally, TNF-α stimulate T lymphocytes 




responsiveness in monocytes and up-regulates the pathways involved in chronic airway 
remodelling and subepithelial fibrosis (Hansbro et al., 2011). Several humanized anti-TNF-α 
neutralizing antibodies (infliximab, adalimumab and golimumab) are available (Desai et al., 
2009). Nonetheless, the research article which demonstrated that infliximab could suppress 
exacerbations in patients with moderate asthma has recently been retracted (2011; Erin et al., 
2006). Blocking of TNF-α with etanercept, which is a human soluble TNF-α receptor (TNFR), 
attenuated AHR and improved lung function in a small study of patients with refractory 
asthma. However, serious concerns remain over the safety of TNF-α blockade, which may 
increase susceptibility to respiratory infection (Berry et al., 2006). 
 
Chemokines and Adhesion Molecules  
During inflammation, leukocytes are recruited into tissues by adhesion molecules and 
chemokines. At sites of inflammation, cytokines produced in the tissue induce endothelial cell 
adhesion molecule expression. The vascular recruitment of leukocytes is a three-step process 
involving low affinity rolling of leukocytes on the endothelium followed by arrest of the 
leukocyte on the endothelium through high affinity adhesion, and the subsequent 
transmigration of the leukocyte through the endothelium. The rolling of leukocytes on the 
vessel wall is mediated by selectins. Selectins are a family of calcium-dependent, type I 
transmembrane glycoprotein family of adhesion molecules (McEver, 2002). The low-affinity 
nature of selectins allows the characteristic "rolling" action of leukocytes. Currently known 
selectins include E-selectin, P-selectin, and L-selectin, named for the cell type in which they 
were originally identified: endothelium, platelet, and leukocyte respectively. IL-1, LPS and 
TNF-α mediate the expression of E-selectin by endothelium (Kelly et al., 2007). Additionally, 
rolling can also be mediated by very late antigen 4 (VLA4) (which is also known as leukocyte 




(VCAM-1) on the endothelium (Alon et al., 1995). Binding of selectins on leukocytes 
increases the affinity of the integrin family of receptors that then bind to the endothelial cell 
adhesion molecules such as ICAM-1 or VCAM-1 which are up regulated by Th2 cytokines 
(Cook-Mills et al., 2011). The high affinity integrin binding of leukocytes mediates the arrest 
of the leukocytes on the endothelium, and the subsequent migrate on chemokine gradients 
into the tissue. While both neutrophils and eosinophils bind to E-selectin, the chemokine 
provided the specificity for leukocyte cell type base on the chemokine receptors it has. 
Eotaxin (CCL11) selectively recruits eosinophils by binding to CCR3 which is not expressed 
by neutrophil and monocytes (Baggiolini et al., 1997).  
Regulated upon activation in normal T cells, expressed, and secreted (RANTES/CCL5) 
are crucial to the delivery of eosinophils and T lymphocytes into the airways during asthma 
and during OVA-induced allergic airway disease (Hogan et al., 2008). RANTES which is 
produced by endothelial cells, fibroblasts, T lymphocytes, eosinophils, platelets and other 
cells (Zhang et al., 2010), may activate cells by binding to CC chemokine receptor-1 (CCR1), 
CCR3, or CCR5, which it shares with other chemokines (Schuh et al., 2003). Although 
RANTES was constitutively expressed in the airways, it expression was elevated in patients 
with asthma (Zhang et al., 2010). 
Monocyte chemotactic protein-1 (MCP-1/CCL2) recruits monocytes and T 
lymphocytes to the sites of inflammation and it is produced by bronchial epithelial cells, 
macrophages, and smooth muscle cells. Levels of MCP-1 are elevated in the airways of 
asthmatics (Sutcliffe et al., 2009). Moreover, IL-13-induced inflammation in mice is 
associated with an increase in MCP-1 release and that the disease process is attenuated in 
MCP-1 hematopoietic cell receptor CC chemokine receptor 2 (CCR2) knockout mice (Zhu et 




cells or basophils, induce production of transforming growth factor-β (TGF-β) and 
procollagen by fibroblast and enhance Th2 lymphocytes polarization (Melgarejo et al., 2009).  
 
Chitinases  
Chitinases have been suggested to play a pivotal role in Th2-mediated allergic 
diseases such as asthma (Guan et al., 2009; Sutherland et al., 2009). Chitinases such as 
chitotriosidase and acidic mammalian Chitinase (AMCase) are enzymes that degrade chitin, 
the second most abundant biopolymer that is an essential structural component of the fungal 
cell wall and is present in the exoskeleton of arthropods and the microfilarial sheath of 
nematodes (Tharanathan et al., 2003). There are also chitinase-like proteins such as YKL-40, 
Ym1 and Ym2 that lack chitinolytic activity but retain chitin-binding ability. Although 
chitinases were originally believed to function in host defense against parasitic infections, 
there is currently ample evidence to support an association of acidic mammalian chitinase and 
YKL-40 with allergic asthma.  Zhu and coworkers reported the first clinically relevant finding 
regarding the role of chitinase in asthma (Zhu et al., 2004) where exaggerated quantities of 
AMCase were detected in the epithelial cells and macrophages of lung biopsies taken from 
patients with asthma. Subsequently, utilizing a 2D gel electrophoresis proteomics approach, a 
concurrent elevation of the BAL fluid protein level of AMCase, Ym1 and Ym2 was also 
observed in a OVA-induced mouse asthma model (Zhao et al., 2005). On the contrary, there 
is no change observed in chitotriosidase protein level in BAL fluids. In addition to AMCase, 
serum and lung tissue levels of a chitinase-like protein YKL-40 have been found to be 
increased in patients with asthma. Moreover, circulating YKL-40 levels correlated positively 
with asthma severity, thickening of the lung subepithelial basement membrane, frequency of 
rescue inhaler use, and deterioration in pulmonary function in asthmatic subjects studied 




dependent allergic airway inflammation, and the AMCase level may be useful for monitoring 
the effectiveness of anti-inflammatory therapy in asthma. 
 
1.2.2.3 Airway Hyperresponsiveness (AHR) 
Physiologically, airway responsiveness describes the ability of the airways to narrow 
after exposure to constrictor agonists. AHR consists of an increased sensitivity of the airways 
to constrictor agonists, which is presented by a smaller concentration of a constrictor agonist 
needed to initiate the bronchoconstrictor response, a steeper slope of the dose-response and a 
higher maximal response to the agonist (Jiang et al., 2012; O'Byrne et al., 2003). AHR is 
therefore an exaggerated constriction of the airways in response to bronchoconstrictor stimuli. 
Viral-induced exacerbations, allergen exposure and occupational exposures can also briefly 
enhance the underlying AHR in individual patients. AHR has been identified as an important 
feature in patients with current, symptomatic asthma and AHR is regarded as a key diagnostic 
criterion of asthma (Bousquet et al., 2007; Busse, 2010). Clinically, AHR is documented by a 
decreased bronchial airflow after inhalation challenge with methacholine or histamine as the 
severity of AHR correlates with the severity of asthma and with the amount of treatment 
needed to control symptoms; The patients with more severe airway disease often have a 
greater degree of AHR  (Galli et al., 2008b). Conversely, an improvement in AHR is 
associated with better control of asthma (Busse, 2010). Thus, the methods for measuring 
airway responsiveness have been standardized and are widely accepted.  
To understand the components that comprise AHR, the factors that contribute to AHR 
has been suggested to be divided into two categories, the persistent and the variable AHR 
(Busse, 2010; Covar, 2007; O'Byrne et al., 2009). The persistent aspects of AHR have been 
largely attributed to structural changes in the airway, particularly in those patients with more 




thicker, less compliant, and more narrowed, all features associated with a greater degree of 
constriction and closure when stimulated by contractile substances. The variable component 
of AHR is believed to relate to inflammatory events in the airway, which are variable and 
influenced by numerous environmental events such as exposure to allergens, respiratory 
infections and treatment. Nonetheless, it is understood that these processes are interrelated 
and likely to be interdependent. Hence, the level of AHR represents both collective and 
synergistic events in the airway and is the result of multiple processes (Busse, 2010).  
 
1.2.3 The mouse model of asthma  
Studies in animal models form the basis for much of our current understanding of the 
pathophysiology of asthma, and are central to the development of drug therapies. While there 
are comparative dissimilarities in genetics, immunology, anatomy and physiology, the use of 
laboratory animals clearly allows investigators to test hypothesis about the causal mechanisms 
underlying disease in ways that cannot be done in man.  
We use mouse asthma model in our study as it has the benefit of being easy to handle, 
together with its obvious practical advantages related to cost and gestation period (Corry et al., 
2006). The mouse has also become the species of choice for our studies because of the 
availability of immunological and molecular tools available to study them as the entire mouse 
genome has been sequenced, and the variety of in-bred strains with different phenotypic traits. 
Our research focused primarily on generating allergic inflammation by sensitizing and 
challenging animals with OVA, leading to an acute inflammatory response and airways 
hyperresponsiveness. The protocol starts by systemically sensitising the animals via 
intraperitoneal injections separated by one week to ovalbumin OVA absorbed onto an 
adjuvant. Aluminium hydroxide (Al(OH)3) was used as the adjuvant as it primes the immune 




exposure to the airways via aerosol administration one week after the last sensitisation. These 
models have provided important insights into the nature of the allergic airway inflammation, 
particularly the significance of the Th2 phenotype in this disease and have been useful in the 
identification of potential drug targets for interventions involving allergic pathways. 
Nonetheless, mouse models are not exact replicas of human asthma. There are a 
number of issues with existing animal models of asthma that must be recognized including the 
requirement for adjuvant during senitisation in most models, the acute nature of the allergic 
response that is induced and the use of adult animals as the primary disease model. It has also 
been proposed that chronic OVA exposure leads to tolerance and poorly maintained 
inflammation, possibly through the induction of Treg lymphocytes, which limits the ability to 
mimic the chronic aspect of asthma and the associated airway remodelling (Stevenson et al., 
2011). 
That being said, the OVA-induced allergic lung inflammation mouse model can 
replicate many of the central features of allergic asthma including increased specific IgE 
production, mucus hypersecretion, bronchoconstriction responses, a Th2-biased inflammation 
rich in eosinophils and nonspecific AHR. Observations from mouse models of allergic asthma 
support many existing paradigms, and therefore it is utilized to examine our hypotheses.  
 
1.2.4 Current Treatment  
The treatment for current asthmatic patients includes the use of medication for short-
term relief, the daily use of preventive medication to avert attacks, monitoring of early 
symptoms, avoiding factors that trigger attacks and removing risks such as tobacco smoke or 
mould from the environments (Akinbami et al., 2011). As the airway obstruction of asthma is 
due to inflammation and AHR, bronchodilating and anti-inflammatory therapy is usually 




adrenoceptor agonists are now the mainstay of asthma treatment. Inhaled glucocorticoids are 
the priority for asthma treatment as airway inflammation in asthma responds well to steroid. 
On the other hand, if an asthma patients only have a mild intermittent asthma, the patient will 
only be treated with short-acting inhaled β-2-selective agonist such as salbutamol (Cazzola et 
al., 2011). Asthma is a disease that can be managed with the use of anti-inflammatory therapy 
as a huge portion of asthmatic patients are reasonably well controlled with inhaled 
corticosteroids, cysteinyl leukotriene receptor antagonists and/or injections of anti-IgE 
antibody, omalizumab. Theophylline has also been used as a bronchodilator, but the cardiac 
and central nervous system side effects and relative low efficacy have led to a marked 
reduction in its use (Hansel et al., 2004).  
The cysteinyl leukotrienes (CysLTs), leukotrienes (LT) C4, D4 and E4 are one of the 
most potent contractile agonists of airway smooth muscle. By interacting with the Cysteinyl 
leukotrienes receptor 1 (CysLT1), they increasing vascular permeability and stimulate mucus 
secretion, all of which would induce an acute asthmatic attack. Corticosteroids treatments are 
not effective against the biosynthesis and the actions of cysteinyl leukotrienes (Gyllfors et al., 
2006). The currently available oral cysteinyl leukotrienes receptor 1 antagonists such as 
montelukast are not only beneficial in treatment of chronic asthma (Reiss et al., 1998), it has 
also recently found to be effective in acute asthma exacerbation (Ramsay et al., 2011). 
Although CysLTs antagonists can be used as a monotherapy in mild to moderate asthma, their 
main use is as an adjunct therapy to inhaled corticosteroids (Polosa, 2007) as these drugs are 
generally less effective than inhaled glucocorticoids (Montuschi et al., 2010).  
Although inhaled corticosteroids are effective at suppressing airway inflammation, 
they do not influence the natural history of the disease, even when the corticosteroids 
treatment is started early in childhood (Bisgaard et al., 2006; Guilbert et al., 2006). Moreover, 




Inhaled corticosteroids are also not effective in virus-induced exacerbations (Harrison et al., 
2004) and in those asthmatics who smoke (Chaudhuri et al., 2003). The failure of 
corticosteroids to decrease the level of expression of TNF-α in asthmatic airways might 
explain why corticosteroids have limited effects in more severe forms of the disease (Truyen 
et al., 2006). 
Despite intensive use of these anti-inflammatory interventions, 5–10% of asthmatics 
have severe asthma, which does not respond to treatment, and continue to have significant 
disabling and/or life-threatening symptoms (Moore et al., 2007). Patients with severe asthma 
account for 50% of asthma-related healthcare costs (Yang et al., 2012). Severe corticosteroid-
refractory asthma patients face the greatest morbidity and mortality. There are currently 
limited therapeutic option for patients whom only have incomplete control and thus, it is 
imperative to derive novel treatment for this group of patients. 
 
1.3 Chronic obstructive pulmonary disease (COPD) 
COPD is a disease state characterized by slow and progressive development of airflow 
limitation that is not fully reversible, in sharp contrast to asthma where there is variable 
airflow obstruction that is usually reversible spontaneously or with treatment. The airflow 
limitation is associated with dysregulated inflammatory response of the lungs to noxious 
particles or gases (Naeije, 2005).  Physiologically, the chronic airflow limitation is reflected 
by reducing expiratory flow, such that a slow forced expiration is required to empty the lungs.  
The severity of COPD is defined by the most popular classification of COPD, the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification (Rabe et al., 
2007) which is based on the forced expiratory volume in 1 second (FEV1) as the most 
important criterion, categorize patients into 4 stages, described as mild (I), moderate (II), 




II due to the chronic respitory symptoms or an exacerbation of their disease but are usually 
unaware of lung function abnormality during stage I. Stage III is characterized by further 
worsening of airflow limitation, greater shortness of breath, reduce exercise capacity, fatigue, 
and repeated exacerbations that almost always have an impact on patients' quality of life. At 
the most severe stage of COPD, stage IV, respiratory failure may occur and quality of life is 
very appreciably impaired and exacerbations may be life threatening (GOLD, 2011). In 
current clinical practice, COPD is diagnosed and monitored via symptoms, lung function and 
the assessment of responses to inhaled pharmacological agents (Rabe et al., 2007). 
The deterioration of lung function in COPD is associated with chronic obstructive 
bronchitis and emphysema that commonly co-exist. Bronchitis, which is an inflammation of 
the bronchus, is resulted from structural remodelling of the lung that includes the narrowing 
of the small airways due to peribronchiolar fibrosis and luminal obstruction by inflammatory 
mucus exudates (Dournes et al., 2012). Airway obstruction occurs long before the patient is 
aware of symptoms because of its slowly progressive nature. Emphysema is a disease with 
enlargement of airspaces, destruction of lung parenchyma which reduce the gas-exchange 
surface area of the lung and loss of lung elasticity as a consequence of skewed activation of 
proteases (Brusselle et al., 2011; Cosio et al., 2009; Mocchegiani et al., 2011). The pathologic 
changes which resulted from repeated injury and repair, correlate with disease severity and 
persist on after smoking cessation (Rabe et al., 2007). In general, inflammatory cell 
infiltration, the imbalance of proteinase-antiproteinase system, oxidative stress and airway 
remodelling contributes to the decline in pulmonary function associated with the development 





1.3.1 Epidemiology and Burden of COPD 
COPD is a global health problem that is estimated to cause the death of at least 2.9 
million people annually (Lopez et al., 1998). As 210 million people worldwide are estimated 
to have COPD, it is predicted to become the third most common cause of death after 
ischaemic heart disease and cerebrovascular disease and the fifth most prevalent disease 
worldwide by 2020 (Lopez et al., 1998) . It affects over 5% adults (age 18-74), is currently the 
fourth leading cause of death worldwide and is the only major cause of death that is still rising 
(Pauwels et al., 2004; Sin et al., 2005). Subsequently, COPD will be the direct underlying 
cause of 7.8% of all deaths by 2030 (Mathers et al., 2006). The economic burden of COPD 
and the health care costs has exceeded those of asthma by more than 3 folds (Barnes, 2000). 
Exacerbations of COPD account for the greatest burden on the health care system in 
developed countries. Indeed, the total direct costs of respiratory disease in the European 
Union are estimated to be about 6% of the total health care budget, where COPD alone 
accounts for 56% of this cost of respiratory disease or aproximately €38.6 billion (Rabe et al., 
2007). In the United State, the direct costs of COPD were $18 billion and the indirect costs 
totalled $14.1 billion (Skrepnek et al., 2004). Because of its persistently increasing prevalence, 
mortality and disease burden, COPD is a major public health concern and the focus of intense 
research. 
 
1.3.2 Etiology  
Cigarette smoking is the single most important identifiable major risk factor for the 
development of COPD (Huvenne et al., 2011). Although COPD also occurs in non-smokers 
that is exposures to a range of both environmental fumes and dusts, such as coal dusts, or 
person with α1-antitrypsin deficiency and history of childhood respiratory infections, cigarette 




al., 2010). Smoking directly correlates with the early onset of chronic obstructive pulmonary 
disease (COPD). Nonetheless, individuals vary greatly in their susceptibility to the effects of 
tobacco smoke (Castaldi et al., 2011). In spite of this, according to the World Health 
Organization (WHO), over 1.3 billion people worldwide continue to smoke (World Health 
Organization., 2005; World Health Organization., 2003).  Cigarette smoke is a rich source of 
potent oxidants both in gaseous and water-soluble phases (Pryor, 1992). The cigarette smoke-
derived oxidants damage airway epithelium and alveolar wall, leading to infiltration of 
macrophages and neutrophils (Cantin, 2010; Foronjy et al., 2008; Yao et al., 2011). In 
additionally, cigarette smoke is not just a direct exogenous source of reactive oxygen species 
(ROS), it also induces endogenous production of ROS from activated inflammatory cells, 
such as alveolar macrophages and neutrophils (MacNee et al., 2001)  in the lung, resulting in 
an imbalance between oxidants and antioxidants (Rahman et al., 2006a). This is likely due to 
the high oxidative burden in the lungs of smokers which has been estimated
 
to be on the order 
of 10
15
 free radicals per
 
puff (Church et al., 1985). Furthermore, the degree of oxidative stress 
increases
 
greatly with the severe exacerbations in COPD (Drost et al., 2005). Hence, reduction 
of oxidative stress in COPD patients is clinically beneficial as it could reduce inflammation 
and reverse corticosteroid resistance. Nonetheless, N-acetyl cysteine, the current and the only 
approved antioxidant is inadequate in reducing progression and exacerbation of COPD 
(Decramer et al., 2005).  Thus, novel anti-oxidant activator is very much needed.  
 
1.3.3 Inflammatory cells  
COPD is a complex disease that involves several types of inflammatory cells (Barnes, 
2003).  Although both asthma and COPD involve chronic inflammation in the respiratory 
tract, there is a discernible difference in the type of inflammatory cells involved and in the site 




observed in sputum and BAL fluid of COPD patients (Keatings et al., 1996; Pesci et al., 
1998a). Similarly, BAL fluid and sputum also demonstrate increased inflammatory 
biomarkers such as cytokines, proteases, and soluble cytokine receptors (Barnes et al., 2006). 
However, in contrast to asthma, eosinophils are not prominent in COPD patients’ lung except 
during exacerbation or when patients have concomitant asthma (Fabbri et al., 2003). 
Inflammation in COPD is not a separate entity by itself but is integrally related to oxidative 
stress and protease–antiprotease imbalance. Chronic inflammation plays a critical role in the 
pathogenesis of COPD through their potential release of ROS, cytokines, chemokines, 
elastase, and metalloproteinase in response to cigarette smoke. Although cigarette smoke is 
the major cause of chronic inflammation of the lungs, the inflammation in COPD patient does 
not stop after cessation of smoking (Lapperre et al., 2006). Moreover, the inflammatory cell 
infiltration correlates well with the severity of airflow obstruction (Hogg et al., 2004). In 
contrast, chronic bronchitis, which is define by a productive cough for more than 3 months for 
more than 2 successive years is not necessarily associated with airflow limitation (Barnes, 
2003). Thus, inflammation is highly implicated in the disease process. 
 
Neutrophils   
Neutrophil accumulation in the lung is a prominent feature of COPD. BAL of smokers 
has an increase in neutrophils compared with nonsmokers as cigarette smoke is known to 
induce macrophages to release neutrophilic chemotactic factors. Higher number of neutrophils 
have been found in bronchial epithelium and lamina propria in smokers compared with 
controls (Pesci et al., 1998b), and the number of neutrophil is higher in the small airways than 
large airways (Battaglia et al., 2007).
 
When compared to healthy nonsmokers and healthy 
smokers, bronchial biopsies from GOLD stage III and IV COPD patients (severe/very severe) 




al., 2009). Furthermore, acute COPD exacerbations are often associated with microbial 
infections and neutrophilic inflammation (Sethi et al., 2009). 
Neutrophils are a rich source of inflammatory mediators, reactive oxygen species and 
tissue proteases (Barnes et al., 2003; Stockley, 1999). Activation of lung neutrophils leads to 
the release of granule proteins such as neutrophil elastase (NE) and myeloperoxidase (MPO) 
(Borregaard et al., 2007) that could contribute to the bronchial inflammation and to structural 
changes such as peribronchiolar fibrosis and emphysema (Baraldo et al., 2004; Woolhouse et 
al., 2005). In emphysema, neutrophil degranulation leads to alveolar wall destruction which 
resulted to mucociliary dysfunction and reduced mucociliary clearance. In chronic bronchitis, 
inflammation which is characterized by mucosal infiltration with neutrophils, macrophages, 
and lymphocytes, resulted in epithelial disruption, smooth muscle hypertrophy and fibrosis 
(Quint et al., 2007). 
Neutrophils are responsible for significant damage when they accumulate at sites of 
inflammation and are harmful to healthy tissue. The neutrophils role in the cellular host 
defence against microorganisms relies in part on their ability to generate large amounts of 
superoxide anion (O2–) and related ROS through activation of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase on the plasma membrane, an ability which is 
known as respiratory bursting. Oxidant such as O2– and hydrogen peroxide (H2O2) serve as 
intracellular signaling molecules for a variety of chemokines, including LTB4, TNF-α, IL-1, 
and TGF-β1, as well as various other growth factors (Circu et al., 2010). 
The accumulation of neutrophils is a dynamic process that consists of recruitment 
from the bloodstream and clearance from the lungs as a result of phagocytosis of apoptotic 
cells. Recently, cigarette smoke has been discovered to impair the ingestion of neutrophils by 
macrophages and decreases the ability of macrophages to phagocytose apoptotic cells through 




would lead to a greater release of destructive neutrophil products. This leads to a cascade of 
events that damages central and peripheral airways along with terminal airspaces, causing the 
physiologic and clinical abnormalities in COPD. 
 
Macrophages  
Macrophages play an important role in the pathophysiology of COPD. Macrophages 
account for the majority of inflammatory cells recovered by airway lavage, regardless of 
whether or not the subjects are non‐smokers, healthy smokers or smokers with airways 
disease(O'Donnell et al., 2006). There is however a significant increase of macrophages in 
airways, lung parenchyma, BAL fluid and sputum in patients with COPD. Moreover, 
macrophage numbers in the airways correlate well with the severity of COPD (Di Stefano et 
al., 1998). The increase of macrophages numbers in COPD patients and smoker are partly due 
to the increased recruitment of monocytes from circulation in response to monocyte-selective 
chemokines and partly due to the increase proliferation and prolonged macrophages survival 
in the lungs.  Macrophages can be directly activated by cigarette smoke to release 
inflammatory mediators including TNF-α, MCP-1, reactive oxygen species (ROS), and 
neutrophil chemotactic factors such as keratinocyte-derived chemokine (KC) (Keatings et al., 
1996). Macrophages also secrete a wide array of tissue proteases, including matrix 
metalloproteinase  (MMP) which mediate the lung parenchymal damage (Barnes et al., 2003).  
 
Epithelial Cell  
Epithelial cells are key regulators of neutrophil trafficking into the airway lumen 
(Quint et al., 2007). Cigarette smoke exposure induced the expression of IL-1β, IL-8 and GM-
CSF in normal human bronchial epithelial cells (NHBE) via the activation of both the NF-κB 
and MAPK pathways (Hellermann et al., 2002). The airway epithelium is one of the first 




increased disproportionately to alveolar cell proliferation in emphysema (Calabrese et al., 
2005). The damage to epithelial cells of the lower respiratory tract is partly due to cigarette 
smoke-derived oxidants which cause direct injury to membrane lipids, proteins, carbohydrates 
and DNA, resulting in loss and destruction of lung tissue (Demedts et al., 2006; Morissette et 
al., 2009). The epithelial barrier breakdown reduce the ability of lung to exclude foreign and 
reactive materials and increase the likelihoods of respiratory infections (Taylor, 2010). 
 
1.3.4 Mediators of COPD  
1.3.4.1 Chemokines 
Neutrophil Chemoattractant 
Neutrophil recruitment to the airways is mediated by various mediators. IL-8 (CXCL8) 
is one of the most notable chemoattractant of neutrophils (Gernez et al., 2010). IL-8 level 
correlate with the increased proportion of neutrophils and are markedly increased in induced 
sputum of patients with COPD (Keatings et al., 1996). Additionally, the level of IL-8 in BAL 
fluid can be used as a marker to determine the susceptibility of current smokers to pulmonary 
emphysema (Tanino et al., 2002).  
Cigarette smoke also induces macrophages to release IL-8 (Quint et al., 2007). 
Additionally, IL-8 are also released by neutrophils themselves to attract more neutrophils and 
therefore, a self-perpetuating inflammatory state may be established (Scapini et al., 2000). 
When anti-IL-8 antibodies are use therapeutically, the neutrophils chemotactic activity is only 
partially reduced, of the order of approximately 30%, signifying blocking IL-8 alone may not 
be sufficient as a therapeutic strategy to attenuate neutrophil inflammation in the respiratory 





Figure 1.4 Cytokines involved in COPD. Inhaled irritants, such as cigarette smoke, activate 
epithelial cells and macrophages to release multiple cytokines, including proinflammatory 
cytokines TNF-α, and IL-1β which amplify inflammation, and several chemokines that attract 
circulating cells into the lungs. MCP-1/CCL2 acts via CCR2 to attract monocytes (which 
differentiate into macrophages in the lungs); KC/CXCL1 and IL-8/CXCL8 act via CXCR2 to 
attract neutrophils and monocytes; and IP-10/CXCL10 act via CXCR3 to attract T 





There are two receptors for IL-8, one of which is CXCR1, which is a low-affinity 
receptor that is specific for IL-8, and CXCR2, which has high affinity and is share by others 
CXC chemokines including CXCL1. IL-8 also induces neutrophils to release of 
myeloperoxidase (MPO) which contributes to further recruitment of inflammatory cells and 
sustain inflammation (Quint et al., 2007).  
CXCL1 is a small cytokine belonging to the CXC chemokine family that is also 
known as Growth-related oncogene-α (GRO-α) or keratinocyte chemoattractant (KC). 
CXCL1/KC is secreted by alveolar macrophages and airway epithelial cells in response to 
stimulation with TNF-α (Schulz et al., 2004). CXCL1 activates both neutrophil and 
monocytes via CXCR2 (Geiser et al., 1993). The concentrations of CXCL1/KC were 
significantly elevated in induced sputum and BAL of patients with COPD compared with 
non-smokers or normal smokers (Traves et al., 2002). In animal models of inflammation, 
blockade of CXCR1 and CXCR2 by specific inhibitors significantly attenuated neutrophilic 
airway inflammation (Chapman et al., 2007). In endobronchial biopsies from patients with 
severe COPD, both CXCR1 and CXCR2 are expressed in high levels and play important roles 
in severe exacerbations (Qiu et al., 2003). 
In the airways of COPD patients, E-selectin, which is necessary for slowing down 
circulating neutrophils, is upregulated on endothelial cells, while ICAM-1, which regulates 
neutrophil adhesion and transcellular migration, is upregulated in on basal epithelial cells. (Di 
Stefano et al., 1994; Scott et al., 2002). Neutrophil influx is also dependent on the presence of 
leukotriene B4 (LTB4), TNF-α, GM-CSF and macrophage-derived matrix metalloproteinase 
(MMP)–12 (Gernez et al., 2010). LTB4 stimulates neutrophil chemotaxis, degranulation, 
release of lysosomal enzymes, and generates reactive oxygen species (ROS). TNF-α also 




(Quint et al., 2007). MMP-12 induced an auto-feedback loop that causes macrophages to 
release TNF-α, further enhancing the neutrophil influx.  
 
Monocyte Chemoattractant   
Monocyte chemotactic protein-1 (MCP-1/CCL2) which is a potent chemoattractant for 
monocytes, is express by alveolar macrophages, T lymphocytes and epithelial cells. MCP-1 
activates CCR2 on monocytes and T lymphocytes (Rose et al., 2003). CCR2 play a key role 
in COPD as sputum, BAL and lung of patients with COPD has an increase of MCP-1 level 
(Traves et al., 2002). Macrophage inflammatory protein-1α (MIP-1α/CCL3) is a 
chemoattractant for monocytes and neutrophils via CCR1. MIP-1α is released by 
macrophages. Interferon-γ-inducible protein 10 (IP-10, CXCL10) is a member of the non-
ELR CXC chemokine family that is produced by several cell types, particularly epithelial 
cells (Sauty et al., 1999). IP-10 has been attributed to several roles, including chemoattraction 
for monocytes (Dufour et al., 2002) and inducing the production of MMP-12 in human 




TNF-α is a pleiotropic inflammatory cytokine that has a broad spectrum of 
inflammatory effects relevant to COPD. TNF-α is produced by alveolar macrophages, 
neutrophils, T lymphocytes, mast cells and epithelial cells following contact with different 
pollutants including cigarette smoke (Chung, 2006). In animal models, TNF-α has been 
shown to induce an inflammatory cell infiltrate into the lungs, pulmonary fibrosis and 
emphysema, all of which are pathological features associated with COPD (Lundblad et al., 




sputum and BALF of patients with stable COPD compared with control subjects. Furthermore, 
TNF-α level in sputum was shown to increase significantly during acute COPD exacerbations 
(Matera et al., 2010). The activation of NF-κB by TNF-α will leads to the transcription of 
inflammatory genes, including cytokines, chemokines and proteases. TNF-α is synthesized as 
a precursor before being converted to the biologically active TNF-α by metalloproteinase 
(MMP). It has been demonstrated that the release of active TNF-α from the macrophages after 
acute smoke exposure is dependent on matrix metalloproteinase-12 (MMP-12) (Churg et al., 
2003). Unexplained weight loss occurs in about 50% of patients with severe COPD and 
chronic respiratory failure. TNF-α release from circulating cells was increased in COPD 
patients with weight loss (Agusti et al., 2008). Infliximab is a monoclonal antibody against 
TNF-α. Infliximab was used to treat autoimmune diseases such as psoriasis, Crohn's disease, 
ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis (Matera 
et al., 2010). Nonetheless, infliximab failed to alleviate symptoms, lung function, and exercise 
performance of COPD patients, as assessed by effects on when administrated at the doses that 
are effective in individuals with rheumatoid arthritis (Rennard et al., 2007). Infliximab was 
also no effective in patients with severe COPD who have cachexia (Dentener et al., 2008). 
These surprising findings may indicate that the drug does not adequately neutralize local 
concentrations of TNF-α or that other cytokines are more important. Moreover, when TNF-α 
are block in COPD patients, there was an increase in the incidence of chest infections and 
cancers, raising concerns that suppression of TNF-α may be detrimental in patients with 









Similar to TNF-α, IL-1β is a potent activator of alveolar macrophages from COPD 
patients (Russell et al., 2002b). IL-1β activates macrophages to secrete various inflammatory 
cytokines and chemokines as well as stimulating the expression of elastolytic MMPs from 
multiple cell types (Culpitt et al., 2003).  In addition, IL-1β also stimulate the bronchial 
epithelial cells to produce extracellular matrix glycoproteins (Chung, 2006). The increases in 
sputum and lavage fluid IL-1β have been documented in smokers compared with non-
smokers (Ryder et al., 2002). Furthermore, IL-1β together with TNF-α has been identified as 
key cytokine that is able to initiate inflammatory cascades during exacerbations of COPD 
(Hackett et al., 2008). As such, studies investigating the efficacy of canakinumab, an fully 
human mAb that neutralizes the bioactivity of human IL-1β in patients with COPD are 
currently in progress (Church et al., 2009). 
 
Granulocyte‐macrophage colony stimulating factor (GM‐CSF) 
GM-CSF play an important role in cigarette smoking-related lung diseases because it 
governs the growth, activation, and survival of leukocytes directly implicated in the 
pathogenesis of COPD (Vlahos et al., 2006). GM‐CSF, which is released from macrophages 
and epithelial cells, exerts its effect by increasing cytokine expression and priming 
inflammatory cells to amplify their responses to other stimuli (Hamilton, 2002). Moreover, 
GM-CSF which is a direct neutrophil chemotactic factor (Gomez-Cambronero et al., 2003) 
increases neutrophil survival in the respiratory tract (Barnes et al., 2003). GM-CSF is also 
directly implicated in the development of small airway fibrosis (Xing et al., 1996). The 
concentrations of GM-CSF in BAL fluid are increased in stable COPD and are significantly 
elevated during exacerbations (Balbi et al., 1997). Similarly, studies have also reveal that the 
levels of GM-CSF in sputum are increased in stable COPD (Saha et al., 2009), and during 




neutralization of GM-CSF by intranasal administration of anti–GM-CSF antibody to mice 
exposed to cigarette smoke significantly reduce cigarette smoke-induced airways 
inflammation and suggested potential therapeutic implication in COPD (Vlahos et al., 2010). 
 
1.3.4.3 Proteases and antiproteases 
The protease-antiprotease imbalance has been proposed to play a major pathogenic 
role in the development of emphysema. The observation that the instillation of papain, an 
plant elastolytic proteinase, into the lungs of hamsters led to pronounced emphysema (Gross 
et al., 1965) was essential to the formation of the proteinase-antiproteinase imbalance 
hypothesis. These observations led to the notion that emphysema develops due to the release 
of uncheck proteases by the inflammatory cells which lead to the destruction of the 
parenchymal matrix (Abboud et al., 2008). Hence, early studies of COPD focus on the effect 
of protease induce lung inflammation and the subsequent lung injuries.  
 
Neutrophil elastase (NE) and α1-antitrypsin (α1-AT) 
NE is a potent serine protease that that hydrolyze many proteins in addition to elastin. 
NE which is stored in azurophilic granules in neutrophils play an important role in host 
defence as mice lacking neutrophil elastase has been demonstrated to have an impaired 
response to gram negative bacterial induce sepsis (Belaaouaj, 2002). However, as a result of 
NE capacity to efficiently degrade extracellular matrix, overproduction of NE has been 
implicated in a variety of destructive diseases including COPD. Administration of elastase, 
either by intratracheal instillation or aerosol inhalation (Wright et al., 2008) not only lead to 
emphysema, it also cause infiltration of neutrophils and lymphomononuclear cells, mucus cell 
metaplasia, pulmonary edema, hemorrhage and rupture of the respiratory epithelium (Birrell 




observed in COPD patients (Birrell et al., 2005b). The alpha-1 antitrypsin (α1-AT) is a serine 
protease inhibitor that protects the pulmonary tissue from deleterious effects of proteolytic 
enzymes (Kohnlein et al., 2008). As such, α1-AT deficiency is known to predispose to COPD 
and is symptomatically treated as COPD (Rabe et al., 2007). However, α1-AT deficiency only 
occur in a small portion of COPD patients and COPD patients with or without α1-AT 
deficiency shows different molecular and cellular characteristics due to the specific deficiency 
present in α1-AT deficiency (Hattesohl et al., 2011).  As elastase can be rapidly induced 
emphysema, many early animal COPD models used elastase as the sole agent to study the 
effect potential drugs in treating COPD. However, as the inflammation of the elastase model 
is transient and resolves within a week of elastase administration, it does not reflect the 
progressive, slowly resolving inflammation associated with COPD and the model has 
gradually fallen out of favours (Stevenson et al., 2011).  
 
MMPs and Tissue inhibitor of MMPs (TIMP) 
MMPs constitute a large family of zinc-dependent endopeptidases that are capable of 
degrading extracellular matrix components. Alveolar macrophages may play a pathogenic role 
in emphysema as they express MMPs when induced by cigarette smoking (Lemaitre et al., 
2006). Among the MMPs, MMP-12 is the prominent MMP in the mouse. MMP-12 knock-out 
mice prevented emphysema induced by chronic cigarette smoke exposure (Hautamaki et al., 
1997). Similarly, MMP-12 knock-out mice has attenuated emphysema (Wang et al., 2000; 
Zheng et al., 2000).  MMP-9 knockout mice however are not protected against cigarette 
smoke induced emphysema (Lanone et al., 2002). Moreover, as aforementioned, MMP-12 
also cleaves membrane-bound 26kDa pro-TNF-α to the 17kDa mature TNF-α protein, acting 
as a “TNF-α converting enzyme” (Black et al., 1997; Moss et al., 1997). The MMPs are 




soluble proteins (TIMP-1, TIMP-2, and TIMP-4) or bound to extracellular matrix (ECM) 
components (TIMP-3) (Melendez-Zajgla et al., 2008). The TIMPs are synthesized by 
connective tissue cells and leukocytes and form non-covalent complexes with MMPs.  TIMPs 
bind to the zinc binding catalytic site of the MMPs with a 1:1 molar ratio (Mocchegiani et al., 
2011). Among the TIMP, only TIMP-1 is highly implicated in COPD. The Secretion of 
TIMP-1 from alveolar macrophages is increased in response to inflammatory stimuli but the 
cells derived from COPD patients has a reduce TIMP-1 and therefore favouring increased in 
elastolysis (Russell et al., 2002a). 
NEs and MMPs “support” each other by inhibiting their counterpart endogenous 
inhibitors. NEs inhibits TIMPs, and MMPs degrade α1-AT (Shapiro, 2002). These proteinases 
cleave components of the ECM to generate elastin fragments or collagen-derived peptides 
such as N-acetyl proline-glycine-proline (PGP), which have been shown to be chemotactic for 
monocytes and neutrophils (Weathington et al., 2006). Although unchecked proteinase has 
deleterious effects on the lungs, the imbalance of protease and anti-protease are largely due to 
oxidative stress in the overall pathogenesis of COPD as oxidant not only induce proteases 
secretion, cigarettes or biomass smoke exposure also can inactivate endogenous antiproteases 
activities (Cavarra et al., 2001).  
 
1.3.4.4 Oxidant and antioxidant  
Oxidative stress is a cardinal feature of COPD. While oxidant generation is part of the 
normal cellular metabolism and is critical for cell homeostasis, oxidative stress can occurs 
when the burden of oxidants is not well counterbalanced by the antioxidant defence system 
and results in harmful effects (Lin et al., 2010). Inhaled reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) and reactive chemicals (e.g. aldehydes) from cigarette smoke, 




neutrophils and macrophages, constitute a major oxidative burden to the lungs (Mak, 2008). 
Oxidants in cigarette smoke may also activate resident cells in the lung such as epithelial cells 
and alveolar macrophages to release chemokine which recruit additional inflammatory cells 
into the lung (Louhelainen et al., 2008). Chronic exposure to cigarette smoke perpetuates this 
response, leading to the increased production of inflammatory cytokines and degradative 
enzymes as well as defects in homeostatic mechanisms such as inactivation of anti-proteases, 
anti-oxidants and repair mechanisms (van der Toorn et al., 2007). The down regulation of 
antioxidant pathways has also been associated with acute exacerbations of COPD (Lin et al., 
2010).  Lung injury due to oxidants is linked to oxidation of proteins, DNA, and lipids 
(Biswas et al., 2009). Pulmonary levels of oxidant biomarkers such as 3-nitrotyrosine (3-NT), 
8-isoprostane and 8-hydroxydeoxyguanosine (8-OHdG) have been shown to correlate 
positively with COPD severity (Inonu et al., 2012; Louhelainen et al., 2008; Yao et al., 2011). 
The degree of pulmonary
 
oxidant-antioxidant imbalance correlates well with the severity
 
of 
COPD (Drost et al., 2005). Thus, the ability of the lungs to respond to oxidative stress
 
is an 
important determinant of their relative resistance
 
or susceptibility to COPD. 
Antioxidants are agents that decrease steady-state ROS and protect cellular 
macromolecules from oxidative modification. An antioxidant rapidly reacts with oxidant to 
produces less reactive species. The lung has a large reserve of endogenous enzymatic and 
non-enzymatic antioxidants. Antioxidant enzymes include superoxide dismutase (SOD), 
catalase, glutathione peroxidases (GPx), glutathione S-transferase (GST) and the heme 
oxygenase-1 (HO-1) system. Non-enzymatic antioxidants include glutathione (GSH), 
bilirubin, carbon monoxide and ferritin.  
GSH is the most abundant free thiol antioxidant that reacts with peroxides to form 
glutathione disulfide (GSSG) and is recycled by glutathione reductases (GR). GPx also 




concentrated in the epithelial lining fluids and plays an important role in maintaining optimal 
redox balance in the lungs. In addition, under catalysis of GST, GSH is capable of rapidly 
detoxifying harmful xenobiotic components of tobacco smoke (Harju et al., 2008). GSH is 
sensitive to oxidative stress. In response to acute cigarette smoke exposure, there is a transient 
upregulation of GSH in the epithelial lining fluids to counteract the increased oxidants, but it 
is eventually overwhelmed by ongoing oxidative stress. Cigarette smoke also affects GPx, GR, 
and GST, all of which are detoxifying enzymes involved in the GSH redox system in the 
lungs. These observations suggest that smokers are predisposed to oxidative injuries (Lin et 
al., 2010). Similar to GPx and GSH, catalase catalyse the decomposition of H2O2 to water and 
oxygen. Polymorphisms of the catalase gene have been shown to be related to an imbalanced 
of oxidant and antioxidant system in COPD patients (Mak et al., 2007). SODs are antioxidant 
enzymes that catalyze the dismutation of superoxide into oxygen and hydrogen peroxide. 
There are three forms of superoxide dismutase, SOD1 (Cu/Zn SOD), SOD2 (MnSOD) and 
SOD3 (extracellular SOD, ecSOD). SOD1 and SOD2 are primarily localized in lung cells and 
SOD3 is mainly in the extracellular space of the lung (Oberley-Deegan et al., 2009). 
Heme oxygenase (HO) is an enzyme that catalyzes the degradation of heme to 
generates biliverdin, iron, and carbon monoxide (CO). The products of heme catabolism 
mediate the antioxidant properties of HO. In the airways, HO-1 is expressed in the epithelium, 
smooth muscle, type II pneumocytes, and alveolar macrophages. HO-1 expression which can 
be induced by heme, hypoxia, hyperoxia, NO, endotoxin and pro-inflammatory cytokines (An 
et al., 2012), is extremely sensitive to agents that cause oxidative stress. HO-1 exhibits 
powerful antioxidant and anti-inflammatory properties. HO-1 expression is upregulated in 
several pulmonary diseases, including COPD and asthma. The over-expression of HO-1 in 




The biliverdin that is generated by HO-1 is subsequently converted to bilirubin, a 
potent endogenous antioxidant (Fredenburgh et al., 2007). In vitro and in vivo studies have 
shown carbon monoxide (CO) has both anti-inflammatory and anti-oxidant capacities 
(Montuschi et al., 2001). In fact, a recent clinical trial which have been carried out to 
determine the effect of CO in the treatment of stable COPD have found that CO treatment led 
to trends in reduction of sputum eosinophils and improvement of responsiveness to 
methacholine (Bathoorn et al., 2007). The generation of iron-catalysed ROS has been 
minimized as free iron produced by HO-1 is taken up by ferritin, a major intracellular iron 
storage protein that removes excess free iron (Lin et al., 2010).  
The association of COPD with genetic variations of antioxidant genes has also been 
reported. There is a decrease of HO-1expression in COPD patients. Studies have shown that 
the polymorphism of the HO-1 gene is associated with increased susceptibility to emphysema 
in smokers (Hirai et al., 2003). Furthermore, in response to oxidative stress, this 
polymorphism resulted in reduced transcriptional activity of the HO-1 gene and decrease HO-
1 antioxidant capacity. Similarly, single-nucleotide polymorphisms (SNPs) in SOD3 have 
been reported to either protect (Young et al., 2006) or promote (Dahl et al., 2008) 
development of COPD.  
Nuclear factor erythroid-2-related factor 2 (Nrf2) is a redox-sensitive basic leucine 
zipper transcription factor and is critical in protecting the lung against oxidative stress. Nrf2 
regulates expression of antioxidants including GPx, GR and HO-1 by binding to the 
Antioxidant Response Element (ARE) present in the promoters of these genes (Adair-Kirk et 
al., 2008; Hubner et al., 2009). The selective inactivating mutations in Kelch-like ECH-
associated protein 1 (KEAP1), an Nrf2 inhibitor, enhances Nrf2-directed constitutive 
expression of multiple antioxidants genes (Singh et al., 2006a). Impaired Nrf2 activities have 




pulmonary fibrosis, asthma and COPD (Boutten et al., 2011; Cho et al., 2006). Studies have 
revealed a significant decline in NRF2-regulated antioxidant defenses such as HO-1 and 
GCLM as well as a higher degree of oxidative damage in peripheral lung tissues of patients 
with COPD as compared with lungs of patients without COPD (Malhotra et al., 2008). In 
animal models, Nrf2 gene disruption resulted in ablated expression of antioxidants gene and 
enhanced susceptibility to emphysema after cigarette smoke exposure (Rangasamy et al., 
2004). Activation of Nrf2 by triterpenoids such as CDDO-imidazolide has demonstrated 
beneficial effects in a cigarette smoke-induced emphysema animal model (Sussan et al., 2009). 
Drug discovery of novel compounds with property of strengthening antioxidant defense is a 
vital strategy for COPD drug development.  
 
1.3.5 Mouse Models of COPD 
Animal models have played an instrumental role in broadening our mechanistic 
understanding of COPD. In our studies, cigarette smoke model were utilized to investigate 
our hypothesis as the model is induced by same insult as in humans. Cigarette smoking model 
are advantages over other models for COPD as it uses the predominant disease-causing agent 
to model several key features of the disease in small animals. Moreover, as there are over 
4000 hazardous compounds, of which 200 are highly toxic (Brunnemann et al., 1991) and it 
has more than 10
15
 free radicals in every puff of smoke (Church et al., 1985), single stimuli 
such as elastase and LPS are not likely to replicate the complex response to smoke. Chronic 
cigarette smoke exposure to animals produces emphysema, airway inflammation and airway 
remodelling. Cigarette smoke also causes lung inflammation where macrophages and 
neutrophils are prominent (Pauwels et al., 2001; Rabe et al., 2007). Moreover, cigarette smoke 
induces inflammation exposure that is not as pronounced as the response to either LPS or 




physiological alterations in humans, cigarette smoking appear to effectively mimic the 
progressive, low-grade, slow resolving and steroid-insensitive inflammation associated with 
COPD. As acute exacerbations in COPD patients, which contribute to the accelerated lung 
function decline and disease progression, are a major cause of hospitalization and death 
(Makris et al., 2007), several groups have begun to attempt to model the pathologies and 
physiological changes associated with late-stage COPD by challenging animals exposed to 
smoke with agents known to cause exacerbations such as bacteria and viruses. Studies 
combining virus and cigarette smoke exposure demonstrated that virus infection may reduce 
or enhance the inflammatory response depending depended on the type of virus (Gualano et 
al., 2008; Meshi et al., 2002) and the dose of virus infection (Robbins et al., 2006). 
Additionally, infecting small animals with bacteria has also been used to model COPD acute 
exacerbation-like changes. The effects of bacterial infection on cigarette smoke exposed mice 
are also dependent on the species of bacteria involved. Bacterial infection generally enhanced 
inflammation but the clearance of bacteria may be enhanced (Gaschler et al., 2009) or 
reduced (Drannik et al., 2004) dependent on the species of bacteria involved. These studies 
underscore the complexity of combining cigarette smoke exposure with human pathogens to 
model these acute events. As the entire mouse genome has been sequenced and mouse can 
readily be manipulated to generate genetically modified mouse models, mouse has become 
the species of choice for investigators to test hypothesis about the causal mechanisms 
underlying disease in ways that cannot be done in human. Mice with Nrf2 (Rangasamy et al., 
2004) and MMP-12 knockout (Hautamaki et al., 1997) have shed light on the molecular 
mechanisms involved in mediating the inflammation and lung pathologies induced by 
cigarette smoke exposures. In our studies, BALB/C mice were preferred over other strain of 
mice as mouse strains comparison studies have found that although the types of changes in 




changes did vary and BALB/C mice consistently had the greatest response to cigarette smoke 
exposure in term of the proportion and numbers of neutrophils and levels of KC in the BAL 
fluid, whereas C57BL/6 mice consistently had the smallest response (Morris et al., 2008). 
Female mice were used in the present study as there is evident that women are more 
susceptible to the effects of smoke than men (Gan et al., 2006; Langhammer et al., 2003; 
Martinez et al., 2007; van Durme et al., 2009). Even in mouse models, female A/J mice 
develop emphysema earlier than male A/J mice (March et al., 2006). However, cigarette 
smoke induced mouse COPD model requires months of smoke exposure (around 4 to 6 
months) to generate pathologies and functional changes consistent to those observed in COPD 
patients. This approach is thus an expensive and time-consuming proposition.  Hence, many 
laboratories use an acute (<1 week) model of cigarette smoke induced lung inflammation as 
primary model to examine the efficacy of prospective therapies. Although emphysema is not 
obvious in the acute model, it does provide preliminary effect on cigarette smoke induce 
oxidative stress and inflammatory response that is useful in guiding further studies as the 
changes are very mild compared to those observed in human. The pathologies and lung 
function changes associated with these models would most likely constitute mild COPD 
(GOLD 1 and 2) (Churg et al., 2007; Rabe et al., 2007). Regrettably, most cases of COPD are 
not diagnosed until the disease has become severe (GOLD 3 and 4) (Rabe et al., 2007). 
Moreover, cigarette smoking models do not produce the severe disabling disease seen in 
humans and the lesions due to cigarette smoking do not appear to progress after cessation of 
smoke exposure (Wright et al., 2008). Thus, we must bear these limitations in mind when we 





1.3.6 Current Drug  
Similar to asthma, current guidelines for COPD management advocate the use of 
inhaled β2-agonists, inhaled anticholinergics and inhaled corticosteroids for symptomatic 
management (GOLD, 2011). Long acting bronchodilators such as the anti-cholinergic 
tiotropium, and the β2-agonists salmeterol and formoterol have all been shown to improve 
lung function, quality of life and reduce the time to first exacerbation when compared to 
placebo (Donohue et al., 2003; Tashkin et al., 2004). Similarly, inhaled steroids have been 
demonstrated to significantly reduce the rate of exacerbations in COPD in several clinical 
trials (Alsaeedi et al., 2002; Calverley et al., 2007). In spite of these beneficial effects and in 
sharp contrast to asthma, neither bronchodilators nor inhaled steroids are able to alter the rate 
of decline of lung function (Vestbo et al., 1999) or improve survival (Calverley et al., 2007) 
in COPD. The inability of current drug therapy to halt the relentless progression of lung 
function deterioration in COPD patients may be due in part to the inability of these drugs to 
fully reverse the inflammatory changes that occur in COPD (Loppow et al., 2001). For 
example, although corticosteroids are effective in attenuating the release of IL-8, TNF-α and 
MMP-9 from macrophages of normal subject and normal smokers in vitro, corticosteroids are 
not effective in macrophages from patients with COPD (Culpitt et al., 2003). Although 
bronchodilators such as phosphodiesterase 4 inhibitor roflumilast has been newly approved 
for the treatment of COPD, it suffers from dose-limiting major side effects such as diarrhoea, 
headache, nausea and weight loss (Page et al., 2012). In addition, current drug do not alter the 
oxidative or apoptotic processes that are critical to the pathogenesis of COPD (Imai et al., 
2005; Zheng et al., 2005). Given the importance of antioxidant in COPD, researchers have 
sought to determine whether antioxidant administration would improve disease outcomes in 
COPD. The most commonly used antioxidant for these studies is n-acetylcysteine (NAC), 




easy to tolerate in its oral form (Dekhuijzen et al., 2006). Nonetheless, the therapeutic use of 
NAC in COPD has yield conflicting results, and while some studies have shown beneficial 
effects of NAC with regard to lung function (Stav et al., 2009) and COPD exacerbations 
(Hansen et al., 1994), some clinical trials concluded that NAC was ineffective at preventing 
deterioration of lung function or preventing exacerbations (Schermer et al., 2009). Although 
smoking cessation, supplemented oxygen therapy for hypoxemic patients, lung reduction 
surgery for selected patients with emphysema alters the course of COPD, there is currently no 
specific treatments halting the relentless progression of COPD, which leads to increasing 
symptoms and disability and increases the risk of premature death in COPD patients (Barnes, 
2008b; Barnes, 2010; Morjaria et al., 2010). As a result, the lack of effective treatments and 
the escalating healthcare burden has created an impetus for researchers to seek novel and 
more effective compounds aimed at reducing the progression of COPD and control the 
underlying disease process.  
 
1.4 Andrographolide and DDAG  
 
1.4.1 Andrographis paniculata 
Andrographis paniculata (Burm. F.) Nees, commonly known as ‘king of bitters’ due 
to its bitterness, is an herbaceous plant belonging to the Family Acanthaceae. Similar to 
weeds, A. paniculata is easily grown and propagate over a broad eco-geographical range 
(Aromdee, 2012). A. paniculata is a plant indigenous to Southeast Asian countries and it is 
highly cultivated for mass production in many Asian countries due to the high demand for its 
active constituents (Aromdee, 2012). A. paniculata has a long history of therapeutic usage in 
Indian and Chinese medicine as it is traditionally was used for the prevention and treatment of 
upper respiratory tract infection in Asian countries and also in Scandinavia (Chang et al., 




known by various vernacular names in various places where it is traditionally use. It is known 
as Kalmegh in India, Chuan-Xin-Lian in China, Fah Tha Lai in Thailand, and Hempedu bumi 
in Malaysia. 
 
1.4.2 Andrographolide  
A number of active constituents are described from the plant, which mainly include 
diterpene lactones, flavonoids and polyphenols (Koteswara Rao et al., 2004). However, 
andrographolide (Fig. 4), 14-deoxy-11,12-didehydroandrographolide (DDAG) (Fig. 5) and 
neoandrographolide are the three prime constituents isolated from A. paniculata (Lim et al., 
2012; Pholphana et al., 2004). Among the isolated compound, andrographolide (C20H30O5) is 
the most abundant diterpenoid in A. paniculata, making up about 4% of dried whole plant, 
0.8~1.2% of dried stem and 0.5~6% of dried leaf extracts (Chao et al., 2010b). 
Andrographolide has been demonstrated to have multiple pharmacological properties 
and it has been proposed to be a potential chemotherapeutic agent (Varma et al., 2009). As 
such, the toxicity profile has been extensively studied. Intraperitoneal injection affording 
doses of 4-50 mg/kg of of andrographolide over body weight in mice (Iruretagoyena et al., 
2005; Mishra et al., 2011) has been investigated. At the doses used, andrographolide was well 
tolerated by mice, and no evidence of toxicity was observed. Indeed, the LD50 for 
intraperitoneal administration of andrographolide was 11.6 g/kg in rats. (Handa et al., 1990). 
Even in human subjects, no side effects were observed when participants were monitored for 
changes in liver and kidney functions, blood counts, and other laboratory measures when 































Andrographolide has also been reported to have diverse pharmacological potential 
including hepatoprotective (Negi et al., 2008), antiviral (Aromdee et al., 2011b; Calabrese et 
al., 2000; Ko et al., 2006; Lin et al., 2008; Wiart et al., 2005), anti-cancer (Kumar et al., 
2004b; Lim et al., 2012; Varma et al., 2009), antipyretic (Suebsasana et al., 2009), 
antibacterial (Aromdee et al., 2011a; Jiang et al., 2009; Wang et al., 2010) and anti-
inflammatory (Abu-Ghefreh et al., 2009; Bao et al., 2009) activities. 
Recently, andrographolide has also been shown to have antioxidant activities by 
inhibiting oxygen radical production in neutrophils and inhibition in phorbol 12-myristate 13-
acetate (PMA) induced superoxide and nitric oxide formation in BALB/c mice (Sheeja et al., 
2006). The exact molecular mechanism that mediates these anti-inflammatory effects of 
andrographolide has not been unequivocally determined. However, andrographolide has been 
reported to have the ability to activate antioxidant system and probably acting thorough Nrf2 
activation pathway. 
It has been demonstrated that intraperitoneal treatment of andrographolide in mice 
significantly increase the glutathione (GSH) concentration and glutathione peroxidase (GPx) 
activities (Neogy et al., 2008). Besides, oral andrographolide administration significantly 
induced the activities of GSH, glutathione reductase (GR) and GPx in the liver of 
hexachlorocyclohexane (BHC)-treated mice. The studies shown that andrographolide 
effectively activate antioxidant in severe liver damage (Trivedi et al., 2007). 
It has been demonstrated that incubation of andrographolide in rat primary hepatocyte 
also increase the expression of glutathione S transferase (GST) protein, mRNA level and 
activities (Chang et al., 2008b). The study showed that GST-P enhancer-1 (GPE1) (a critical 
promoter of GST) luciferase activities was up regulated by andrographolide treatment. This 
finding further supports the notion that Nrf2 activities was up-regulated by andrographolide as 




Studies using a hypoxia/reoxygenation model has showed that treatment with 
andrographolide protected the stressed cardiomyocytes by up-regulating the cellular-reduced 
glutathione (GSH) level and antioxidant enzyme activities. After treating the cell with 
andrographolide alone, the enzymatic activities of GPX, GR and the cellular GSH level were 
all increased when compare to vehicle controls (Woo et al., 2008). Subsequently, to determine 
the molecular mechanism of andrographolide in activating the endogenous antioxidant system, 
it was discover that the glutamate-cysteine ligase, catalytic subunit (GCLC) and glutamate-
cysteine ligase, modifier subunit (GCLM) mRNA and protein level were up-regulated upon 
andrographolide treatment (Woo et al., 2008). The GSH synthesis is regulated by the 
induction of the GCL transcript which is controlled by antioxidant response elements (ARE) 
(Rahman et al., 2000). These findings have shown for the first time the direct effect of 
andrographolide on Nrf2 activities as Nrf2 is the essential positive regulator of ARE-mediated 
gene expression.  
In addition, to better understand the specific effect andrographolide has on gene 
expression, an mRNA microarray analysis on andrographolide treated cells is conducted to 
screen for andrographolide’s effect in mouse gene transcription. Out of the 28,853 genes 
analysed, the study found that 25µM of andrographolide treatment of primary mouse 
hepatocytes up-regulated 18 genes and almost all of them were related to metabolism, and 
oxidation/reduction. Among the genes that were up-regulated, genes such as Gst, Srxn1, Gclm, 
Nqo1, Gpx2 and Gsr (Glutathione reductase gene) are Nrf2-dependent genes (Rangasamy et 
al., 2004).  That study further support the notion that andrographolide is a Nrf2 activator.    
Andrographolide has been shown to promote Nrf2 nuclear translocation in a human 
endothelial cell line. By probing Nrf2 protein in the cell nuclear extracts, and by measuring 
Nrf2-induced antioxidant response element (ARE) activation in cells transfected with ARE-




dependent Nrf2 nuclear translocation and increase in transcriptional activities (Yu et al., 
2010).  
Given that the known anti-oxidative effects of andrographolide and the protective 
effect against oxidative stress, it is therefore proposed that andrographolide protects the lung 
against cigarette smoke-induced lung inflammation.  
 
1.4.3 14-deoxy-11,12-didehydroandrographolide 
DDAG is another major naturally occurring analogue isolated from A. paniculata, and 
DDAG has also been identified as a metabolite of andrographolide when given systemically 
to rats (He, 2003). Both andrographolide and DDAG are structurally similar, although 
andrographolide contains a hydroxyl group and two additional hydrogen atoms (Tzeng et al., 
2012). 
At low doses, both andrographolide and DDAG compounds were not cytotoxic, and 
both of the compounds are effective in inhibiting pro-inflammatory cytokine secretion 
induced by TNF-α activation in astrocyte cultures (Tzeng et al., 2012) 
In some cases, there are difference in activities between andrographolide and DDAG. 
For instance, DDAG is known to inhibit α-glucosidase more potently than andrographolide 
(Dai et al., 2006). Conversely, DDAG has been reported to be less cytotoxic to a variety of 
tumour cell lines as compared to andrographolide (Kumar et al., 2004b; Nanduri et al., 2004; 
Tan et al., 2005). DDAG has been shown to have lower cytotoxicity as the 50% of cytotoxic 
concentrations (CC50) to Vero cells for DDAG was 243µM, but CC50 of Andrographolide 
and 14-deoxyandrographolide to Vero cells were 76µM and 80µM, respectively. These 
findings indicate that DDAG is safer to be used for activities other than anticancer purpose 



















In addition, DDAG which demonstrated a potent hypotensive effect (Zhang et al., 
1998), has been shown to effectively inhibit cytokine and nitric oxide production from Raw 
264.7 macrophage cell line stimulated with LPS and IFN-. DDAG has also been shown to 
attenuate high glucose-induced fibrosis and apoptosis in a renal mesangial cell line (Chao et 
al., 2010a; Lee et al., 2010). Nonetheless, while andrographolide prevented PC12 toxicity due 
to the synergistic effects of H2O2 and astrocyte-conditioned medium (ACM), DDAG on the 
other hand was not able to rescue PC12 cell death that occurs due to the same treatment (H2O2 
and ACM). 
The differences in pharmacological activities of these compounds are related to their 
structures. The molecular mechanism that mediates the actions of DDAG has not been 
unequivocally determined. Nevertheless, as both andrographolide and DDAG significantly 
attenuated TNF-α, IL-6, macrophage inflammatory protein-2 (MIP-2), and nitric oxide (NO) 
secretions from LPS/IFN-γ stimulated RAW 264.7 cells, the inhibition of NF-B 
transcriptional activity by these compounds are strongly supported (Chao et al., 2010a; Xia et 
al., 2004). Since we have recently reported a broad-spectrum of anti-inflammatory effects for 
andrographolide in an OVA-induced allergic lung inflammation model (Bao et al., 2009), it is 






























COPD and asthma are global pandemics that are major causes of morbidity and 
mortality. COPD is currently the fourth leading cause of death worldwide (Pauwels et al., 
2004) while asthma is an airway disease which affects around 300 million people of all ages 
and ethnic backgrounds (Masoli et al., 2004). Despite the fact that cigarette smoke is a major 
cause for COPD, efforts sought to restrict tobacco consumption have thus far ineffective, 
leading to an increase in prevalence of COPD especially in less develop countries (Huvenne 
et al., 2011). The increase incidence of COPD will lead to a significant increase in economic 
and social burden as currently there is no effective drug for the treatment of COPD as most 
current drugs only reduce the symptoms but fail to attenuate the underlying inflammation and 
the progressive deterioration of lung function (Barnes, 2010). On the other hand, current 
mainstay therapies for asthma are β2 agonists and inhaled corticosteroids which although are 
effective in controlling asthma, 5-10% of patients who suffer from uncontrollable asthmatic 
symptoms are refractory to corticosteroids treatment (Moore et al., 2007). There is an 
imperative need to discover and develop novel, safe and potent drugs for both asthma and 
COPD.  
Andrographolide and DDAG are both bioactive compounds isolated from the plant 
Andrographis paniculata (Lim et al., 2012). Andrographolide has been shown to activate 
nuclear factor erythroid-2-related factor 2 (Nrf2), a redox-sensitive antioxidant transcription 
factor (Yu et al., 2010). As Nrf2 activity is reduced in COPD, we hypothesize that 
andrographolide may have therapeutic value for COPD. On the other hand, although novel 
anti-inflammatory effects of andrographolide in a mouse asthma model have been reported 
(Abu-Ghefreh et al., 2009; Bao et al., 2009), andrographolide has been shown to possess 
cytotoxic activity, especially in tumour cell lines (Nanduri et al., 2004; Tan et al., 2005). We 
hypothesized that DDAG, as an analogue of andrographolide, may retain the anti-




The main aim of these studies was to explore the potential therapeutic effects of 
andrographolide as a novel anti-oxidative stress compound on COPD in a cigarette smoke 
induce lung injury model and to examine the potential anti-inflammatory DDAG in allergic 
asthma mouse model and elucidate their molecular mechanisms. The findings in this study 
may shed light on novel molecular drug target for both asthma and COPD and broaden our 
understanding in rational drug design. The studies could also lead to the development of 





























3.1. Materials and reagents  
Drugs and chemicals used in this PhD project are as follows:  
 3-[(E)-2-[(1R,4aβ)-Decahydro-6α-hydroxy-5α-(hydroxymethyl)-5,8aα-dimethyl-2-
methylenenaphthalen-1-yl]vinyl]furan-2(5H)-one (14-Deoxy-11,12-
didehydroandrographolide) (>98% purity, TCM Institute of Chinese Materia Medica, 
Nanjing, People's Republic of China);  
 
 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,8α-dimethyl-2-methylene-1- 
napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone (andrographolide),  
 anti-β-actin monoclonal antibody, 10% neutral buffered formalin, acetyl-β-
methylcholine chloride, aluminium hydroxide (Al(OH)3), bovine serum albumin 
(BSA), chicken ovalbumin (OVA), dimethyl sulfoxide (DMSO), eosin Y, Harris 
hematoxylin solution, hematoxylin solution Gill no. 3, heparin, periodic acid solution, 
Schiff’s reagent, skim milk powder (Fluka) and Tween 20 (Sigma-Aldrich, St Louis, 
MO, USA);  
 
 3R4F research cigarettes (Tobacco and Health Research Institute, University of 
Kentucky, Lexington, KY, USA);  
 
 Fast SYBR Green Master Mix, RNAlater (Applied  Biosystems, Foster  City,  CA,  
USA);  
 
 Alkaline phosphatase (AP) conjugate substrate kit, agarose, blotting paper, 




3,3´,5,5´-tetramethylbenzidine (TMB) substrate kit, Triton X-100 (Bio-Rad  
Laboratories, Hercules,  CA,  USA);  
 
 Ammonium chloride (NH4Cl) (BDH Laboratory Supplies, Poole, England);  
 
 Agarose, phosphate buffered saline (PBS), sodium dodecyl sulfate (SDS), and tris-
acetate-EDTA (TAE) (1st  BASE, Singapore);  
 
 Diethylpyrocarbonate (DEPC)-treated water, penicillin, streptomycin, random primer, 
Roswell Park Memorial Institute (RPMI) medium, Trizol, and trypan blue (Invitrogen, 
Carlsbad, CA, USA);  
 
 Mouse keratinocyte chemoattractant (KC/CXCL1) Duoset, mouse interferon-γ-
inducible protein 10 (IP-10/CXCL10/CRG-2) DuoSet, mouse monocyte 
chemoattractant protein-1 (MCP-1/CCL2/JE) DuoSet and Mouse IL-1 beta DuoSet, 
Mouse IL-13 DuoSet,  mouse CCL11/Eotaxin DuoSet (R&D  Systems,  Minneapolis,  
MN,  USA);  
 
 Avidin-horseradish  peroxidase (HRP), biotinylated anti-mouse IgE, biotinylated anti-
mouse IgG1, biotinylated anti-mouse IgG2a, OptEIA
TM
 mouse total IgE set, 
OptEIA
TM
 mouse IL-4 set, and OptEIA
TM
 mouse IL-5 set, (BD  Biosciences  





 Bicinchonic acid (BCA) protein assay kit, calf serum, fetal bovine serum (FBS), 
Restore™ PLUS western blot stripping buffer (Thermo Fisher Scientific Inc, Waltham, 
MA ,USA);  
 
 M-PER Mammalian Protein Extraction Reagent containing HALT protease inhibitor 
cocktail (Pierce, Rockford, IL, USA);  
 
 Cotinine ELISA (Bio-Quant, San Diego, CA, USA);  
 
 8-isoprostane (8-iso-PGF2) and 8-OHdG EIA kit (Cayman Chemicals, Ann Arbor, 
MI, USA);  
 
 3-nitrotyrosine (3-NT) ELISA kit (Upstate/Millipore, Billerica, MA, USA);  
 
 Sodium carbonate (Na2CO3)  (Kanto  Chemical, Tokoyo, Japan);  
 
 Absolute ethanol, isopropanol (Merck, Darmstadt, Germany);  
 
 HistoClear and Histomount (National Diagnostics, Atlanta, GA,  USA);  
 
 Avian myeloblastosis virus (AMV) reverse transcriptase, dNTP mix, polymerase 
chain reaction (PCR) master mix, and  ribonuclease inhibitor (Promega, Madison, WI, 
USA);  
 




 Anti-β actin and anti-p65 polyclonal antibody (Cell Signaling Technology, Beverly, 
MA, USA);  
 
 Anti-TATA binding protein (TBP, Abcam, Cambridge, UK);  
 
 Enhanced chemiluminescent (ECL), western blotting detection reagents, and 
hyperfilm (GE Healthcare, Piscataway, NJ, USA);  
 
 Protease inhibitor cocktail (complete) (Roche Diagnostics, Indianapolis, IN, USA);  
 
 HRP-conjugated anti-mouse Ig, HRP-conjugated anti-rabbit Ig, AP-conjugated anti-
mouse Ig, and AP-conjugated anti-rabbit Ig (Dako, Glostrup, Denmark);  
 
 TNF-α (BioSource, Camarillo, CA, USA); and 
 
 Nuclear extract kit, TransAM™ NF-κB p65 Kit,  TransAM™ Nrf2 Kit (ActiveMotif, 
Carlsbad, CA, USA). 
 
3.2. Mouse Model 
Female BALB/c mice of 6 to 8 weeks old (Animal Resources Centre, Canning Vale, 
Western Australia, Australia) were maintained in the animal housing unit on a 12-hours light-
dark cycle with food and water available ad libitum. The temperature in the animal room 
ranged from 18°C to 26°C with an average temperature of 22°C. Maintenance diets generally 
contain 4-5% fat and 14 % protein. Generally a minimum of 3 days of acclimatization is 




according to the Institutional guidelines for Animal Care and Use Committee of the National 
University of Singapore. 
 
3.2.1. Asthma mouse model and DDAG treatment protocol 
BALB/c mice, were sensitized and challenged with ovalbumin (OVA) as described 
previously (Bao et al., 2009). Briefly, mice were sensitized by intraperitoneal (i.p.) injections 
of 20 g OVA and 4 mg Al(OH)3  as adjuvant suspended in 0.1 ml saline on day 0 and 14. 
Aluminium hydroxide is the most commonly used adjuvant as it primes the mice immune 
response towards a Th2 phenotype. Following this, the mice were challenged with 1% OVA 
aerosol for 30 minutes administer by DeVilbiss Ultra-Neb Large-Volume Ultrasonic 
Nebulizer (Sunrise Medical Respiratory Products, Somerset, PA) as shown in figure 3.1 on 
day 22, 23 and 24. DDAG (0.1, 0.5, and 1 mg/kg) or vehicle (1% DMSO) in 0.1 ml saline was 
given by i.p. injections 2 hours before and 10 hours after each OVA aerosol challenge. Saline 
aerosol was used as a negative control. To ensure the strict hygiene standard of the cages’ 




















Figure 3.1.  Allergen aerosol delivery system.  The ultrasonic nebulizer  was  used  to 
aerosolize  1%  of  OVA  saline  solution  and  pump  the  aerosol  mist  into  an  adjacent 
chamber where the aerosolized solution was inhaled into the airways of the mice. Up to 8 





















Figure 3.2. Cigarette smoke and Sham Air delivery system. Peristaltic pump are used to 
deliver room air or cigarette smoke to the chamber. Both sham air and cigarette smoke 
chamber receive a constant flow of fresh air and have an exhaust tubing to keep the chamber 
ventilated. Additionally, the smoke chamber receives a constant flow of cigarette smoke while 
the sham air chamber receives the similar flow of room air. 
  





3.2.2. Cigarette smoke-induced lung injury and andrographolide treatment protocol 
Mice were placed in a ventilated chamber filled with 4% cigarette smoke delivered by 
a peristaltic pump (Masterflex, Cole-Parmer Instrument Co., Niles, IL, USA) at a constant 
rate of 1 L/min as shown in figure 3.2 according to methods described by Chan et al. (Chan et 
al., 2009). Total suspended particulate of 4% cigarette smoke was 493.549.6 mg/m3 (n=4) 
recorded using the MicroDust Pro-aerosol monitor (Casella CEL, Bedford, UK). To develop 
cigarette smoke-induced lung injury, mice were exposed to 10 sticks of 3R4F research 
cigarettes (Tobacco and Health Research Institute, University of Kentucky, Lexington, KY, 
USA) over a period of 60 minutes a day for 5 consecutive days (Braber et al., 2011). Mice in 
the sham air group were simultaneously placed in another ventilated chamber but exposed to 
fresh air. Andrographolide (0.1, 0.5, and 1 mg/kg; Sigma, St. Louis, MO, USA) or vehicle (1% 
DMSO) in 0.1 mL saline was given by intraperitoneal injection 2 hours before each cigarette 
smoke exposure as described by Bao et al. (Bao et al., 2009). Mice were sacrificed 24 hours 
after the last cigarette smoke or sham air exposure, and lung samples were collected for 
various analyses. 
 
3.3. Collection of bronchoalveolar lavage (BAL) fluid from mice 
BAL fluid was collected 24 hours after the last saline or OVA challenge as previously 
described (Bao et al., 2009) for the asthma mouse model or 24 hours after the last cigarette 
smoke exposure for the cigarette smoke induce lung injury model. Mice were anaesthetized 
by an i.p. injection of 300 µl of an anaesthetic mixture (ketamine: medetomidine: H2O = 3: 4: 
33, Parnell, Alexandria NSW, Australia & Pfizer, Auckland, New Zealand). Tracheotomy was 
performed by inserting a blunt needle (20G) into the trachea. Ice-cold PBS (0.5 ml × 3) was 
instilled into the lungs and a final volume of 1.2~1.3 ml of BAL fluid was retrieved from the 




fluid extraction. BAL fluid supernatants were stored at −80 °C for cytokine, chemokine levels 
and oxidative lung damage markers analysis. 
 
3.4. Total and differential BAL fluid cell counts  
The BAL fluid was centrifuged at 3000 rpm for 5 minutes at 4°C. Supernatant was 
collected and stored at -80°C until further experiments. The pellet was resuspended in 200 µl 
of 8.5 mg/ml NH4Cl for 5 min at room temperature to remove red blood cells. The cell 
suspension was centrifuged at 3000 rpm for 5 min at 4°C and the supernatant was discarded. 
Subsequently, the cell pellet was resuspended in 200 µl of RPMI supplemented with 10 
mg/ml BSA. A total number of viable cells was enumerated using a haemocytometer (10 µl 
cell suspension: 10 µl 0.4 % trypan blue) under a microscope (magnification ×200). 
Following the total cell count, aliquots (10
5 
cells/150 µl) of the cell suspension were 
cytospinned onto a slide in a Shandon Cytospin 3 (Thermo Electron Corporation, Pittsburgh, 
PA) at 600 rpm for 10 min at room temperature. The BAL fluid cells were stained with a 
modified Wright staining (Bao et al., 2009). Briefly, cytospin slides were fixed and stained 
with 800 µl of Liu A for 30 seconds followed by 1600 µl of Liu B for 90 seconds. Differential 
cell count was then performed on a minimum of 500 leukocytes (magnification ×1000). Four 
types of inflammatory cells, namely eosinophils, macrophages, neutrophils, and lymphocytes 
were identified and their respective percentage in the total inflammatory cells was enumerated, 
based on standard morphological criteria and staining (Figure 3.3 and Figure 3.4). The 
absolute number of four types of inflammatory cells was calculated by their percentages and 






















Figure 3.3. Type of cells found in BAL fluid of mice. (A) Control BAL fluid collected 
from the mouse sensitized with OVA and challenged with saline; (B) BAL fluid collected 
from the mouse sensitized with OVA and challenged with OVA. Mac, macrophages; Eos, 



























Figure 3.4. Type of cells found in BAL fluid of mice. (A) Control BAL fluid collected 
from mouse exposed to Sham Air; (B) BAL fluid collected from mouse exposed to cigarette 









3.5. Lung total protein extraction  
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or saline 
challenge and stored in -80°C until study. Before the lungs were remove, cardiac puncture 
carried out after the mice were anaesthetized by an i.p. injection of 300µl of an anesthetic 
mixture (ketamine: medetomidine: H2O = 3: 4: 33, Parnell, Alexandria NSW, Australia &  
Pfizer, Auckland, New Zealand). Lung lobes were then cut into small pieces using scissors 
and homogenized in ice-cold M-PER Mammalian Protein Extraction Reagent containing 
HALT protease inhibitor cocktail (Pierce, Rockford, IL, USA) with a homogenizer 
(SilentCrusher M, Heidolph Elektro GmbH & Co, Kelheim, Genman). Lysates were then 
incubated on ice for 30 minutes before centrifugation (18,000g for 5 minutes); supernatants 
were collected, and protein concentrations were determined using a BCA protein assay kit 
(Thermo Fisher Scientific Inc, Waltham, MA ,USA).  
 
3.6. ELISA  
3.6.1. Cytokines and chemokine levels in BAL fluid  
For the asthma mouse model, levels of IL-4, IL-5, IL-13 and eotaxin in the 
supernatant of the BAL fluid were determined by ELISA according to the manufacturer’s 
instructions. IL-4 and IL-5 ELISA were obtained from BD PharMingen (San Diego, CA). 
Eotaxin and IL-13 were purchased from R&D Systems (Minneapolis, MN). For the cigarette 
smoke model, BAL fluid levels of keratinocyte chemoattractant (KC/CXCL1), interferon-γ-
inducible protein 10 (IP-10/CXCL10), monocyte chemoattractant protein-1 (MCP-1/CCL2) 
and IL-1 were measured using ELISA R&D Systems (Minneapolis, MN) according to the 
manufacturer’s instructions. Briefly, 50 µl of diluted capture antibody (diluted to the 




plate (NUNC, Denmark). The plate was sealed with parafilm and incubated overnight at 4°C. 
Next day, the coating buffer was aspirated and the plate was washed with wash buffer (PBS 
with 0.05% Tween-20). Following the last wash, any remaining wash buffer was removed by 
inverting the plate and blotting it against clean paper towels. Ensuing washing, the plate was 
blocked with 300 µl PBS with 10% FBS for 2 hours. Following blocking, 50 µl of standards 
or BAL fluid samples were added into each well accordingly and incubated for 2 hours at 
room temperature. Next, after washing away the unbound samples and standards, the plate 
was incubated with biotinylated-detection antibody plus HRP for 1 hour (BD OptEIA™ Kit) 
or with biotinylated-detection antibody for 1 hour followed by HRP for 45 minutes (R&D). 
Subsequently, after washing, 50 µl of a substrate solution was added to each well, and 
incubated for 30 min in the dark, followed by addition of 50 µl stopping solution (1M H2SO4). 
Finally, the optical density of each well in the plate was read at 450 nm with λ correction at 
570 nm within 30 min. The detection limits for the cytokines and chemokine used are as 
follows: 4 pg/ml for IL-4; 4 pg/ml for IL-5; 15.6 pg/ml for IL-13; and 2 pg/ml for eotaxin. 9 
pg/ml for IL-1; 15 pg/ml for IP-10; and 16 pg/ml for both MCP-1 and KC. 
 
3.6.2. Oxidative damage marker level in BAL fluid 
BAL fluid levels of oxidative damage markers were measured using competitive 
ELISA kit for 3-nitrotyrosine (3-NT) (Upstate/Millipore, Billerica, MA, USA), in addition to 
8-isoprostane (8-iso-PGF2) and 8-hydroxy-2-deoxy Guanosine (8-OHdG) (Cayman 
Chemicals, Ann Arbor, MI, USA) according to the manufacturers' instructions (Ho et al., 
2012). This assay was based on competition between the samples’ oxidative damage markers, 
the antigen (8-isoprostane, 8-OHdG and 3-NT) and the supplied competing antigen (8-
isoprostane-acetylcholinesterase conjugate/8-isoprotane tracer, 8-OHdG-acetylcholinesterase 




antibodies. Both 8-isoprostane and 8-OHdG kits come with secondary antibody pre-coated 
plate and enzyme link antigen (8-isoprostane Tracer, 8-OH-dG Tracer respectively) while the 
3-NT kits comes with the enzyme link secondary antibody and antigen (nitrated BSA) for 
well coating.  Briefly, for the 3-NT assay, 96-well plates were coated with 5 μg/mL nitrated 
bovine serum albumin (BSA) overnight, and blocked with blocking buffer for 2 hours. 50 μl 
of BALF sample or standard samples and 50 μl of 2×anti-nitrotyrosine were added to each 
well. Subsequently, the plates were incubated at 37 °C for 60 min. After un-bound antibody 
were remove by washing, 100 μl per well of enzyme link secondary antibody (1× anti-rabbit 
IgG, HRP-conjugate) was added and incubated at 37 °C for 60 min. For the 8-isoprostane and 
8-OHdG assay, a 50 μl BALF sample or standard, 50 μl competing enzyme link antigen and 
the primary antibody (8-OHdG monoclonal antibody and 8-Isoprostane antiserum) were 
added to each pre-coated well, incubating for 14 hours at 4°C.  For the entire assays, the 
plates were washed between each step. Following competitive binding, substrate solution 
(Ellman’s reagent for 8-isoprostane and 8-OH-dG, LumiGlo Chemiluminescent® Substrate 
for Nitrotyrosine) were added into each well in the dark. The product of the enzymatic 
reaction for 8-isoprostane and 8-OH-dG assay produces a distinct yellow colour which was 
determined spectrophotometrically at wavelength between 405-420 nm. While the products 
for the enzymatic reaction for 3-NT was measured with the luminescence as relative light 
units (RLU). Luminescence was measured using a microplate reader and the background 
luminescence subtracted from the values. The levels were calculated with the standard curve 
and expressed as picograms per milliliter of BAL fluid (8-isoprostane, 8-OH-dG) or 





3.6.3. Immunoglobulin levels in serum  
For the asthma mouse model, blood was collected from the mouse through cardiac 
puncture, and allowed to clot by leaving at room temperature for 3 hours. The clear 
supernatant was collected as the serum, and stored at -80°C until further experiments. Serum 
levels of total IgE, OVA-specific IgE, OVA-specific IgG1 and OVA-specific IgG2a were 
assayed by ELISA. Briefly, ELISA plate was incubated at 4°C overnight with coating buffer 
containing either 20 µg/ml OVA (for OVA-specific IgE, OVA-specific IgG1 and  OVA-
specific IgG2a) or IgE capture antibody (for total IgE measurement). The following day, the 
plate was blocked with 10% FBS in 300 µl PBS for 2 hours at room temperature.  Following 
blocking, total IgE standards or diluted serum samples were added into the respective wells 
and incubated for 2 hours. Next, the respective detection antibodies were added and the 
mixtures were incubated for 1 hour. After that, HRP-conjugated antibody was added and 
incubated for 45 min, followed by substrate solution for 30 minutes in the dark. Finally, the 
optical density of each well was read at 450 nm with λ correction at 570 nm within 30 
minutes of adding stopping solution. The detection limit for total IgE is 2 ng/ml. 
 
3.6.4. Cotinine Measurement  
For the cigarette smoke model, cotinine is the major metabolite of nicotine (Benowitz, 
2009). Plasma cotinine levels was measured as a marker of cigarette smoking. Immediately 
after sham air or cigarette smoke exposure, blood was drawn and the blood samples were 
centrifuged for 15 minutes at 5,000 g at 4° C. The resultant plasma cotinine levels were 
measured by ELISA (Bio-Quant, San Diego, CA, USA) according to the manufacturer’s 






3.7. Measurements of airway hyperresponsiveness (AHR) 
Mice were anesthetized and tracheotomy was performed as described (Bao et al., 
2009). The animal was intubated with a cannula that is connected to a multiport that leads to 
the pneumotach, ventilator and nebulizer within the FinePointe Series RC Sites (Buxco 
Research System, Wilmington, NC). The mouse was ventilated at a fixed breathing rate of 




Figure 3.5. The FinePointe™ system (Buxco Research Systems, Wilmington, NC, United 
States). The system measures the resistance and compliance of mouse in response to 





increasing concentrations of nebulized methacholine (0.5– 8.0 mg/ml) were recorded using 
FinePointe data acquisition and analysis software (Buxco Research System). The 
methacholine used was dissolved in PBS and administered through the system nebulizer at a 
volume of 10μl per aerosol. PBS is nebulised before and after methacholine administration to 
serve as a baseline and to clean up the nebulizer. A different nebulizer was used for different 
animal and the system was air dried before proceeding to the next animal. Results are 
expressed as a percentage of the respective basal values in response to PBS. 
 
3.8. Histology 
Histological studies were performed for the allergic mouse model studies. Essentially, 
lungs were isolated from the thoracic cavity 24 hours after the last OVA or saline challenge 
after the injection with a lethal dose of anaesthesia  (300µl of an anaesthesia mixture) and 
after cardiac puncture was performed, fixed in 10% neutral buffered formalin solution for at 
least 48 hours, and processed in a tissue processor (Leica Microsystems, Wetzler, Germany). 
Briefly, lungs were dehydrated in a series of ethanol mixtures (70% to 80% to 90% to 
100%, 30 minutes each and 2 hours for 100%), and immersed in xylene for 10.5 hours. Lungs 
were infiltrated with hot paraffin for 3 hours and embedded in paraffin wax. The specimens 
were then cut into 5 µm sections using a microtome (Leica Microsystems, Wetzler, Germany) 
and fixed on slides. For H&E staining, slides were deparaffinized with HistoClear for 10 min 
and rehydrated in a series of ethanol to water mixtures (100% to 90% to 70% to water and 
each for 2 minutes). The sections were then stained with Harris haematoxylin for 5 minutes, 
washed in the distilled water, and differentiated in 0.1% acid alcohol solution for 30 seconds. 
The sections were washed with tap water for 5 minutes and counter stained with Eosin for 1 
minute. Subsequently, the sections were dehydrated in a series of ethanol solutions (70 % to 




Evaluation of inflammation around peribronchial and perivascular areas was semi-
quantitatively performed in a blind manner as previously described (Myou et al., 2003). A 
subjective scale (0 - 4) was assigned as follows: 0: no inflammatory cells; 1: occasional 
cuffing with few inflammatory cells; 2: most bronchi or vessels surrounded by a thin layer of 
inflammatory cells; 3: most bronchi or vessels surrounded by a thick layer (2 - 4 cells layer 
deep) of inflammatory cells; 4: most of bronchi or vessels surrounded by a thicker layer (more 
than 4 cells layer deep) of inflammatory cells.  Likewise, for periodic acid Schiff (PAS) 
staining, slides were deparaffinized with HistoClear for 10 minutes and rehydrated in a series 
of ethanol to water mixtures (100% to 90% to 70% to water and each for 2 minutes). 
Subsequently, the sections were sequentially immersed in the periodic acid (5 minutes), water 
(5 minutes), and Schiff`s reagent (15 minutes). The sections were washed with tap water for 5 
minutes and stained in Gill Haematoxylin for 90 seconds. Next, the sections were dehydrated 
in a series of ethanol mixtures (70% to 90% to 100% and each for 2 minutes) and cleared with 
HistoClear for 10 minutes. Evaluation of mucus production or goblet cell hyperplasia was 
semi-quantitatively performed in a blind manner as previously described (Grunig et al., 1998). 
According to the percentage of PAS-positive mucin-producing cells in the epithelium, scores 
(0 - 4) were assigned as follows: 0, no goblet cells; 1, < 25%; 2, 25–50%; 3, 50–75%; 
4, >75%.  Lung tissue mast cells were stained using toluidine-blue, and the number of intact 
and degranulating mast cells was counted in the entire lung sections as described (Pushparaj 
et al., 2009). Briefly, toluidine-blue staining for lung mast cells were perfomed by 
deparaffinized paraffin sections slides with HistoClear for 10 minutes and rehydrated in a 
series of ethanol to water mixtures (100% to 90% to 70% to water and each for 2 minutes). 
Next, the sections were rinsed in water and immersed in the toluidine-blue stains for 2 
minutes. The sections were washed with tap water for 10 minutes and dehydrated in a series 




HistoClear for 10 minutes. Mast cells were identified as those cells that contained toluidine 
blue–positive granules. For both H&E and PAS staining, bronchioles with the maximum 
internal diameter two times greater than the minimum internal diameter were not used for 
analysis. The scoring of inflammatory, goblet cells as well as intact and degranulating mast 
cells was performed in 2 - 4 preparations of each mouse and mean scores were calculated 
from 4 - 5 mice. 
 
3.9. Cell cultures 
A549 human lung epithelial cells, BEAS-2B human transformed lung epithelial cells, 
and RBL-2H3 rat basophilic leukemia cells were obtained from the American Type Tissue 
Collection (American Type Tissue Collection, Rockville, MD, USA). A549 and BEAS-2B 
cells were cultured in RPMI 1640, while RBL-2H3 cells were grown in DMEM. Both media 
were supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100μg/mL), and 
cells were grown at 37°C in a humidified 5% CO2 incubator.  
 
3.9.1. Cell viability assay 
A549 cells (3×10
4
/well), BEAS-2B cells (5×10
4
/well) and RBL-2H3 cells (3×10
4
/well) 
were seeded on flat-bottomed 96-well plates for overnight, and then incubated with increasing 
concentrations (3–120 M) of DDAG or andrographolide for 24 hours and 48 hours at 37°C. 
Both DDAG and andrographolide was dissolved in DMSO.  Cell viability was analyzed using 
the CellTiter 96
®
 AQueous non-radioactive cell proliferation assay (Promega,
 
Madison, WI) 
according to the manufacturer’s protocol. This MTS assay is based on the ability of viable 




recorded at 490  nm (Tecan microplate reader infinite M200; Mannedorf, Switzerland) and 
equal volume of DMSO treated cells were used as control. 
 
3.9.2. In Vitro Inflammation model  
To explore the anti-inflammatory mechanism of action of DDAG, A549 cells (1×10
6
 
cells) were seeded in a 100 mm Petri dish, and at 90% confluence, cells were treated with 
30μM DDAG or vehicle (0.1% DMSO) for 4 h before stimulation with 10 ng/mL TNF-α for 
30 min and protein lysates were prepared for analysis. 
 
3.9.3. In vitro cigarette smoke exposure model  
Cigarette Smoke Extract (CSE) was freshly prepared immediately before each 
experiment by bubbling smoke from one cigarette to 10 mL of RPMI 1640 medium 
supplemented with 1% FBS at a rate of one cigarette every 10 min as described (Kode et al., 
2008). CSE was adjusted to pH 7.4 and sterile-filtered through a 0.45-m Acrodisc filter (Pall, 
Ann Arbor, MI, USA). CSE preparation was standardized by setting the optical density at 0.8 
±0.05 with absorbance wavelength at 340 mm. Control medium was prepared in the same 
way as CSE except for bubbling fresh air into 10 mL of RPMI medium. BEAS-2B were 
cultured in RPMI 1640 supplemented with 1% FBS. Cells were pre-incubated with a non-
toxic concentration of 30 M andrographolide (Bao et al., 2009) or vehicle (0.05% DMSO) 
for 1 h before exposure to 2% CSE for indicated times to explore the anti-oxidants mechanism 
of action of andrographolide in cigarette smoke extract exposed medium. Using the MTS 





3.10. Nuclear Protein extraction  
For the allergic inflammation model, nuclear proteins were extracted from lung tissues 
and A549 cells using a Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA). Using the 
same kit, for the cigarette smoke exposure model, cytoplasmic and nuclear extractions were 
performed according to manufacturers’ instructions. Briefly, the cells are firstly collected in 
ice-cold PBS in the presence of phosphatase inhibitors to limit further protein modifications 
such as proteolysis, and dephosphorylation. Subsequently, the cells are resuspended in 
hypotonic buffer to swell the cell membrane and make it fragile. Detergent was then added to 
cause the leakage of the cytoplasmic proteins into the supernatant. After collection of the 
cytoplasmic fraction, the nuclei are lysed and the nuclear proteins are solubilized in the lysis 
buffer in the presence of the protease inhibitor cocktail. The extracted proteins were used for 
immunoblotting studies or transcription factor transactivation assay.  
 
3.10.1. NF-B and Nrf2 DNA-transactivation Assay  
For the allergic inflammation model, nuclear proteins were also analyzed for NF-B 
DNA-binding activity using the TransAM™ NF-B p65 transcription factor assay kit (Active 
Motif). For the cigarette smoke exposure model, nuclear extracts were used for measuring 
Nrf2 binding activity to immobilized antioxidant response elements (ARE) using a 
TransAM™ Nrf2 kit (Active Motif). Briefly, both of this kit contains a 96-well plate with 
immobilized oligonucleotide containing either the NF-κB consensus binding sequence (5'-
GGGACTTTCC-3') or ARE consensus binding site (5'-
GTCACAGTGACTCAGCAGAATCTG-3') which the active form of Nrf2 contained in the 
nuclear extract will specifically bind to. Nuclear extracts (5 µg) were incubated in the wells 




wells following washing. A HRP-conjugated secondary antibody was subsequently added to 
detect the bound primary antibody. Developing solution and stopping solution were used to 
develop a colorimetric reaction. The absorbance was measured at 450 nm with a reference 
wavelength of 655 nm by a microplate reader (Tecan microplate reader infinite M200; 
Mannedorf, Switzerland). In addition, the wild-type or mutated NF-κB or Nrf2 consensus 
oligonucleotide was added into the reactions as the competitive or mutated competitive 
control to monitor the specificity of the assay. 
 
3.11. Immunoblotting 
For the NF-B p65 nuclear translocation studies, lung and cell culture nuclear proteins 
were utilized while for Nrf2 nuclear translocation studies, both cell culture cytoplasmic and 
nuclear proteins were used for immunoblotting studies. A similar amount of protein (30 µg) 
mixed with sample buffer were separated by 10% SDS-PAGE in a Trans-Blot tank (Bio-Rad 
Laboratories, Hercules, CA, USA) and transferred to a PVDF membrane using a semi-try 
transblotter (ATTO Corp, Tokyo, Japan). The PVDF membrane was blocked with 5% skim 
milk powder (Fluka, Sigma) in Tween-20 Tris buffered saline (TTBS) for 2 hours and probed 
overnight at 4°C with either with anti-p65 (Cell Signaling Technology, Beverly, MA) for NF-
B p65 nuclear translocation studies or with rabbit anti-Nrf2 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) antibodies for Nrf2 nuclear translocation studies.  The PVDF was 
subsequently washed with TTBS for 10 times (2 - 3 min each), and incubated in HRP-
conjugated anti-rabbit or anti-mouse antibodies for two hours before being developed on 
hyperfilms using an ECL reagent. After washing several times in TTBS, ECL reagent was 
removed with western blot stripping buffer. Subsequently, the PVDF was blocked again, 
reprobed with anti-TATA box binding protein (TBP) (Abcam, Cambridge, UK) or mouse 




kit. Band intensity was quantitated using ImageJ software (NIH) as described previously (Goh 
et al., 2012). 
 
3.12. RNA extraction and Reverse Transcription 
Lungs were isolated from the thoracic cavity 24 hours after the last OVA or saline 
challenge for the allergic mouse model as well as 24 hours after the last cigarette smoke 
exposure for the cigarette smoke lung injury model. The isolated lung are immediately stored 
in RNAlater at -80°C. Before RNA isolation, lung tissues were removed from the RNAlater 
with sterile forceps, immersed in 1 ml Trizol (Invitrogen, Carlsbad, CA, USA), and 
homogenized on ice using the homogenizer. Next, RNA isolation was performed using Trizol 
according to the instructions from Invitrogen. Similarly, for Nrf2 transactivation in vitro 
studies, mRNA is extracted at the mentioned time point using Trizol following manufacturer 
instructions. After dissolving the isolated RNA in DEPC water, spectrophotometric 
measurements was perform using NanoDrop ND-1000 (Thermo Fisher Scientific Inc, 
Waltham, MA, USA) to quantify the amount and purity of the RNA present in the sample. 
Both A260/A280 (DNA/protein) and A260/A230 (DNA/organic contaminants) ratio were 
recorded as an indicator of purity of RNA. An acceptable level of purity for RNA extracts 
should be around 1.9 to 2.1 for both A260/A280 and A260/A230 ratio. Subsequently, cDNA 
was synthesized from 1 µg of isolated RNA by a random primer and AMV reverse 
transcriptase using a multi-well thermal cycler (GeneAmp PCR system 2700, Applied 





3.13. Polymerase Chain Reaction (PCR)  
For the allergic mouse model studies, PCR amplifications were then performed on 1 µl 
of cDNA template in a 25 µl reaction volume containing 12.5 µl of 2×PCR master mix (50 
units/ml TaqDNA polymerase, 400 µM dATP, 400 µM dGTP, 400 µMdCTP, 400 µM dTTP, 
and 3 mM MgCl2), 9.5 µl nuclease-free water, 1 µl forward primer (10 µM) and 1 µl reverse 
primer (10 µM) using the multiwell thermal cycler. Primers used in the PCR reactions are 
listed in Table 3.1. PCR products were separated by electrophoresis on 2% agarose gels 
stained with ethidium bromide (100 V, 30 min) and were visualized under an ultraviolet 
transilluminator. Furthermore, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as a housekeeping gene to normalize variations between sample loadings. For the 
cigarette smoke exposed mouse and Beas-2B cells studies, quantitative real time PCR were 
perform to quantify the gene expression profile. Template cDNA (100ng) in PCR mixture 
containing Fast SYBR Green Master Mix (Applied Biosystems, Foster City, California, USA) 
with a total reaction mixture volume of 20 μl were added in MicroAmp optical 96-well 
reaction plates. Plates were sealed, centrifuged, and then subjected to amplification. 
Quantitative real time PCR was performed using a sequence detection system (ABI 7500 
Cycler; Applied Biosystems, Foster City, CA). The PCR protocol consisted of 2 minutes at 
50°C and 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 
60°C. All measurements were done in triplicate. The primers for inflammatory and 
antioxidant genes are listed in Table 3.2. The mRNA expression levels for all samples were 
normalized to the level of the housekeeping gene 18S. Following amplification, melting curve 
analysis was performed to determine the specificity of the amplified products. Data 















      
AMCase 
(gi|37999744) 
Forward  5’-TGGGTTCTGGGCCTACTATG-3’ 32 483 (Zhao et al., 
2005) Reverse  5’-GCTTGACAATGCTGCTGGTA-3’ 
      
Ym1 
(gi|285015) 
Forward  5’-CTGGAATTGGTGCCCCTACA-3’ 32 624 (Zhao et al., 
2005) Reverse  5’-CAAGCATGGTGGTTTTACAGGA-3’ 
      
Ym2 
(gi|22123907) 
Forward  5’-CAGAACCGTCAGACATTCATTA-3’ 32 429 (Zhao et al., 
2005) Reverse  5’-ATGGTCCTTCCAGTAGGTAATA-3’ 
      
YKL-40 
(gi|142347793) 
Forward  5’-GTACAAGCTGGTCTGCTACT-3’ 30 277 (Bao et al., 
2009) Reverse  5’-GTTGGAGGCAATCTCGGAAA-3’ 
      
E-selectin 
(gi|118130193) 
Forward  5’-AACGCCAGAACAACAATTCC-3’ 35 227 Primer 3 
Reverse  5’-TGAATTGCCACCAGATGTGT-3’ 
      
COX-2 
(gi|118130137) 
Forward  5’-GGAGAGACTATCAAGATAGT-3’ 40 861 (Jung et al., 
2007) Reverse  5’-ATGGTCAGTAGACTTTTACA-3’ 
      
Muc5ac 
(gi|114431223) 
Forward  5’-GAGTGACATTGCAGGAAGCA-3’ 38 361 Primer 3 
Reverse  5’-CAGAGGACAGGAAGGTGAGC-3’ 
      
IL-17A 
(gi|142367609) 
Forward  5’-CCGCAATGAAGACCCTGATAGA-3’ 35 187 (Egan et al., 
2008) Reverse  5’-CAGCATCTTCTCGACCCTGAAA-3’ 
      
IL-33 
(gi|257900494) 
Forward  5’-TCCTTGCTTGGCAGTATCCA-3’ 35 52 (Verri et al., 
2008) Reverse  5’-TGCTCAATGTGTCAACAGACG-3’ 
      
VCAM-1 
(gi|31981429) 
Forward  5’-CAAGGGTGACCAGCTCATGAA-3’ 30 518 (Bao et al., 
2009) Reverse  5’-TGTGCAGCCACCTGAGATCC-3’ 
      
GADPH 
(gi|126012538) 
Forward  5’- AGGTCGGTGTGAACGGATTTG-3’ 30 95 (Lampton et 
al., 2008) Reverse  5’-GGGGTCGTTGATGGCAACA-3’ 
























al., 2005) Reverse  5’-GGTCAAAGACAGCTGCATCA-3’ 
     
TIMP-1 
(gi|113205064) 
Forward  5’-GTGGGAAATGCCGCAGAT-3’ 67 (Manoury et 
al., 2006) Reverse  5’-GGGCATATCCACAGAGGCTTT-3’ 
     
GM-CSF 
(gi|145301581) 
Forward  5’-GGGCGCCTTGAACATGAC-3’ 76 (Wuthrich et 
al., 2005) Reverse  5’-TTGTGTTTCACAGTCCGTTTCC-3’ 
     
TNF- 
(gi|133892368) 
Forward  5’-TCGAGTGACAAGCCCGTAGC-3’ 68 (Mashreghi et 
al., 2008) Reverse  5’- CTCAGCCACTCCAGCTGCTC-3’ 
     
MIP-2 
(gi|118130527) 
Forward  5’-AGTGAACTGCGCTGTCAATGC-3’ 143 (Hu et al., 
2004) Reverse  5’-AGGCAAACTTTTTGACCGCC-3’ 
     
iNOS 
(gi|146134510) 
Forward  5’-CGGGCAAACATCACATTCAGATCCCG-3’ 69 (Boyer et al., 
2011) Reverse  5’-TATATTGCTGTGGCTCCCATGTT-3’ 
     
GCLM 
(gi|53759142) 
Forward  5’-AATCAACCCAGATTTGGTCAGG-3’ 56 Primer Bank 
Reverse  5’-GAGATACAGTGCATTCCAAGACA-3’ 
     
GCLC 
(gi|308199422) 
Forward  5’-GGAGGAAACCAAGCGCCAT-3’ 79 Primer Bank 
Reverse  5’-CTTGACGGCGTGGTAGATGT-3’ 
     
GR 
(gi|305410788) 
Forward  5’-CACTTGCGTGAATGTTGGATG-3’ 242 Primer Bank 
Reverse  5’-TGGGATCACTCGTGAAGGCT-3’ 
     
GPx-2 
(gi|375163496) 
Forward  5’-GGTAGATTTCAATACGTTCCGGG-3’ 52 Primer Bank 
Reverse  5’-AGCCACATTCTCAATCAGCAC-3’ 
     
HO-1 
(gi|298676487) 
Forward  5’-GCAGAGGGTGATAGAAGAGGC-3’ 46 Primer Bank 
Reverse  5’-GATGTTGAGCAGGAACGCAGT-3’ 
     
18S 
(gi| 225637497) 
Forward  5’-GCCGCTAGAGGTGAAATTCTTG-3’ 66 (Medicherla et 
al., 2008) Reverse  5’-CATTCTTGGCAAATGCTTTCG-3’ 






3.14. Biochemical Assay Antioxidant Activities  
3.14.1. Antioxidant Activities in Lung Tissue 
Frozen lung tissues were homogenized in PBS and used for assessment of the 
activities of catalase, superoxide dismutase (SOD), glutathione peroxidase (GPx) and 
glutathione reductase (GR) using specific biochemical assays, according to the manufacturer’s 
instruction (Cayman Chemical, Ann Arbor, Michigan, USA). Catalase activity was 
determined based on the reaction of the enzyme with methanol in presence of an optimal 
concentration of hydrogen peroxide. The formaldehyde produced is measured 
spectrophotometrically with 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole as the 
chromogen. The catalase activity was expressed as nmol/min/mg of protein in the sample. The 
quantification of SOD activity was determined by using tetrazolium salt for detection of 
superoxide radicals generated by xanthine oxidase and hypoxanthine. The SOD assay 
measures all three types of SOD (Cu/Zn, Mn, and FeSOD). One unit of superoxide is defined 
as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical. The 
glutathione peroxidase (GPx) activity was examined spectrophotometrically in lung through 
an indirect couple reaction with glutathione reductase. Oxidized glutathione, produced on 
reduction of hydroperoxide by GPx, is recycled to its reduced state by glutathione reductase 
and NADP reduced. The oxidation of NADP reduced to NADP
+
 is accompanied by a 
decrease in absorbance at 340 nm. Under conditions in which the GPx activity is rate limiting, 
the rate of decrease in the A340 is directly proportional to the GPx activity in the sample. The 
GR activity was monitor by measuring the rate of NADPH oxidation. The oxidation of 
NADPH to NADP
+
 is accompanied by a decrease in absorbance at 340nm and is directly 





3.14.2. Glutathione Assay  
BEAS-2B cells were stimulated with CSE for 24 hours as describe above. Glutathione 
(GSH) levels were determined using glutathione assay kit (Cayman Chemical, Ann Arbor, MI) 
according to manufacturer instructions. Briefly, BEAS-2B cells were harvested by gently 
scraping the culture dish and centrifuged. The cells are subsequently resuspended in PBS 
buffer before sonication and centrifugation to obtain the cell lysate supernatant. 50 μl of 
supernatant are used for the quantification of GSH.  Principally, the kit used glutathione 
reductase (GR) for the quantification of GSH. The sulfhydryl group of GSH reacts with 
DTNB and produces a yellow coloured TNB (5-thios-2-nitrobenzoic acid). The mixed 
disulfide is reduced by GR to recycle the GSH and produce more TNB. Therefore, the rate of 
TNB production is directly proportional to this recycling reaction which in turn is directly 
proportional to the concentration of GSH in the sample. The estimation of GSH in the sample 
is measured by absorbance at 405 nm.  
 
3.15. Statistical analysis 
Data are presented as means ± SEM. One-way ANOVA followed by Dunnett’s test was 
used to determine significant differences between treatment groups. Significant levels were 

























4. ANTI-INFLAMMATORY EFFECTS OF 14-DEOXY-11,12-
DIDEHYDROANDROGRAPHOLIDE IN ALLERGIC ASTHMA 







4.1.1.  DDAG is less cytotoxic than andrographolide  
To determine the cytotoxicity profile of DDAG and andrographolide, both of these 
compounds were incubated with 3 different cell-lines at two different time points, 24 hours 
and 48 hours. MTS assays were carried out to determine the viability profile with DMSO as 
vehicle control for both andrographolide and DDAG. MTS assay are colorimetric assays 
generally used to determine cytotoxicity of potential medicinal agents as these agents would 
stimulate or inhibit cell viability and growth. Our present findings reveal that andrographolide 
dose-dependently and time-dependently reduced the viability of A549 (Figure 4.1) and 
BEAS-2B human lung epithelial cells (Figure 4.2) and RBL-2H3 mast cells (Figure 4.3). At 
low dosage, andrographolide were less cytotoxic toward BEAS-2B cells,  which is an 
epithelial virus transformed normal human bronchial epithelium obtained from autopsy of 
non-cancerous individuals as compare to the tumour cell lines tested, such as A549 and RBL-
2H3 cells. At 30 µM, andrographolide treatment at 48 hours reduced the viability of A549 and 
RBL-2H3 cells to approximately 60% and 40% of control respectively while maintaining the 
viability of BEAS-2B cells lines of above approximately 90% compared to control at the 
same concentration of andrographolide treatment. In contrast, DDAG did not reduce cell 
viability of these cultured cells at all concentrations tested and at both 24 and 48 hours of 
exposure. On the other hand, even with 48 hours of high dosage of DDAG (120 µM) 
treatment, all the cell lines tested show an show a viability above approximately 90% as 
compare to vehicle control.  These data suggest that andrographolide treatments are more 




















Figure 4.1.  Effects of andrographolide (open circles) and 14-deoxy-11,12-
didehydroandrographolide (DDAG) (filled squares) on cell viability of A549 cells at 24 and 
48 h time intervals. Andrographolide dose-dependently decreased the cell viability of A549 
ccells. In contrast, DDAG had no effect on the viability of A549 cells at all concentrations 
used and both time intervals. Values shown are the means ± SEM of six separate experiments. 











































































Figure 4.2.  Effects of andrographolide (open circles) and 14-deoxy-11,12-
didehydroandrographolide (DDAG) (filled squares) on cell viability of BEAS-2B cells at 24 
and 48 h time intervals. Andrographolide dose-dependently decreased the cell viability of 
BEAS-2B cells. In contrast, DDAG had no effect on the viability of BEAS-2B cells at all 
concentrations used and both time intervals. Values shown are the means ± SEM of six 






























































































Figure 4.3.  Effects of andrographolide (open circles) and 14-deoxy-11,12-
didehydroandrographolide (DDAG) (filled squares) on cell viability of RBL-2H3 cells at 24 
and 48 h time intervals. Andrographolide dose-dependently decreased the cell viability of 
RBL-2H3 cells. In contrast, DDAG had no or minor effects on the viability of RBL-2H3 cells 
at all concentrations used and both time intervals. Values shown are the means ± SEM of six 




























































4.1.2.  DDAG reduces bronchoalveolar lavage fluid Th2 cytokines 
BAL fluid was collected 24 hours after the last OVA or saline aerosol challenge. After 
separation of infiltrating cells, the bronchoalveolar lavage (BAL) fluids were quickly stored in 
-80°C until ELISA. By using ELISA, we observed that OVA challenge caused a notable 
increase in IL-4, IL-5, IL-13 and eotaxin levels in BAL fluid of OVA sensitize mice as 
compare to Saline challenge mice. The increase of these cytokines represent an enhance Th2 
response typically observe in allergic asthma patients. IL-5 together with eotaxin lead to an 
increase of eosinophils infiltration while IL-4 and IL-13 are critical in IgE class switching.  
DDAG significantly (p < 0.05) reduced IL-4, IL-5, and IL-13 and, to a lesser extent, eotaxin 
levels in BAL fluid, in a dose-dependent manner (Figure 4.4).  
 
4.1.3.  DDAG reduces serum immunoglobulins 
To study the effects of DDAG on the continuing OVA-specific Th2 response in vivo, 
levels of total IgE, OVA-specific IgE, OVA-specific IgG1 and OVA-specific IgG2a were 
determined using ELISA. Substantial elevation in serum total IgE, OVA-specific IgE, and 
OVA-specific IgG1 levels was observed, with no changes in OVA-specific IgG2a levels, in 
OVA-sensitise and challenged mice (Figure 4.5). DDAG significantly (p < 0.05) suppressed 
OVA-specific IgE levels and, to a lesser extent, the serum levels of total IgE and OVA-
specific IgG1 (Figure 4.5). DDAG had no effects on the serum level of OVA-specific IgG2a. 
The production of subclasses of immunoglobulins is regulated by cytokines derived mainly 
from T helper cells. The Th2 cytokine IL-4 induces IgG1 and IgE production, whereas the 
Th1 cytokine IFN-γ induces IgG2a in mice. Therefore, these findings imply that DDAG is 































Figure 4.4.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on BAL fluid 
Th2 cytokines. BAL fluids were collected 24 h after the last OVA aerosol challenge. Levels 
of IL-4, IL-5, IL-13, and eotaxin were analyzed using ELISA (n = 6–9 mice). Lower limits of 
detection were as follows: IL-4 and IL-5 at 4 pg/mL, IL-13 at 15.6 pg/mL, and eotaxin at 2 






























































































Figure 4.5.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on serum 
immunoglobulins. Mouse serum was obtained 24 hours after the last OVA aerosol challenge. 
The levels of total IgE, OVA-specific IgE, OVA-specific IgG1, and OVA-specific IgG2a 
were analysed using ELISA (n = 6–9 mice). Values shown are the means ± SEM. *Significant 


















































4.1.4.  DDAG reduces lung inflammatory biomarkers  
To study the effects of DDAG on the profile of expression of inflammatory 
biomarkers, lungs were harvested 24 hours after the last aerosol challenge.  The reverse 
transcription PCR data shows that OVA challenge markedly up-regulated lung mRNA levels 
of the inducible endothelial cell adhesion molecules, such as vascular cell adhesion molecule 
1 (VCAM-1) and E-selectin (or endothelial-leukocyte adhesion molecule 1), and chemokines 
such as monocyte chemotactic protein-1 (MCP-1/CCL2), which are pivotal for the 
recruitment of inflammatory cells (Hogan et al., 2008; Kelly et al., 2007).  MCP-1 recruits 
monocytes to sites of tissue injury, infection, and inflammation. Chitinases including acidic 
mammalian chitinase (AMCase), and chitinase like protein such as Ym1, Ym2, and YKL-40 
have been shown recently to play critical roles in airway inflammation and remodelling 
(Chupp et al., 2007; Guan et al., 2009; Zhao et al., 2005; Zhu et al., 2004). Furthermore, 
AMCase and YKL-40 are highly associated with allergic bronchial asthma in patients (Shuhui 
et al., 2009). IL-17 and IL-33, a member of the IL-1 cytokine family, are two effector 
cytokines that have been shown to be essential for airway inflammation and remodelling 
(Kearley et al., 2009; Nembrini et al., 2009). Both IL-17 and IL-33 have been associated with 
severe and steroid insensitive asthma (Alcorn et al., 2010; Prefontaine et al., 2009). 
Cyclooxygenase-2 (COX-2) is known to be essential for PGD2-mediated airway eosinophilia 
and AHR (Shiraishi et al., 2008), and Muc5ac, essential for mucus hypersecretion (Morcillo 
et al., 2006). Pretreatment with DDAG (1 mg/kg) strongly suppressed the expression of 
VCAM-1, E-selectin, MCP-1, AMCase, Ym-2, YKL-40, Muc5ac, COX2, IL-17, and IL-33 
levels in the allergic airways of OVA sensitize and challenge mice lungs (Figure 4.6). Taken 




































Figure 4.6.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on lung 
inflammatory biomarkers. Lung tissues were collected 24 h after the last OVA aerosol 
challenge. Total mRNA was extracted using TriZol reagent, and the PCR products were 
separated in a 2% agarose gel visualized under UV light. GADPH was used as an internal 




















4.1.5.  DDAG suppresses allergic airway inflammation  
OVA challenge markedly increased total cell and eosinophil counts. A minor but 
significant increase of lymphocyte and neutrophils upon OVA challenge was also observed 
(Figure 4.7). DDAG (0.1, 0.5, and 1 mg/kg) significantly decreased total cell and eosinophil 
counts in BAL fluid in a dose-dependent manner (Figure 4.8). At 1 mg/kg, DDAG also 
reduced macrophage and lymphocyte counts.  
Lung tissue was collected 24 hours after the last OVA challenge. OVA aerosol 
challenge induced substantial inflammatory cell infiltration into the peribronchiolar and 
perivascular connective tissues as compared to saline challenge (Figure 4.9). The majority of 
the infiltrated inflammatory cells were eosinophils. Pre-treatment with DDAG (1 mg/kg) 
markedly diminished the eosinophil-rich leukocyte infiltration (Figure 4.9). OVA-challenged 
but not saline challenge mice developed goblet cell hyperplasia and mucus hypersecretion in 
the bronchi. The OVA-induced mucus secretion was markedly suppressed by DDAG (1 
mg/kg) as visualize by PAS staining (Figure 4.10). 
 
4.1.6.  DDAG prevents lung mast cell degranulation 
OVA aerosol challenge markedly decreased intact mast cell number and increased 
degranulating mast cells in the lungs. Increase in OVA specific IgE will lead to mast cell 
activation upon OVA challenge in OVA sensitize mouse as mast cell contain the high affinity 
IgE binding receptor, FcεR1. Activated mast cell would release score of preform mediators, 
newly formed lipid mediators and cytokines such as eosinophil chemotactic factors leading to 
an enhance inflammatory response. DDAG (1 mg/kg) reduced mast cell degranulation and 


























Figure 4.7.  Inflammatory cell counts in BAL fluid obtained from sensitized mice 24 h 
after the last saline aerosol (n = 7 mice) or OVA aerosol (n = 7 mice) challenge. OVA 
challenge induced marked infiltration of inflammatory cells into the peribronchiolar and 

























































Figure 4.8.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on OVA-
induced inflammatory cell recruitment. DDAG dose-dependently reduced OVA-induced 
inflammatory cell counts in BAL fluid from sensitized mice 24 h after the last OVA aerosol 
challenge (DMSO, n = 7; 0.1 mg/kg, n = 8; 0.5 mg/kg, n = 7; and 1 mg/kg, n = 10). 
Differential cell counts were performed on a minimum of 500 cells to identify eosinophils 








































































Figure 4.9.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on OVA-
induced inflammatory cell recruitment. Histological slides showing lung tissue eosinophilia 
(magnification 200×) 24 h after the last challenge of saline aerosol, OVA aerosol, OVA 
aerosol plus DMSO, or OVA aerosol plus 1 mg/kg DDAG are displayed. Quantitative 
analyses of inflammatory cell infiltration in lung sections were performed as previously 
described (Bao et al., 2009). Scoring of inflammatory cells was performed in at least three 
different fields for each lung section. Mean scores were obtained from four animals. 

































































Figure 4.10.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on OVA-
induced mucus hypersecretion. Histological slides showing lung mucus secretion 
(magnification 200×) 24 h after the last challenge of saline aerosol, OVA aerosol, OVA 
aerosol plus DMSO, or OVA aerosol plus 1 mg/kg DDAG are displayed. Quantitative 
analyses of inflammatory cell infiltration and mucus production in lung sections were 
performed as previously described (Bao et al., 2009). Scoring of goblet cells was performed 
in at least three different fields for each lung section. Mean scores were obtained from four 































































Figure 4.11.  Effects of DDAG on OVA-induced lung mast cell degranulation. Lung tissue 
mast cells were stained using toluidine-blue, and the number of intact and degranulating mast 
cells was counted (magnification x 200) in the entire lung sections. Black arrow heads point 
to intact mast cells. Red arrow heads indicate degranulating mast cells. Mean scores were 







































4.1.7.  DDAG reduces AHR  
OVA-challenged mice developed AHR, which is typically reflected by high lung 
resistance (Rl) (Figure 4.12) and low dynamic compliance (Cdyn) (Figure 4.13). Rl is defined 
as the pressure driving respiration divided by flow. Cdyn refers to the distensibility of the 
lung and is defined as the change in volume of the lung produced by a change in pressure 
across the lung. DDAG (1 mg/kg) dramatically reduced Rl and restored Cdyn in OVA-
challenged mice in response to methacholine, suggesting that the immune-mediated airway 
pathology in vivo was modified 
 
4.1.8.  DDAG inhibits NF-κB activation  
To determine if DDAG, like andrographolide, could inhibit NF-κB in ovalbumin 
(OVA)-challenged mice (Bao et al., 2009), the nuclear translocation of the p65 subunit and 
p65 DNA-binding activity in lung tissues from mice treated with DDAG were examined. 
OVA challenge markedly raised the level of p65 subunit in the nuclear extract of lung tissues 
and promoted nuclear p65 DNA-binding activity (Figure 4.14). DDAG (1 mg/kg) 
significantly (p < 0.05) reduced both nuclear p65 translocation and DNA-binding activity to 
the basal levels.  
The mechanism of action of DDAG in TNF-α-stimulated A549 human lung epithelial 
cells in vitro was verified. TNF-α plays a critical role in asthma (Brightling et al., 2008; 
Vroling et al., 2007) and is a potent stimulator of human airway epithelial cells (Newton et al., 
2007). A sharp increase in total nuclear p65 level and p65 DNA-binding activity was 
observed upon TNF-α treatment, and DDAG markedly abated these TNF-α-mediated 




























Figure 4.12.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on OVA-
induced AHR. Airway responsiveness of mechanically ventilated mice in response to 
aerosolized methacholine was measured. AHR is expressed as the percent change from the 
baseline level of lung resistance (Rl, n = 7–9 mice). Rl is defined as the pressure driving 

















































Figure 4.13.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on OVA-
induced AHR. Airway responsiveness of mechanically ventilated mice in response to 
aerosolized methacholine was measured. AHR is expressed as the percent change from the 
baseline level of dynamic compliance (Cdyn, n = 7–9 mice). Cdyn refers to the distensibility 
of the lung and is defined as the change in volume of the lung produced by a change in 

















































Figure 4.14.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on NF-κB 
activity in OVA-challenged lungs. Immunoblotting of p65 NF-κB in nuclear extract of lung 
tissues isolated from mice 24 h after the last OVA challenge. TBP nuclear protein was used as 
an internal control. The experiments were repeated three times with a similar pattern of results. 
Nuclear p65 DNA-binding activity was determined using a TransAM p65 transcription factor 
ELISA kit. Values shown are the mean ± SEM of three separate experiments. *Significant 


































Figure 4.15.  Effects of 14-deoxy-11,12-didehydroandrographolide (DDAG) on NF-κB 
activity in in TNF-α-stimulated A549 human lung epithelial cells. Immunoblotting of p65 NF-
κB in nuclear extract of A549 cells stimulated with 10 ng/mL TNF-α for 5 min, in the 
presence and absence of DDAG (30 μM). TBP nuclear protein was used as an internal control. 
The experiments were repeated three times with a similar pattern of results. Nuclear p65 
DNA-binding activity was determined using a TransAM p65 transcription factor ELISA kit. 
Values shown are the mean ± SEM of three separate experiments. *Significant difference 





















4.2.  Discussion  
DDAG is the next most abundant of the naturally occurring labdane diterpene lactones 
in Andrographis paniculata besides andrographolide (Koteswara Rao et al., 2004; Pholphana 
et al., 2004). DDAG has been shown to be a metabolite of andrographolide and can also be 
synthesized chemically from the parent compound (He, 2003; Nanduri et al., 2004). 
Nevertheless, the present knowledge of the pharmacological actions of DDAG is much less 
than for andrographolide. Indeed, a clinical study of andrographolide in upper respiratory tract 
infection has been reported (Chang et al., 2008a), whereas investigations of DDAG are still at 
the early preclinical stage. Despite their structurally similarity, there is a notable difference 
between these two diterpenoids with regard to cytotoxicity. Andrographolide contains an α-
alkylidene γ-butyrolactone moiety and three hydroxyls at C-3, C-19 and C-14 that are 
accountable for the cytotoxic activities of andrographolide against numerous cancer cell lines 
(Varma et al., 2009). The lacking of an OH group at the C14 position and the double bond at 
C11 and C12 in DDAG structure might be related to the non-cytotoxic properties. Our present 
findings reveal that andrographolide exerted a strong dampening effect on the cell viability of 
human lung epithelial cell lines and rat mast cell line, but DDAG appeared to be non-
cytotoxic to these culture cells. These data are consistent with observations reported by other 
laboratories on other cell lines (Nanduri et al., 2004; Tan et al., 2005) and strongly support 
the notion that DDAG is a noncytotoxic analogue of andrographolide. 
Th2 cytokines play an essential role in the pathogenesis of the allergic airway 
inflammation (Galli et al., 2008a; Medoff et al., 2008), and NF-B is a critical transcription 
factor for Th2 cell differentiation (Das et al., 2001). IL-4 in conjunction with IL-13 are 
imperative for B cell antibodies isotype switching from IgM to IgE. Whereas IL-5 is vital for 
the growth, differentiation, recruitment, and survival of eosinophils which contribute to 




13 also plays a pivotal role in the effector phase of Th2 responses such as eosinophilic 
inflammation, airway-smooth-muscle hyperplasia, the induction of goblet-cell hyperplasia 
with mucus hypersecretion, the recruitment of monocytes, macrophages and T cells into the 
airway spaces, AHR and airway remodelling (Wills-Karp, 2004; Wynn, 2003). IL-4, IL-5 and 
IL-13 can be produced by various lung resident cells such as bronchial epithelial cells, tissue 
mast cells and alveolar macrophages as well as infiltrated inflammatory cells such as 
lymphocytes and eosinophils. Our results show that DDAG significantly reduced the levels of 
IL-4, IL-5, IL-13 and eotaxin in BAL fluids from OVA-challenged mice. Similar findings 
were observed in OVA-challenged mice with disrupted NF-κB function via conditional 
knockout of IKKβ in the airway epithelium (Broide et al., 2005). In addition, repression of the 
NF-κB signalling pathway has been shown to block IL-13-induced eotaxin production in 
cultured human airway smooth muscle cells (Li et al., 1999). Therefore, the observed 
reduction of IL-4, IL-5, IL-13, and eotaxin levels in BAL fluid from DDAG-treated mice may 
be due to inhibition of NF-κB activation in the inflammatory and airway resident cells. 
The most abundant immunoglobulin isotype in the blood is IgG, an immunoglobulin 
that provides the bulk immunity to most blood borne infectious agents. There are different 
IgG subclasses such as IgG1, IgG2a, IgG2b, and IgG3. During a T-cell dependent immune 
response, a progressive change takes place in the predominant immunoglobulin class of the 
specific antibodies. This subclass switch is influenced by T-cells and their cytokines. In mice, 
IL-4 preferentially switch activated B cells to the IgG1 isotype (associated with Th2 immune 
response) while IFN-γ and IL-12 enhances IgG2a responses (associated with Th1 immune 
response) (Pulendran et al., 1999). The reduction of IgG1 by DDAG treatment in our 
observation further substantiates the notion that DDAG significantly reduce the Th2 response 
thereby attenuating the role Th2 cytokines play in orchestrating the complex series of events 




activation of the primary effector cells of the allergic response such as mast cells and 
eosinophils. 
Elevated serum IgE levels are a hallmark of the Th2 immune response. Clinical 
studies have shown that humanized mAbs against IgE such as omalizumab was effective in 
patients with poorly controlled, moderate to severe allergic asthma (Busse et al., 2011; Lin et 
al., 2004). When the serum concentration of unbound IgE were decrease by omalizumab 
treatment, the expression of high-affinity IgE receptor FcεRI on several cell types were 
decrease as well (Lin et al., 2004). This will also decrease the amplification of the 
inflammatory response mediated by T helper cells to prevent IgE-dependent allergen 
presentation. IgE in turn is produce by B-Cell. NF-κB plays a crucial role in B-cell 
proliferation and development (Schulze-Luehrmann et al., 2006; Siebenlist et al., 2005). IL-4 
and IL-13 are important in directing B-cell growth, differentiation, and secretion of IgE (Li-
Weber et al., 2003; Wills-Karp, 2004). Therefore the significantly reduced serum level of 
OVA-specific IgE in OVA-challenged mice by DDAG treatment may be attributed to the 
inhibition of NF-κB during B-cell activation and of IL-4- and IL-13-mediated class switching 
to IgE. 
The biological activities of IgE are mediated through its interaction with the high-
affinity IgE receptor FcεRI on mast cells and basophils. Once the mice is sensitized to OVA 
as allergen, subsequent encounters with OVA cause crosslinking of IgE bound to the FcεRI 
which initiates multiple signaling cascades leading to NF-B activation and stimulate the 
release of granule-associated and newly generated mediators that are responsible for the early 
allergic response (Galli et al., 2008a; Klemm et al., 2006). Subsequently, the release of 
cytokines and chemokines that recruit macrophages and eosinophils will leads to the late 





Eosinophils play a central role in the pathogenesis of allergic inflammation (Hogan et 
al., 2008; Takatsu et al., 2008). IL-5 is a unique cytokine for the differentiation and survival 
of eosinophils in response to allergen provocation. Study has demonstrated specific anti-IL-5 
therapy is efficacious in severe asthma patients who had frequent exacerbations and showing 
eosinophilic sputum (Haldar et al., 2009). Their findings suggest that eosinophils have a role 
as important effector cells in the pathogenesis of severe exacerbation of asthma. The view 
expressed in Haldar et al. were further supported by Nair et al. when they show that systemic 
steroids can be withdrawn in severe asthma patients who had eosinophilic sputum when 
treated with mepolizumab, a monoclonal antibody against interleukin-5 (Nair et al., 2009). 
Our present findings demonstrate that DDAG prevented inflammatory cell infiltration into the 
airways as shown by a significant drop in total cell counts and eosinophil and lymphocyte 
counts in BAL fluid, and in tissue eosinophilia in lung sections.  
Leukocyte transmigration into the airways is orchestrated by cytokines such as IL-4, 
IL-5, and IL-13 and coordinated by specific chemokines such as eotaxin and RANTES in 
combination with adhesion molecules as exemplified by VCAM-1 and E-selectin (Hogan et 
al., 2008; Kelly et al., 2007).  Upon OVA provocation, autacoid mediators release by mast 
cell such as histamine and the cysteinyl leukotrienes (CysLTs) increase endothelial expression 
of E-selectin which initiate leukocyte rolling, followed by the expression of intercellular 
adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1), which 
interact with integrin receptors to arrest the leukocyte and assist its passage into the 
perivascular space (Kelly et al., 2007). The activation of VCAM-1 gene expression is 
regulated by the transcription factors nuclear factor kappa B (NFκB) as VCAM-1 expression 
is induced by the cytokines TNF-α and IL-1β (Cook-Mills et al., 2011). Chemokines such as 
monocyte chemotactic proteins-1 (MCP-1/CCL2) and eotaxin-1 (CCL11) direct and prime 




cysteinyl leukotrienes, eotaxin also plays a role in promoting eosinophil recruitment in 
response to allergic provocation via CCR3 (Luster et al., 1997). IL-13 is by far the most 
potent inducer of eotaxin expression in airway epithelial cells (Li et al., 1999). IL-17 has been 
shown to induce eotaxin production from airway smooth muscle cells (Rahman et al., 2006c), 
whereas IL-33 can promote eotaxin release from macrophages (Liew et al., 2010).  
DDAG markedly suppressed E-selectin, VCAM-1, MCP-1, IL-17 and IL-33 mRNA 
expression and eotaxin production in OVA-challenged lungs. These findings are likely to be 
due to DDAG-mediated NF-κB inhibition, as the genes for E-selectin, VCAM-1, MCP-1 and 
eotaxin contain the κB site for NF-κB within their promoters (Kumar et al., 2004a). These 
finding may also associated with reduced mast cell degranulation with DDAG treatment as 
mast cells has recently been demonstrated to play a key role in a Th2 cytokine-dependent 
asthma model through production of adhesion molecules, including ICAM-1 and VCAM-1, 
by liberation of TNF-α (Chai et al., 2011). Taken together, the suppression of these 
inflammatory cytokines and chemokines by DDAG treatment in OVA-challenged lungs may 
be one of the main reasons for the reduction in eosinophil infiltration.    
A family of chitinase proteins including AMCase, Ym1, Ym2 and YKL-40 has 
recently been found to be elevated in allergic airway inflammation in human and in mouse 
asthma models (Chupp et al., 2007; Zhao et al., 2005; Zhu et al., 2004). They are mainly 
expressed in airway epithelium and alveolar macrophages. AMCase level is increased in a 
mouse asthma model and in asthmatic subjects in an IL-13-dependent manner (Zhu et al., 
2004). When given intratracheally, IL-13 elevates Ym1 and Ym2 levels in BAL fluid from 
mice in vivo (Webb et al., 2001). Besides, YKL-40 serum level correlates positively with 
asthma severity, airway remodelling and deterioration of pulmonary function in asthmatic 
subjects (Chupp et al., 2007). In a chronic asthma mouse model, only AMCase and Ym2 




BAL fluid (Wong et al., 2008). Overall, chitinases may play a role in airway inflammation 
and remodelling. Our data show that DDAG markedly down-regulated AMCase, Ym2 and 
YKL-40 mRNA expression in the lungs of OVA-challenged mice. These may be a 
consequence of the major drop in IL-4 and IL-13 levels in the airways with DDAG treatment 
and may contribute to the diminished pulmonary eosinophilia. 
We observed a dramatic reduction in airway mucus production in DDAG-treated mice 
as compared with DMSO control. Cumulative evidence indicates that IL-4, IL-5, IL-13, and 
IL-17 play a critical role in goblet cell hyperplasia and mucin Muc5ac gene and protein 
expression in mice (Fujisawa et al., 2009; Justice et al., 2002; Morcillo et al., 2006). Muc5ac 
gene expression is dependent on the transcriptional activity of NF-B (Justice et al., 2002; 
Morcillo et al., 2006). In addition, selective ablation of NF-κB function in the airway 
epithelium has been shown to reduce OVA-induced mucus production in mice (Birrell et al., 
2005a). As such, the reduction in mucus production and Muc5ac mRNA expression in the 
lungs of DDAG-treated mice may be attributable to a significant drop in IL-4, IL-5, IL-13, 
and IL-17 levels and an inhibitory action on NF-κB in the airway epithelium.  
IL-4, IL-5, and IL-13 have been shown to induce AHR, in which major basic protein 
and cysteinyl-leukotrienes have been implicated (Hogan et al., 2008; Leigh et al., 2004; 
Takatsu et al., 2008; Wills-Karp, 2004). Recently, IL-33 was found to directly trigger AHR in 
mice (Liew et al., 2010). In addition, IgE-mediated mast cell activation may contribute to 
airway hyperresponsiveness by producing a wide array of mast cell-derived lipid mediators 
and inflammatory cytokines (Galli et al., 2008a; Klemm et al., 2006; Woodruff et al., 2009). 
Thus, the observed reduction in AHR by DDAG treatment may be associated with the 
reduction in Th2 cytokine and IL-33 production, tissue eosinophilia, serum IgE levels and 





Persistent NF-κB activation has been observed in allergic airway inflammation in 
humans and in animal model of asthma (Edwards et al., 2009). p65 protein levels in 
peripheral blood mononuclear cells (PBMCs) were higher in moderate and severe asthmatics 
than in normal individuals. In addition, while high amount of IκB phosphorylation were 
characteristic of asthmatic patients, greater p65 activation was also observe in severe 
asthmatics (Gagliardo et al., 2003). Similarly, p65 protein abundance and IκB 
phosphorylation are also higher in PBMCs of children with moderate asthma when compared 
to normal individuals (La Grutta et al., 2003). Moreover, when compared to non-asthmatic 
individuals, nuclear extracts from bronchial biopsies and induced sputum cells (Hart et al., 
1998) of patients with asthma show higher NF-κB activation as measured by gel shift assays 
and immunohistochemical examination of bronchial biopsy specimens with an antibody to 
p65. Likewise, bronchial epithelial cells from stable, corticosteroid naïve asthmatics have also 
shown greater levels of NF-κB activation (Zhao et al., 2001). The importance of NF-κB in 
disease pathogenesis has also been highlighted in the mouse models of allergic asthma. 
Compared to control mice, bronchial epithelium of mice sensitise and challenge with OVA 
exhibits robust and rapid inhibitory κB kinase α/β (IKK-α/β) activity and p65 nuclear 
translocation (Poynter et al., 2002). Mice lacking p50 on the other hand have reduced 
eosinophil infiltration in response to OVA challenge. This effect could be attributed to a lack 
of Th2 cytokines such as IL-4, IL-5, IL-13 (Das et al., 2001), and the chemokine eotaxin 
(Yang et al., 1998). This study further demonstrated the importance of NF-κB signalling in 
both allergic inflammation and mucus production. On the other hand, activation of 
doxycycline-inducible constitutively active IKK-β transgene not only induces p65 nuclear 
translocation, inflammatory cell infiltration and concomitant production of pro-inflammatory 
mediators, it was able to induced AHR, even without allergen sensitization and challenge 




cells culminates in NF-κB activation (Cheng et al., 2011; Galli et al., 2008a; Klemm et al., 
2006; Schulze-Luehrmann et al., 2006; Shinohara et al., 2009). In addition, TNF-α 
stimulation of airway epithelial cells triggers NF-κB activation and gene expression (Newton 
et al., 2007). These studies further underscore the importance of NF-κB signalling in the 
generation of pro-inflammatory cytokines, chemokines and adhesion molecules. Furthermore, 
various therapeutic strategies targeted at the NF-B activity such as NF-B-specific decoy 
oligonucleotide (Desmet et al., 2004), p65-specific antisense oligonucleotide (Choi et al., 
2004),  p65-targeting siRNA (Platz et al., 2005) and inhibitory B kinase- (IKKβ)-selective 
small molecule inhibitor (Birrell et al., 2005a) have demonstrated beneficial effects in 
experimental asthma models. Our data revealed a significant inhibition of p65 nuclear 
translocation and B DNA-binding activity by DDAG in OVA-challenged lungs in vivo and 
in TNF-α-stimulated human lung epithelial cells in vitro. Our findings show for the first time 
that DDAG, like andrographolide, may exert anti-inflammatory actions via inhibition of NF-
κB activity both in OVA-challenged lungs in vivo and in TNF-α-stimulated human lung 
epithelial cells in vitro.  
We report here for the first time that 14-deoxy-11,12-didehydroandrographolide 
(DDAG), a naturally occurring noncytotoxic analogue of andrographolide, effectively reduced 
OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13, and eotaxin 
production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion, mast cell 
degranulation, and AHR in a mouse asthma model, probably via inhibition of NF-κB activity. 
These findings support a potential therapeutic role for DDAG in the treatment of asthma 
























5. ANTI-OXIDATIVE STRESS EFFECTS OF 
ANDROGRAPHOLIDE IN CIGARETTE SMOKE INDUCE 






5.1.1.  Andrographolide attenuates cigarette smoke-induced lung inflammation  
Cotinine is a stable metabolite of nicotine and it is often used as a surrogate maker for 
nicotine exposure (Benowitz, 2009). Plasma cotinine levels in 4% cigarette smoke-exposed 
mice were sharply elevated above 100 ng mL
-1
. In contrast, plasma cotinine level in sham air 
control mice was undetectable (Figure 5.1). The cotinine level was similar with the level 
observed by others groups (Lu et al., 2007) and in serum of human smokers (Scott et al., 
2000). BAL fluid was collected 24 hours after the last cigarette smoke or sham air exposure. 
Cigarette smoke inhalation markedly increased BAL fluid total cell and neutrophil counts, 
with moderate but significant elevation in macrophage counts, as compared with sham air 
control (Figure 5.2). The low level of total BAL fluids’ cell count in cigarette smoke 
inhalation models is reflective of the low grade of inflammation found in COPD patients. To 
examine the effect of andrographolide in cigarette smoke induce lung injury mouse model, 
cigarette expose mouse was treated prophylactically with andrographolide. Our study show 
that andrographolide (0.1, 0.5 and 1 mg kg
-1
) significantly suppressed the total inflammatory 
cell and neutrophil counts in BAL fluid in a dose-dependent manner as compared with the 
DMSO control (Figure 5.3). Andrographolide (1 mg kg
-1
) also showed a moderate inhibitory 


















Figure 5.1. Effects of cigarette smoke in mice.  Blood was collected immediately after 1 h 
4% cigarette smoke exposure and plasma cotinine levels were measured using ELISA (n = 6). 








































Figure 5.2. Effects of cigarette smoke-induced inflammatory cell recruitment. 
Inflammatory cell counts in BAL fluid obtained from mice 24 h after the last sham air (n = 9 
mice per group) or cigarette smoke (n = 9 mice per group) exposure. Values shown are the 















































Figure 5.3. Effects of andrographolide on cigarette smoke-induced inflammatory cell 
recruitment. Andrographolide dose-dependently reduced cigarette smoke-induced 
inflammatory cell counts in BAL fluid from mice 24 h after the last cigarette smoke challenge 
(DMSO, n = 6; 0.1 mg kg
-1
, n = 6; 0.5 mg kg
-1
, n = 6; and 1 mg kg
-1
, n = 8 mice per group). 
Differential cell counts were performed on a minimum of 500 cells to identify eosinophil 
(Eos), macrophage (Mac), neutrophil (Neu), and lymphocyte (Lym). Values shown are the 







































5.1.2.  Andrographolide attenuates cigarette smoke-induced inflammatory cytokine 
and chemokine Level  
IL-1β plays a critical role in the inflammatory response induced by cigarette smoke 
exposure. KC (CXCL1), IP-10 (CXCL10) and MCP-1 (CCL2) are key chemokines in 
attracting macrophages and neutrophils.  BAL fluid levels of IL-1β, IP-10 (CXCL10), MCP-1 
(CCL2) and KC (CXCL1) were significantly raised in cigarette smoke-exposed mice as 
compared to sham air control mice (Figure 5.4). Andrographolide was able to abate the BAL 
fluid levels of IL-1β, IP-10, MCP-1 and KC in a dose-dependent manner, reaching significant 




5.1.3.  Andrographolide attenuates cigarette smoke-induced inflammatory and 
proteolytic mediators’ gene expression  
Andrographolide (1 mg kg
-1
) significantly suppressed the elevated gene expression of 
lung tissue GM-CSF, TNF- and MIP-2 (as known as GRO- or CXCL2) induced by 
cigarette smoking (Figure 5.5). Cigarette smoke also up-regulated the gene expression of 
inducible nitric oxide synthase (iNOS), a pro-oxidant enzyme responsible for NO production 
and subsequent oxidative lung damage. Andrographolide markedly reversed the iNOS gene 
expression down to basal level (Figure 5.5). Furthermore, the increase in gene expression of 
matrix metalloproteinase-12 (MMP-12) and tissue inhibitor of metalloproteinase-1 (TIMP-1), 
a metalloproteinase and an anti-metalloproteinase critical for lung remodelling and repair in 
COPD, by cigarette smoke was significantly inhibited by 1 mg kg
-1

































Figure 5.4. Effects of andrographolide on cigarette smoke BAL fluid cytokine and 
chemokine levels. BAL fluid levels of IL-1β, MCP-1, KC, and IP-10 were analyzed using 
ELISA (n = 6 mice per group). Lower limits of detection were as follows: IL-1 at 9 pg mL-1; 
IP-10 at 15 pg mL
-1
; and MCP-1 and KC at 16 pg mL
-1
.  Values shown are the mean  SEM. 


















































































































Figure 5.5. Effects of andrographolide on cigarette smoke-induced lung tissue pro-
inflammatory and proteolytic mediator gene expression in mice. Real-time PCR analyses of 
cytokine, chemokine and protease gene expressions in lung tissues (n = 6 mice per group). 
The mRNA expression levels for all samples were normalized to the level of the 
housekeeping gene 18S. Values shown are the mean  SEM. *Significant difference from 




































































5.1.4.  Andrographolide protects against cigarette smoke-induced oxidative lung 
damage  
BAL fluid was used to assay for 3-NT, a product of protein nitration indicative of 
oxidative protein damage; 8-OHdG, a marker for oxidative DNA damage; and 8-isoprostane, 
an indicator for lipid peroxidation, using ELISA. Cigarette smoking significantly elevated 
BAL fluid levels of 3-NT, 8-OHdG and 8-isoprostane as compared to the sham air control 
(Figure 5.6). Andrographolide markedly suppressed the levels of 3-NT, 8-OHdG and 8-
isoprostane at all three doses used, ameliorating oxidative damage to proteins, DNA and 
lipids induced by cigarette smoking. 
 
5.1.5.  Andrographolide augments the GPx and GR activities 
Cigarette smoke exposure induced a marked adaptive increase in the lung catalase 
activity as compared to sham air. Andrographolide (1 mg kg
-1
) significantly reduced the 
catalase activity. In contrast, lung SOD activity was not altered by cigarette smoke challenge 
or by andrographolide treatment (Figure 5.7). The activity of GPx, an antioxidant enzyme 
capable of reducing H2O2 to H2O by oxidizing GSH, was not altered by cigarette smoke but 
was substantially augmented in cigarette smoke-exposed mouse lungs by andrographolide. On 
the other hand, lung GR activity was markedly abated by cigarette smoke exposure, but 
andrographolide treatment totally restored GR activity (Figure 5.7). In brief, andrographolide 























Figure 5.6. Effects of andrographolide on cigarette smoke-induced BAL fluid oxidative 
damage marker levels. 8-Isoprostane, 8-OHdG and 3-NT levels were measured using ELISA. 
Lower limits of detection were as follows: 8-isoprostane at 2.7 pg mL
-1
; 8-OHdG at 33 pg 
mL
-1
; and 3-NT at 0.1 M.  Values are means ± SEM for 6 mice per group. *Significant 

























































































Figure 5.7. Effects of andrographolide on cigarette smoke-induced lung antioxidant 
enzymatic activities. Mice were exposed to 4% cigarette smoke for 1 h daily for 5 consecutive 
days with or without andrographolide treatment. Enzymatic activities of SOD, catalase, GPx 
and GR in lung tissues obtained 24 h after the last cigarette smoke challenge were measured 
using ELISA. Values are means ± SEM for 6 mice per group. *Significant difference from 






















































































































5.1.6.  Andrographolide promotes nuclear Nrf2 accumulation  
To investigate the molecular mechanism of andrographolide anti-oxidative effects, we 
studied nuclear Nrf2 translocation and transactivation in BEAS-2B human bronchial epithelial 
cells. Addition of 2% CSE to BEAS-2B cells which don’t have an impair Nrf2 system like 
those in COPD patients, resulted in marked nuclear translocation of Nrf2 at 4 hours, and 
andrographolide (30 M) does not affect the nuclear Nrf2 level at this time point. Thus, the 
data suggest that andrographolide does not affect normal Nrf2 activation induced by cigarette 
smoke. In contrast, at 24 hours after CSE exposure, nuclear Nrf2 of CSE only and DMSO 
treated cells dropped to the basal level, but andrographolide treatment maintained the nuclear 
Nrf2 level elevated in BEAS-2B cells (Figure 5.8). On the other hand, cytoplasmic levels of 
Nrf2 were scarcely detectable in control and all treatment groups (Figure 5.8).  This 
observation is expected as under basal conditions, Keap1 constantly targets Nrf2 for 
ubiquitination and proteasomal degradation. As a consequence, there are minimal cytoplasmic 
levels of Nrf2. To further substantiate the finding, Nrf2 ARE binding activities were studied 
using Nrf2 transactivation assay. The transactivation activities of Nrf2 were found to be 
significantly higher in andrographolide-treated BEAS-2B 24 hours after 2% CSE exposure 
(Figure 5.9).  
5.1.7.  Andrographolide promotes GSH level 
Glutathione (GSH), a ubiquitous tripeptide thiol, is a vital cellular protective 
antioxidant in the lungs as the cellular stress response induced by cigarette smoke extract is 
critically dependent on the intracellular GSH concentration (Muller et al., 1998). Cellular 
GSH level was also strongly elevated by andrographolide in BEAS-2B cells exposed to 2% 
CSE for 24 h (Figure 5.10). Our data suggest that andrographolide is able to sustain nuclear 
Nrf2 accumulation and activation in cells exposed to cigarette smoke, leading to augmented 
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Figure 5.8. Effects of andrographolide on nuclear Nrf2 level. Cytoplasmic and nuclear 
extracts of BEAS-2B cells treated with 2% CSE in the presence and absence of 30 µM 
andrographolide for 4h and 24h were separated in 10% SDS-PAGE. Immunoblots were 
probed for Nrf2. -actin and TBP were used as internal controls for cytosolic and nuclear 
proteins, respectively. The experiments were repeated four times with similar pattern of 
results. Protein band intensities were quantified using ImageJ software and were normalized 
to β-actin controls. Values shown are the mean ± SEM. *significant difference from DMSO, 























































Figure 5.9. Effects of andrographolide on nuclear Nrf2 level. Nuclear extracts of BEAS-
2B cells treated with 2% CSE in the presence and absence of 30 µM andrographolide for 4h 
and 24h ARE-binding activity of Nrf2 in nuclear extracts of BEAS-2B cells stimulated with 
2% CSE in the presence and absence of 30 µM andrographolide for 4 h and 24 h was 
determined using a TransAM Nrf2 ELISA kit. *significant difference from DMSO, P < 
0.05. 
  
CSE - + + + - + + + 
DMSO - - + + - - + + 
































Figure 5.10. Effects of andrographolide on cellular GSH levels. Cellular GSH levels at 24 h 
after exposure to 2% CSE in the presence and absence of 30 µM andrographolide were 
measured using a GSH assay kit. Experiments were repeated four times and values are 





























5.1.8.  Andrographolide augments Nrf2-regulated gene targets  
Nrf2 is the primary transcription factor that plays an important role in cellular defence 
against oxidative stress (Kobayashi et al., 2005). Nrf2 is critical for maintaining the GSH 
redox state via transcriptional regulation of GR and in GSH level by regulating gene that 
essential in the de novo synthesis of GSH (Harvey et al., 2009). To investigate biological 
responses to nuclear Nrf2 accumulation and activation, we examined Nrf2-specific 
antioxidant gene expressions including GR, GPx-2 and HO-1 as well as biosynthetic enzymes 
of the glutathione such as glutamate-cysteine ligase catalytic (GCLC) subunit and glutamate-
cysteine ligase modifier (GCLM) subunit in BEAS-2B cells exposed to 2% CSE for 12 hours 
and 24 hours. Andrographolide treatment significantly enhanced the expression of 
antioxidants GCLM, GCLC, GR, GPx-2 and HO-1 in CSE-exposed BEAS-2B cells as 
compare to DMSO or CSE-exposed only BEAS-2B cells (Figure 5.11 and 5.12). Specifically, 
both GCLM and GCLC gene expression level was significantly increase at both 12 and 24 
hours. Notably, andrographolide augmented gene expression of both GPx-2 by about 12 folds 
as compare to DMSO controls at 24 hours of CSE exposure and HO-1 by about 8 folds as 
compared to DMSO controls at 12 hours of CSE exposure. The observation further 
substantiate the notion that andrographolide treatment active Nrf2 as both GPx-2 and HO-1 
are highly regulated by Nrf2 transactivational activities. Taken together, our results clearly 
indicate that andrographolide is a potent enhancer of antioxidant gene expression in response 
























Figure 5.11. Effects of andrographolide on antioxidant gene expression. Total RNA was 
extracted from BEAS-2B cells treated with 2% CSE in the presence and absence of 30 µM 
andrographolide for 12 h and 24 h, and gene expression was quantified using real-time PCR 
and normalized to 18S control gene. Experiments were repeated three times and values are 

































































Figure 5.12. Effects of andrographolide on antioxidant gene expression. Total RNA was 
extracted from BEAS-2B cells treated with 2% CSE in the presence and absence of 30 µM 
andrographolide for 12 h and 24 h, and gene expression was quantified using real-time PCR 
and normalized to 18S control gene. Experiments were repeated three times and values are 















































5.2. Discussion  
Cigarette smoke contains high concentrations of potent oxidants and free radicals 
including reactive aldehyde, quinone, hydroquinone, semiquinone and superoxide (Cantin, 
2010; Yao et al., 2011). Exposure to cigarette smoke causes lung epithelial cell damage and 
triggers production of pro-inflammatory cytokines and chemokines, leading to inflammatory 
cell infiltration and activation, especially the neutrophils and macrophages. Both neutrophils 
and macrophages are rich sources of endogenous reactive oxygen species (ROS), reactive 
nitrogen species (RNS) and tissue proteases such as elastase and metalloproteinases, entailing 
additional oxidant burden to the lungs and facilitating destruction of alveolar walls. Our 
findings reveal for the first time that andrographolide prevented cigarette smoke-induced lung 
infiltration of neutrophils and, to a lesser extent, macrophages in a dose-dependent manner. 
The decrease in inflammatory cell accumulation could be associated with a decrease in BAL 
fluid cytokine and chemotactic factor. 
Keratinocyte-derived chemokine (KC/CXCL1; an IL-8 homologue in mice) and 
macrophage inflammatory protein-2α (MIP-2α/CXCL2) are pivotal for neutrophil lung 
infiltration while monocyte chemotactic protein-1 (MCP-1/CCL2) and interferon-γ-inducible 
protein 10 (IP-10/CXCL10) are essential for recruitment of macrophages and monocytes 
(Brusselle et al., 2011; Conti et al., 1995; Cosio et al., 2009; Dufour et al., 2002; Lee et al., 
1995; Louhelainen et al., 2008). Granulocyte‐macrophage colony stimulating factor 
(GM‐CSF) is another direct neutrophil chemotactic factor (Gomez-Cambronero et al., 2003) 
and survival factor in the respiratory tract (Barnes et al., 2003) that is up regulated by 
cigarette smoke (Vlahos et al., 2006). Our findings demonstrated that andrographolide was 
able to suppress the increase of KC, IP-10, MCP-1, MIP-2 and GM-CSF in lungs from 




Among the chemokine studied, MCP-1, KC, MIP-2α, IP-10, and GM-CSF can be 
stimulated by tumour necrosis factor-α (TNF-α) (Becker et al., 1994; De Plaen et al., 2006; 
Ohmori et al., 1993; Standiford et al., 1991). Cigarette smoke has been reported to induces 
the alveolar macrophages to release TNF‐α (Keatings et al., 1996), which is considered to be 
a key inflammatory mediator in lung pathology (Barnes, 2004) as the activation of TNF-α 
receptor also induces the production and release of several inflammatory mediators, such as 
Interleukin-1β (IL-1β), and protease such as MMP-12. Andrographolide treatment 
significantly attenuated the mRNA expression of both TNF‐α and IL-1β.  
We also observed a sharp rise in lung matrix metallopeptidase-12 (MMP-12) 
expression together with an adaptive increase in lung TIMP-1 expression in cigarette smoke-
exposed mice. MMP-12, which is produced by macrophages and induced by the presence of 
IP-10 (Grumelli et al., 2004), is able to degrade elastin, disrupting lung architecture leading to 
airspace enlargement (Hautamaki et al., 1997; Mocchegiani et al., 2011). The resulting elastin 
fragments can also lead to a positive feedback loop that further increasing macrophage 
recruitment (Hunninghake et al., 2009). Mice deficient in MMP-12 were protected against 
cigarette smoke-induced lung inflammation and emphysema (Hautamaki et al., 1997). An 
association study has strongly suggested that MMP12 plays a role in determining lung 
function and susceptibility to COPD in adult smokers (Hunninghake et al., 2009). 
Nonetheless, histological examination of cigarette smoke exposed mouse lung was not 
performed as acute cigarette smoke exposure was shown not to cause a significant air space 
enlargement, a canonical feature in emphysema (Rajendrasozhan et al., 2010). 
Andrographolide reversed the elevation of lung MMP-12 expression and the adaptive increase 
in TIMP-1 in cigarette smoke-exposed mice. These findings implicate a protective role of 




Oxidative stress emitted by the cigarette smoke and generated from the infiltrated 
macrophages and neutrophils play a pivotal role in the pathogenesis in COPD (Rahman et al., 
2006b). Excessive accumulation of ROS and RNS in the lungs results in protein denaturation, 
lipid peroxidation, and DNA damage as determined by the levels of 3-nitrotyrosine (3-NT) 
(Sugiura et al., 2011), 8-isoprostane (Louhelainen et al., 2008) and 8-hydroxydeoxyguanosine 
(8-OHdG) (Aoshiba et al., 2012; Tzortzaki et al., 2012), respectively in BAL fluid or in 
induced sputum. Lipid peroxidation, which leads to destruction of membrane lipid, is a well-
established mechanism of
 
cellular injury (Rahman et al., 1996; Rahman et al., 2002). 
Oxidative stress leads to peroxidation of arachidonic acid form a unique series of 
prostaglandin-like compound knows as isoprostanes. The isoprostanes possess potent 
biological activities, which includes bronchoconstriction and plasma exudation (Janssen, 
2008). Moreover, patients with COPD have increased exhaled breath condensate 8-
isoprostanes compared to healthy smokers and non-smokers (Montuschi et al., 2000). 
Reactive oxygen species (ROS) attack guanine bases in DNA easily and form 8-OHdG 
(Cheng et al., 2003) which can cross the cell membrane and is usually detected in the urine or 
serum of patients who have diseases associated with oxidative stress (Svoboda et al., 2008). 
Indeed, sputum 8-OHdG was statistically significant increase in COPD when compared with 
non-COPD smokers and healthy subjects (Tzortzaki et al., 2011). Nitrotyrosine on the other 
hand is an indicator of the involvement of reactive nitrogen species in irreversible oxidative 
reactions and has been associated with altered protein function (Davis et al., 2002; Murata et 
al., 2004). 3-nitrotyrosine is one of the most common products of the action of reactive 
nitrogen species on proteins. As peroxynitrite from cigarette smoke is able to nitrate tyrosine 
(Yamaguchi et al., 2007), nitrotyrosine levels are increased in the sputum of patients with 
COPD compared to healthy subjects and those with asthma (Ichinose et al., 2000). We 




in BAL fluid from cigarette smoke-exposed mice in a dose-dependent manner. The 
suppression of 3-NT level can be partly explained by the inhibitory effect of andrographolide 
on the inducible nitric oxide synthase (iNOS) expression. The reduction in iNOS, partly due 
to the down regulation of cytokines such as TNF-α and IL-1β which regulate is expression 
(Radomski et al., 1993), may leads to a drop in nitric oxide (NO) production, peroxynitrite 
(ONOO
−
) formation, and protein nitration of tyrosine residues (Sugiura et al., 2011). When 
nitric oxide is produced in high concentrations, such as with inducible NOS, it can react with 
oxygen or superoxide to form the highly reactive compounds nitrogen dioxide and 
peroxynitrite, which shifts the cellular redox potential to a more oxidized state. In addition, 
andrographolide has also demonstrated potent antioxidant activity by enhancing both 
glutathione peroxidase (GPx) and glutathione reductase (GR) activities in lung tissues from 
cigarette smoke-exposed mice, which further augment the lung antioxidant capacity. In 
agreement with our results, studies by Neogy et al.(Neogy et al., 2008) demonstrated that 
intraperitoneal treatment of andrographolide significantly increase the glutathione peroxidase 
activities. 
 Cigarette smoke exposures induce both oxidative stress and inflammatory response.  
Administration of andrographolide in mice ameliorated oxidative stress in lungs, suppressing 
the subsequent up-regulation of chemokines and eventually reducing the neutrophil and 
macrophage influx. To investigate the molecular mechanism of antioxidant action for 
andrographolide, we studied the effects of andrographolide on nuclear translocation and 
activation of the redox-sensitive transcription factor, nuclear factor erythroid 2-related factor 
2 (Nrf2) and the gene expression of Nrf2-regulated antioxidant gene targets in cigarette smoke 
extract (CSE)-treated human bronchial epithelial cells (BEAS-2B). Nrf2 are studied because it 
plays a predominant role in antioxidant protection against oxidative damage in the lungs 




enhanced susceptibility to emphysema and oxidative stress induced by cigarette smoke 
exposure (Rangasamy et al., 2004). More significantly, Nrf2 activities in patients with 
advanced COPD are reduced in peripheral lungs, resulting in reduced antioxidant responses 
and persistent oxidative stress. The reduction of Nrf2 activity may be due to a drop in the 
Nrf2-positive regulator DJ-1 level, which permits destabilization of Nrf2 protein via rapid 
proteasomal degradation by Keap1 (Malhotra et al., 2008). Nonetheless, even in DJ-1-
disrupted human epithelial cells, Nrf2 activator such as sulforaphane was able to enhance 
Nrf2 antioxidant defence in response to cigarette smoke (Malhotra et al., 2008), indicating 
that Nrf2 activation is an attractive therapeutic approach to the treatment of COPD (Boutten et 
al., 2011). 
In line with other studies (Lee et al., 2011; Taguchi et al., 2011), our data show that 
cytoplasmic levels of Nrf2 in BEAS-2B cells of control and all treatment groups were almost 
undetectable. It is mainly due to rapid ubiquitination and proteasomal degradation of Nrf2 
targeted by Kelch-like ECH-associated protein 1 (Keap1), a E3 ubiquitin ligase. At nuclear 
fraction however, andrographolide strongly promoted Nrf2 nuclear stabilization and 
accumulation, and binding to antioxidant response element (ARE) in BEAS-2B cells exposed 
to CSE for 24 hours. Indeed, andrographolide has been shown to elevate Nrf2 nuclear level in 
human endothelial cells (Yu et al., 2010). Furthermore, in the process of developing a reporter 
gene assay for monitoring Nrf2 activation, andrographolide was found to be the most potent 
Nrf2 activator among 2000 biologically active compounds tested (Smirnova et al., 2011). By 
enhancing Nrf2 protein nuclear accumulation and transactivational activity, our finding 
further substantiate the notion that andrographolide is an effective Nrf2 activator.  
Glutathione (GSH) is an endogenous non-protein thiol with potent free radical 
scavenging capacity (Biljak et al., 2010; Cantin, 2010; Gould et al., 2011). GSH is an 




integrity, and its deficiency leads to airway injury and epithelial damage (Rahman et al., 
1999).  Andrographolide noticeably enhanced cellular level of GSH in BEAS-2B cells in 
response to CSE, providing a powerful first line antioxidant defence against cigarette smoke-
induced epithelial damage. In agreement with our studies, andrographolide has also been 
shown to promote GSH level in nicotine-stimulated peripheral blood lymphocytes (Das et al., 
2009). 
Consistent with the Nrf2 activation by andrographolide in BEAS-2B cells, we have 
also observed robust inductions of Nrf2-regulated gene targets including GCLC, GCLM, GR, 
GPx-2 and HO-1 (Adair-Kirk et al., 2008; Hubner et al., 2009) by andrographolide in 
response to CSE.  
Glutamate-cycteine ligase (GCL), which is the rate-limiting enzyme in the GSH 
biosynthesis pathway, is a heterodimer comprising of the catalytic subunit (GCLC) and the 
regulatory subunit (GCLM) (Biljak et al., 2010; Gould et al., 2011). The increase of GSH 
level may be attributed to the increase in GCLC and GCLM expression as GCL contribute to 
the de-novo synthesis of GSH. In agreement with this result, overexpression of GCLM 
increases the cellular GSH, rendering cells resistant to oxidative stress (Tipnis et al., 1999). 
Similarly, up-regulation of GCLC alone has also been reported to support high levels of 
intracellular GSH (Mulcahy et al., 1995). Recently, overexpression of GCL in human 
granulosa tumor cells has been shown to increase total GSH levels and protect against H2O2-
induced cell death (Cortes-Wanstreet et al., 2009). 
In addition, GSH also functions as a reducing substrate in the redox cycle to facilitate 
the reduction of H2O2 by GPx to H2O and glutathione disulphide (GSSG), to prevent 
peroxide-induced
 
DNA damage, lipid peroxidation and protein degradation. As the oxidative 
burden in the lungs of smokers has been estimated
 
to be on the order of 10
14
 free radicals per
 




semiquinone that can generate H2O2, GSH and GSH-related enzymes present in the lower 
respiratory tract are believed to act as a first line of defense against attacks by cigarette smoke 
(DeLeve et al., 1990). GPx also have been shown to reduce of peroxynitrite to nitrite (Sies et 
al., 1997) and thus further attenuating the free radical stress impose by cigarette smoke.  
Beside de novo synthesis, GSH level are also sustain in the redox cycle by GR, which 
play an important role in reducing glutathione disulfide (GSSG) to the sulfhydryl form of 
glutathione (GSH) (Biljak et al., 2010; Cantin, 2010). GPx and GR are important endogenous 
antioxidant enzymes responsible for the oxidative balance in the lungs in response to cigarette 
smoke (Biljak et al., 2010; Gould et al., 2011). It has been reported that GPx activity was 
markedly decreased in patients with COPD (Biljak et al., 2010; Kluchova et al., 2007; Santos 
et al., 2004; Vibhuti et al., 2007). It is noteworthy that andrographolide was able to augment 
the GPx-2 expression level by at least 12 folds in BEAS-2B cells in response to CSE 
stimulation. The observed slow rate of GPx-2 gene induction starting at 24 h is consistent 
with that reported by Singh et al. (Singh et al., 2006b) that Nrf2 activation-induced GPx-2 
expression occurred after 24 h and peaked at 72 h. In their studies, activation of Nrf2 by
 
specific knock down of Keap1 by siRNA upregulated the expression of
 
GPx-2, whereas Nrf2 
siRNA down-regulated the expression of GPX2
 
in lung epithelial cells (Singh et al., 2006b). 
The slow induction of GPx-2 might be due to the slow degradation rate of this protein (Chu et 
al., 1999). Our findings clearly indicate that activation of Nrf2 activity leading to up-
regulation of GSH level is an antioxidant mechanism of action for andrographolide against 
cigarette smoking.  
Aside from the GSH cycle, andrographolide also induced a rapid 8-fold increase in 
HO-1 gene expression in BEAS-2B cells exposed to CSE within 12 h. Our findings are in line 
with those reported that HO-1 mRNA induction peaked at 6-8 h and returned to basal level at 




bronchial epithelial cells treated with Nrf2 activator (Kumar et al., 2011b). Under oxidative 
stress condition, free heme, a pro-oxidant catalysing production of free radicals, is released 
from hemoproteins to induce oxidative damages. HO-1 can be rapidly induced under the 
control of the Nrf2 transcription factor to catabolize heme into labile iron (Fe), carbon 
monoxide and biliverdin. The latter end product can be further converted by biliverdin 
reductase into bilirubin. All three reactive products have been shown to possess antioxidant 
and anti-inflammatory actions (Fredenburgh et al., 2007; Gozzelino et al., 2010). HO-1 
overexpression in macrophages reduces TNF-α (Otterbein et al., 2000) secretion and inhibits 
GM-CSF production in response to LPS stimulation (Sarady et al., 2002). In addition, 
transgenic mice overexpressing HO-1 have reduced levels of macrophage inflammatory 
protein (MIP)-2 in BAL fluid during endotoxemia (Ryter et al., 2007). More importanly, 
patients with COPD showed reduced levels of HO-1 in BAL fluid alveolar macrophages 
(Fredenburgh et al., 2007). Adenovirus-mediated gene transfer of HO-1 in mice ameliorated 
elastase-induced inflammation and airspace enlargement (Shinohara et al., 2005). 
Polymorphisms of the HO-1 promoter associated with reduced HO-1 expression have been 
linked to increased susceptibility to emphysema development (Exner et al., 2004). The 
antioxidant actions of andrographolide against cigarette smoke-induced lung injury may also 
be linked to augmented HO-1 expression. 
In conclusion, this study reveals for the first time that andrographolide can augment 
antioxidant gene expression and activities probably via up regulation of Nrf2 activity in 
experimental models of cigarette smoke exposure. Besides, inhibition of nuclear factor-B 
(NF-B) is another well-established mechanism of action for andrographolide to bring about 
anti-inflammatory effects (Bao et al., 2009; Lim et al., 2012), which may contribute to some 
of the protective effects observed in the present study. The reduction in cigarette smoke-




significant decline in BAL fluid inflammatory cell counts, in chemokine, cytokine and 
protease productions, and the up-regulation of GSH redox defence system and HO-1 
expression. These findings support a novel therapeutic value for andrographolide in the 
treatment of COPD. 
 Although our COPD is an acute model, the study provides us with positive preliminary 
data. For future study, we should proceed with a chronic cigarette smoke-induced COPD 
mouse model with clinical features similar to COPD patients, such as reductions in Nrf2 































Andrographolide and DDAG are both biologically active constituents that can be 
extracted from Andrographis paniculata (Lim et al., 2012; Pholphana et al., 2004). The plant 
extract have been traditionally used in upper respiratory tract infections. Current studies have 
further expanded our understanding on the effects of both of these compounds in an allergic 
asthma and COPD mouse models and the molecular targets involved.  
Although DDAG and andrographolide are structurally similar, our present data 
showed that DDAG was less cytotoxic to tumour cell lines but still maintained similar anti-
inflammatory effects as andrographolide in an allergic asthma mouse model (Bao et al., 2009). 
There was however subtle difference between the anti-inflammatory effects of 
andrographolide and DDAG treatment in the allergic mouse models and the difference could 
be further explore to enhance our understanding on the mechanism of action for both of these 
compounds. Additionally, our studies also demonstrated that andrographolide have a strong 
anti-oxidative and anti-inflammatory effects on cigarette smoke induce oxidative damage and 
inflammation and thus position andrographolide as a multi-potential drug candidate.  
Nonetheless, while DDAG was shown to be less cytotoxic than andrographolide, the 
effects of DDAG was not examined in the COPD mouse models as studies has demonstrated 
that andrographolide but not DDAG treatment protects cardiomyocyte against hypoxia and 
reoxygenation injury. Furthermore, only andrographolide but not DDAG treatment enhances 
the antioxidant potential of cardiomyocyte through the activities of a number of antioxidant 
enzymes and the GSH level (Woo et al., 2008). Andrographolide also cost less than DDAG 
and therefore made a better drug candidate. Hence, only the effects of andrographolide in 
oxidative damage models were studied.  
The differences between andrographolide and DDAG are very intriguing and could be 





COPD and asthma are both obstructive respiratory diseases that have high mortality 
and morbidity but currently lack effective treatments. The effects of andrographolide on 
cigarette smoke induced lung injury model and the effects of DDAG on allergic asthma 
mouse model has been explore on this study.  
This study demonstrates that andrographolide possesses anti-oxidative properties 
against cigarette smoke-induced lung injury possibly via the augmentation of Nrf2 activity. 
Upon andrographolide treatment, cigarette smoke induced oxidative stress markers are 
markedly reduced while both GR and GPx activities were augmented. Andrographolide also 
markedly reduced neutrophil and macrophages infiltration, inflammatory cytokine and 
protease production. Additionally, the significant increase of GPx-2 and HO-1 expression as 
well as the cellular GSH level by andrographolide treatment strongly exemplified a Nrf2 
pathway activation.   
This study also shown that DDAG as a non-cytotoxic analogue of andrographolide, 
retains the anti-inflammatory activities of andrographolide for the treatments of OVA induce 
allergic asthma via the inhibition of NF-κB. DDAG effectively reduce OVA induced 
inflammatory cell infiltration, BAL fluid Th2 cytokine and eotaxin level as well as serum total 
and OVA specific IgE level. Together with the reduction or AHR, the anti-inflammatory 
effects of DDAG were further reinforced by the reduction in pulmonary eosinophilia, mucus 
hypersecretion and mast cell degranulation observed histologically. 
This study demonstrated that Nrf2 activation by andrographolide may have therapeutic 
potential for treating COPD while DDAG may be considered as a safer analogue of 
andrographolide for the potential treatment of asthma. Thus, it is crucial to further substantiate 
the effects of both of these compounds in chronic and exacerbation models, ideally under 




therapeutic potential. These findings also warrant future research into both andrographolide 
and DDAG derivative as to further elucidate the active functional group in this compound so a 
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